:: CLDF ::

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

Díaz-González Á¹, Sanduzzi-Zamparelli M¹, Gomes da Fonseca LL¹, Di Costanzo GG², Alves R³, Iavarone M⁴, Leal C⁵, Sacco R⁶, Matilla AM⁷, Hernández-Guerra M⁸, Aballay Soteras G⁹, Wörns MA¹⁰, Pinter M¹¹, Varela M¹², Ladekarl M¹³, Chagas AL¹⁴, Mínguez B¹⁵, Arenas JI¹⁶, Granito A¹⁷, Sánchez-Torrijos Y¹⁸, Rojas Á¹⁸, Rodríguez de Lope C¹⁹, Alvares-da-Silva MR²⁰, Pascual S²¹, Rimassa L²², Lledó JL²³, Huertas C²⁴, Sangro B²⁵, Giannini EG²⁶, Delgado M²⁷, Vergara M²⁸, Perelló C²⁹, Lue A³⁰, Sala M³¹, Gallego A³², Coll S³³, Hernáez T³⁴, Piñero F³⁵, Pereira G³⁶, França A³⁷, Marín J³⁸, Anders M³⁹, Mello V⁴⁰, Lozano M⁴¹, Nault JC⁴², Menéndez J⁴³, García Juárez I⁴⁴, Bruix J¹, Reig M¹. Liver Int. 2020 Mar 14. doi: 10.1111/liv.14436. [Epub ahead of print]

2.	Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective
	Pearson H¹, Marshall LV^1,2, Carceller F^1,2. Pediatr Hematol Oncol. 2020 Mar 17:1-12. doi: 10.1080/08880018.2020.1740844. [Epub ahead of print]

3.	Hepatocellular Carcinoma-How to Determine Therapeutic Options
	Mehta N¹. Hepatol Commun. 2020 Jan 22;4(3):342-354. doi: 10.1002/hep4.1481. eCollection 2020 Mar.

4.	Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
	Simon TG¹, Duberg AS¹, Aleman S¹, Chung RT¹, Chan AT¹, Ludvigsson JF¹. N Engl J Med. 2020 Mar 12;382(11):1018-1028. doi: 10.1056/NEJMoa1912035.

5.	Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis
	Wei T^1,2, Zhang XF¹, Bagante F^3,4, Ratti F⁵, Marques HP⁶, Silva S⁶, Soubrane O⁷, Lam V⁸, Poultsides GA⁹, Popescu I¹⁰, Grigorie R¹⁰, Alexandrescu S¹⁰, Martel G¹¹, Workneh A¹¹, Guglielmi A⁴, Hugh T¹², Lv Y¹, Aldrighetti L⁵, Pawlik TM¹³. J Gastrointest Surg. 2020 Mar 3. doi: 10.1007/s11605-020-04553-2.

6.	Short- and long-term mortality after liver transplantation in patients with and without hepatocellular carcinoma in the UK
	Wallace D^1,2, Cowling TE¹, Walker K¹, Suddle A², Rowe I^3,4, Callaghan C⁵, Gimson A⁶, Bernal W², Heaton N², van der Meulen J¹. Br J Surg. 2020 Mar 3. doi: 10.1002/bjs.11451.

"Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher waitlist progression or post-transplant recurrence"

Piñero F^1,2, Boin I³, Chagas A⁴, Quiñonez E⁵, Marciano S⁶, Vilatobá M⁷, Santos L⁸, Anders M⁹, Hoyos Duque S¹⁰, Lima AS¹¹, Menendez J¹², Padilla M¹³, Poniachik J¹⁴, Zapata R¹⁵, Maraschio M¹⁶, Chong Menéndez R¹⁷, Muñoz L¹⁸, Arufe D¹⁹, Figueroa R²⁰, Mendizabal M¹, Hurtado Gomez S⁷, Stucchi R³, Maccali C⁴, Vergara Sandoval R⁵, Bermudez C⁶, McCormack L⁹, Varón A⁸, Gadano A⁶, Mattera J⁵, Rubinstein F²¹, Carrilho F⁴, Silva M^1,2. Liver Transpl. 2020 Mar 4. doi: 10.1002/lt.25744.

8.	The association of nonalcoholic steatohepatitis and hepatocellular carcinoma
	Asfari MM^1,2, Talal Sarmini M², Alomari M², Lopez R³, Dasarathy S^4,5,6, McCullough AJ^4,5,6. Eur J Gastroenterol Hepatol. 2020 Feb 18. doi: 10.1097/MEG.0000000000001681. [Epub ahead of print]

9.	Ramucirumab: A Review in Hepatocellular Carcinoma
	Syed YY¹. Drugs. 2020 Feb 7. doi: 10.1007/s40265-020-01263-6. [Epub ahead of print]

10.	Liquid biopsies for Hepatocellular cancer and their potential in clinical practice
	Jeffrey GP^1,2, Gordon LG^3,4,5, Hill MM^3,4, Ramm GA^3,4. Hepatology. 2020 Feb 7. doi: 10.1002/hep.31168. [Epub ahead of print]

11.	Outcomes of liver resection for hepatocellular carcinoma in octogenarians
	Sanyal S¹, Kron P¹, Wylie N¹, Hildalgo E¹, Toogood GJ¹, Lodge P². HPB (Oxford). 2020 Feb 1. pii: S1365-182X(20)30011-3. doi: 10.1016/j.hpb.2020.01.006. [Epub ahead of print]

12.	Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception
	Cannon RM¹, Davis EG², Goldberg DS³, Lynch RJ⁴, Shah MB⁵, Locke JE⁶, McMasters KM², Jones CM². J Am Coll Surg. 2020 Jan 30. pii: S1072-7515(20)30107-1. doi: 10.1016/j.jamcollsurg.2019.12.022. [Epub ahead of print]

13.	The Impact of Direct Acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.: An International Multicenter Study
	Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. Transplantation. 2020 Jan 16. doi: 10.1097/TP.0000000000003115. [Epub ahead of print]

14.	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers
	Elliot B. Tapper, Shengchen Hao, Menghan Lin, John N. Mafi, Heather McCurdy, Neehar D. Parikh, Anna S. Lok

15.	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
	Cheng AL¹, Hsu C², Chan SL³, Choo SP⁴, Kudo M⁵. J Hepatol. 2020 Feb;72(2):307-319. doi: 10.1016/j.jhep.2019.09.025.

16.	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
	Sangro B¹, Chan SL², Meyer T³, Reig M⁴, El-Khoueiry A⁵, Galle PR⁶. J Hepatol. 2020 Feb;72(2):320-341. doi: 10.1016/j.jhep.2019.10.021.

17.	Molecular therapies for HCC: Looking outside the box
	Faivre S¹, Rimassa L², Finn RS³. J Hepatol. 2020 Feb;72(2):342-352. doi: 10.1016/j.jhep.2019.09.010.

18.	Epidemiology and surveillance for hepatocellular carcinoma: New trends
	Singal AG¹, Lampertico P², Nahon P³. J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025.

19.	Advances in resection and transplantation for hepatocellular carcinoma
	Vibert E¹, Schwartz M², Olthoff KM³. J Hepatol. 2020 Feb;72(2):262-276. doi: 10.1016/j.jhep.2019.11.017.

20.	Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors
	Ladhani S¹, Ohri A¹, Wong RJ². J Clin Gastroenterol. 2020 Jan 7. doi: 10.1097/MCG.0000000000001313. [Epub ahead of print]

21.	Elevated Serum a-Fetoprotein is Associated with Abbreviated Survival for Patients with Fibrolamellar Hepatocellular Carcinoma Who Undergo a Curative Resection
	McDonald JD¹, Gupta S¹, Shindorf ML¹, Gamble LA¹, Ruff SM¹, Drake J¹, Heller T², Wan JY³, Dickson PV³, Glazer ES³, Davis JL¹, Deneve JL³, Hernandez JM⁴. Ann Surg Oncol. 2020 Jan 10. doi: 10.1245/s10434-019-08178-x. [Epub ahead of print]

22.	Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival
	Lee MW^1,2, Kang D^3,4, Lim HK^5,6, Cho J^3,4, Sinn DH⁷, Kang TW¹, Song KD¹, Rhim H^1,2, Cha DI¹, Lu DSK⁸. Eur Radiol. 2020 Jan 3. doi: 10.1007/s00330-019-06575-0. [Epub ahead of print]

23.	Developments in predictive biomarkers for hepatocellular carcinoma therapy
	Andrea CG¹, Giulia O¹, Francesco C¹, Giorgio E^2,3. Expert Rev Anticancer Ther. 2020 Jan 7:1-12. doi: 10.1080/14737140.2020.1712198. [Epub ahead of print]

24.	Advances in delivery vectors for gene therapy in liver cancer
	Redd Bowman KE¹, Lu P¹, Vander Mause ER¹, Lim CS¹. Ther Deliv. 2020 Jan;11(1):833-850. doi: 10.4155/tde-2019-0076. Epub 2019 Dec 16.

25.	Recurrent hepatocellular carcinoma in pregnancy: A case report and literature review
	McCarthy CM¹, McCarthy M¹, O'Donoghue K^1,2. Obstet Med. 2019 Dec;12(4):202-204. doi: 10.1177/1753495X18784074. Epub 2018 Jul 20.

26.	Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check
	Lee A¹, Lee FC². Front Med. 2019 Dec 21. doi: 10.1007/s11684-019-0728-2. [Epub ahead of print]

27.	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
	Finn RS¹, Ryoo BY², Merle P³, Kudo M⁴, Bouattour M⁵, Lim HY⁶, Breder V⁷, Edeline J⁸, Chao Y⁹, Ogasawara S¹⁰, Yau T¹¹, Garrido M¹², Chan SL¹³, Knox J¹⁴, Daniele B¹⁵, Ebbinghaus SW¹⁶, Chen E¹⁶, Siegel AB¹⁶, Zhu AX¹⁷, Cheng AL¹⁸; KEYNOTE-240 investigators. J Clin Oncol. 2019 Dec 2:JCO1901307. doi: 10.1200/JCO.19.01307. [Epub ahead of print]

28.	Socioeconomic And Survival Differences Among Minorities With Hepatocellular Carcinoma In Florida
	Jones PD^1,2, Scheinberg AR³, Muenyi V³, Gonzalez-Diaz J¹, Martin PM^1,2, Kobetz E^2,4. J Hepatocell Carcinoma. 2019 Nov 15;6:167-181. doi: 10.2147/JHC.S212401. eCollection 2019.

29.	Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center
	Rutledge B¹, Jan J², Benjaram S², Sahni N², Naylor P², Philip P³, Ehrinpreis M², Mutchnick M². J Gastrointest Cancer. 2019 Dec 2. doi: 10.1007/s12029-019-00342-6. [Epub ahead of print]

30.	Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival
	Adler Jaffe S¹, Myers O², Meisner ALW³, Wiggins CL⁴, Hill DA⁵, McDougall JA⁶. Cancer Epidemiol Biomarkers Prev. 2019 Dec 3. pii: cebp.0902.2019. doi: 10.1158/1055-9965.EPI-19-0902. [Epub ahead of print]

31.	Complications of liver transplant
	Craig EV¹, Heller MT². Abdom Radiol (NY). 2019 Dec 3. doi: 10.1007/s00261-019-02340-5. [Epub ahead of print]

32.	Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions
	Dendy MS¹, Ludwig JM^1,2, Stein SM^3,4, Kim HS^1,3,4. Liver Cancer. 2019 Oct;8(5):326-340. doi: 10.1159/000494843. Epub 2019 Jan 16.

33.	Systemic Treatment for Advanced Hepatocellular Carcinoma
	Bouattour M¹, Mehta N², He AR³, Cohen EI⁴, Nault JC^5,6. Liver Cancer. 2019 Oct;8(5):341-358. doi: 10.1159/000496439. Epub 2019 Mar 6.

34.

HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication

Ogawa E¹, Toyoda H², Iio E³, Jun DW⁴, Huang CF⁵, Enomoto M⁶, Hsu YC⁷, Haga H⁸, Iwane S⁹, Wong G^10,11, Lee DH¹², Tada T², Liu CH^13,14, Chuang WL⁵, Hayashi J¹⁵, Cheung R^16,17, Yasuda S², Tseng CH⁷, Takahashi H^9,18, Tran S¹⁶, Yeo YH¹⁶, Henry L¹⁶, Barnett SD¹⁶, Nomura H¹⁹, Nakamuta M²⁰, Dai CY⁵, Huang JF⁵, Yang HI²¹, Lee MH²², Jung Jun M¹², Kao JH^13,14, Eguchi Y⁹, Ueno Y⁸, Tamori A⁶, Furusyo N¹, Yu ML⁵, Tanaka Y³, Nguyen MH¹⁶; REAL-C Investigators, Ahn SB²³, Azuma K²⁴, Dohmen K²⁵, Yoon Jeong J²⁶, Jung JH²⁷, Kajiwara E²⁸, Kato M²⁹, Kawano A³⁰, Koyanagi T³¹, Ooho A³², Park SH³³, Satoh T³⁴, Shimoda S³⁵, Song DS³⁶, Takahashi K³⁷, Yeh ML⁵, Yoon EL³⁸. Clin Infect Dis. 2019 Nov 28. pii: ciz1160. doi: 10.1093/cid/ciz1160. [Epub ahead of print]

35.	Quality of Life after Radioembolization for Hepatocellular Carcinoma Using a Digital Patient-Reported Outcome Tool
	Salem R¹, Hassan S², Lewandowski RJ², Grace K², Martin RCG³, Sichlau MJ⁴, Fung J⁵, Kim E⁵, Chao S⁶, Rosner BI⁷. J Vasc Interv Radiol. 2019 Nov 12. pii: S1051-0443(19)30600-1. doi: 10.1016/j.jvir.2019.06.018. [Epub ahead of print]

36.	Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection
	Ruff SM¹, Rothermel LD², Diggs LP¹, Wach MM¹, Ayabe RI¹, Martin SP¹, Boulware D², Anaya D², Davis JL¹, Mullinax JE³, Hernandez JM⁴. HPB (Oxford). 2019 Nov 13. pii: S1365-182X(19)32273-7. doi: 10.1016/j.hpb.2019.10.1531. [Epub ahead of print]

37.	Review article: new therapeutic interventions for advanced hepatocellular carcinoma
	Bangaru S¹, Marrero JA¹, Singal AG¹. Aliment Pharmacol Ther. 2019 Nov 20. doi: 10.1111/apt.15573. [Epub ahead of print]

38.	A Role for the Biological Clock in Liver Cancer
	Mazzoccoli G¹, Miele L², Marrone G², Mazza T³, Vinciguerra M⁴, Grieco A². Cancers (Basel). 2019 Nov 11;11(11). pii: E1778. doi: 10.3390/cancers11111778.

39.	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis
	McDonald SA¹, Pollock KG², Barclay ST³, Goldberg DJ¹, Bathgate A⁴, Bramley P⁵, Dillon JF⁶, Fraser A⁷, Innes HA¹, Kennedy N⁸, Morris J⁷, Went A⁹, Hayes PC⁴, Hutchinson SJ¹. J Viral Hepat. 2019 Nov 6. doi: 10.1111/jvh.13232. [Epub ahead of print]

40.

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

Han G¹, Berhane S², Toyoda H³, Bettinger D⁴, Elshaarawy O⁵, Chan AWH⁶, Kirstein M⁷, Mosconi C⁸, Hucke F⁹, Palmer D¹⁰, Pinato DJ¹¹, Sharma R¹¹, Ottaviani D¹², Jang JW¹³, Labeur TA¹⁴, van Delden OM¹⁵, Pirisi M¹⁶, Stern N¹⁷, Sangro B¹⁸, Meyer T¹⁹, Fateen W^20,21, García-Fiñana M², Gomaa A⁵, Waked I⁵, Rewisha E⁵, Aithal GP^20,21, Travis S²², Kudo M²³, Cucchetti A²⁴, Peck-Radosavljevic M⁹, Takkenberg RB¹⁴, Chan SL²⁵, Vogel A⁷, Johnson PJ¹⁰. Hepatology. 2019 Nov 7. doi: 10.1002/hep.31022. [Epub ahead of print]

41.	The use of cell free DNA in the diagnosis of HCC
	Banini BA¹, Sanyal AJ¹. Hepatoma Res. 2019;5. pii: 34. doi: 10.20517/2394-5079.2019.30. Epub 2019 Sep 23.

42.	Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3?cm: Science, Evidence, and Future Directions
	Lewis AR¹, Padula CA¹, McKinney JM¹, Toskich BB¹. Semin Intervent Radiol. 2019 Oct;36(4):303-309. doi: 10.1055/s-0039-1697641. Epub 2019 Oct 31.

43.	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
	Keenan BP^1,2, Fong L^3,4, Kelley RK^3,4. J Immunother Cancer. 2019 Oct 18;7(1):267. doi: 10.1186/s40425-019-0749-z.

44.	Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
	Longo V¹, Brunetti O², Gnoni A³, Licchetta A⁴, Delcuratolo S⁵, Memeo R⁶, Solimando AG^7,8, Argentiero A⁹. Medicina (Kaunas). 2019 Oct 17;55(10). pii: E698. doi: 10.3390/medicina55100698.

45.	Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma
	Nguyen L¹, Chapel S², Tran BD³, Lacy S³. J Pharmacokinet Pharmacodyn. 2019 Oct 21. doi: 10.1007/s10928-019-09659-y. [Epub ahead of print]

46.

Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis

Bettinger D^1,2, Pinato DJ³, Schultheiss M¹, Sharma R³, Rimassa L⁴, Pressiani T⁴, Burlone ME⁵, Pirisi M⁵, Kudo M⁶, Park JW⁷, Buettner N¹, Neumann-Haefelin C¹, Boettler T¹, Abbasi-Senger N⁸, Alheit H⁹, Baus W¹⁰, Blanck O¹¹, Gerum S¹², Guckenberger M¹³, Habermehl D^14,15, Ostheimer C¹⁶, Riesterer O¹³, Tamihardja J¹⁷, Grosu AL^18,19,20, Thimme R¹, Brunner TB^19,20,21, Gkika E¹⁸. Erratum. [Liver Cancer. 2019] Liver Cancer. 2019 Jul;8(4):281-294. doi: 10.1159/000490260. Epub 2018 Jul 12.

47.	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
	Macek Jilkova Z^1,2,3, Aspord C^4,5,6, Decaens T^7,8,9. Cancers (Basel). 2019 Oct 14;11(10). pii: E1554. doi: 10.3390/cancers11101554.

48.	Cabozantinib for the treatment of hepatocellular carcinoma
	Personeni N^1,2, Rimassa L^1,2, Pressiani T¹, Smiroldo V¹, Santoro A^1,2. Expert Rev Anticancer Ther. 2019 Oct;19(10):847-855. doi: 10.1080/14737140.2019.1674141. Epub 2019 Oct 11.

49.	Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
	Noonan A¹, Pawlik TM². Expert Opin Investig Drugs. 2019 Oct 7. doi: 10.1080/13543784.2019.1677606. [Epub ahead of print]

50.	International trends in hepatocellular carcinoma incidence, 1978-2012
	Petrick JL^1,2, Florio AA¹, Znaor A³, Ruggieri D⁴, Laversanne M³, Alvarez CS¹, Ferlay J³, Valery PC⁵, Bray F³, McGlynn KA¹. Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32723. [Epub ahead of print]

51.	Multiple regional listing increases liver transplant rates for those with MELD score less than 15
	Brown S¹, Savva Y¹, Barth R², LaMattina J², Thuluvath PJ¹. Transplantation. 2019 Sep 18. doi: 10.1097/TP.0000000000002965. [Epub ahead of print]

52.	Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
	Shlomai A¹, Leshno M², Goldstein DA³. Therap Adv Gastroenterol. 2019 Sep 23;12:1756284819878304. doi: 10.1177/1756284819878304. eCollection 2019.

53.	Childhood Liver Cancer Treatment (PDQ®): Health Professional Version
	PDQ Pediatric Treatment Editorial Board.

54.	A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk
	Frenette CT¹, Isaacson AJ², Bargellini I³, Saab S⁴, Singal AG⁵. Mayo Clin Proc Innov Qual Outcomes. 2019 Jul 11;3(3):302-310. doi: 10.1016/j.mayocpiqo.2019.04.005. eCollection 2019 Sep.

55.	Evolving Surgical Options for Hepatocellular Carcinoma
	Wilson GC¹, Geller DA². Surg Oncol Clin N Am. 2019 Oct;28(4):645-661. doi: 10.1016/j.soc.2019.06.006. Epub 2019 Aug 10.

56.	Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis
	Glassberg MB¹, Ghosh S², Clymer JW³, Qadeer RA⁴, Ferko NC⁴, Sadeghirad B⁴, Wright GW⁴, Amaral JF². Onco Targets Ther. 2019 Aug 13;12:6407-6438. doi: 10.2147/OTT.S204340. eCollection 2019.

57.	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population
	Simon TG¹, Duberg AS², Aleman S³, Hagstrom H⁴, Nguyen LH¹, Khalili H⁵, Chung RT¹, Ludvigsson JF⁶. Ann Intern Med. 2019 Aug 20. doi: 10.7326/M18-2753. [Epub ahead of print]

58.	Evolving Surgical Options for Hepatocellular Carcinoma
	Wilson GC¹, Geller DA². Surg Oncol Clin N Am. 2019 Oct;28(4):645-661. doi: 10.1016/j.soc.2019.06.006. Epub 2019 Aug 10.

59.	Modern Outcomes Following Treatment of Hepatocellular Carcinoma in Hereditary Hemochromatosis: A Matched Cohort Study
	McPhail MJW¹, Khorsandi SE¹, Abbott L¹, Al-Kadhimi G¹, Kane P², Karani J², O'Grady J¹, Heaton N¹, Bomford A¹, Suddle A¹. Am J Clin Oncol. 2019 Aug 20. doi: 10.1097/COC.0000000000000583. [Epub ahead of print]

60.	A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy
	Jackson WC¹, Suresh K¹, Maurino C¹, Feng M², Cuneo KC¹, Ten Haken RK¹, Lawrence TS¹, Schipper MJ¹, Owen D³. Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33020-8. doi: 10.1016/j.radonc.2019.07.027. [Epub ahead of print]

61.	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients
	Tovoli F¹, Ielasi L², Casadei-Gardini A³, Granito A², Foschi FG⁴, Rovesti G⁵, Negrini G², Orsi G⁵, Renzulli M⁶, Piscaglia F². J Hepatol. 2019 Aug 23. pii: S0168-8278(19)30482-9. doi: 10.1016/j.jhep.2019.08.015. [Epub ahead of print]

62.	Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy
	Wallace MC^1,2,3, Sek K⁴, Francis RJ^5,4, Samuelson S⁶, Ferguson J⁶, Tibballs J⁶, Asad A⁷, Preen DB⁸, MacQuillan G^9,5, Garas G^9,5, Adams LA^9,5, Jeffrey GP^9,5. Dig Dis Sci. 2019 Aug 22. doi: 10.1007/s10620-019-05781-6. [Epub ahead of print]

63.	Liver Transplant for Hepatocellular Carcinoma in the United States: Evolving Trends over the Last Three Decades
	Puigvehí M¹, Hashim D², Haber PK¹, Dinani A³, Schiano TD⁴, Asgharpour A³, Kushner T³, Kakked G³, Tabrizian P⁴, Schwartz M⁴, Gurakar A⁵, Dieterich D³, Boffetta P², Friedman SL³, Llovet JM^1,6,7, Saberi B³. Am J Transplant. 2019 Aug 22. doi: 10.1111/ajt.15576. [Epub ahead of print]

64.	No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis
	Rutledge SM^1,2, Zheng H², Li DK^1,2, Chung RT^1,2. Hepatoma Res. 2019;5. pii: 31. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.

65.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

Moehler M¹, Heo J², Lee HC³, Tak WY⁴, Chao Y⁵, Paik SW⁶, Yim HJ⁷, Byun KS⁸, Baron A⁹, Ungerechts G¹⁰, Jonker D¹¹, Ruo L¹², Cho M¹³, Kaubisch A¹⁴, Wege H¹⁵, Merle P¹⁶, Ebert O¹⁷, Habersetzer F¹⁸, Blanc JF¹⁹, Rosmorduc O²⁰, Lencioni R²¹, Patt R²², Leen AM²³, Foerster F¹, Homerin M²⁴, Stojkowitz N²⁵, Lusky M²⁶, Limacher JM²⁷, Hennequi M²⁸, Gaspar N²⁹, McFadden B³⁰, De Silva N³¹, Shen D³¹, Pelusio A³¹, Kirn DH³², Breitbach CJ³¹, Burke JM³¹. Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019.

66.	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
	Ricke J¹, Klumpen HJ², Amthauer H³, Bargellini I⁴, Bartenstein P⁵, de Toni E⁶, Gasbarrini A⁷, Pech M⁸, Peck-Radosavljevic M⁹, Popovic P¹⁰, Rosmorduc O¹¹, Schott E¹², Seidensticker M¹³, Verslype C¹⁴, Sangro B¹⁵, Malfertheiner P¹⁶. J Hepatol. 2019 Aug 14. pii: S0168-8278(19)30472-6. doi: 10.1016/j.jhep.2019.08.006. [Epub ahead of print]

67.	Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
	Meringer H¹, Shibolet O¹, Deutsch L². World J Gastroenterol. 2019 Aug 7;25(29):3929-3940. doi: 10.3748/wjg.v25.i29.3929.

68.	Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies
	Penrice D¹, Simonetto DA². Hepatology. 2019 Aug 20. doi: 10.1002/hep.30905. [Epub ahead of print]

69.	Health-Related Quality of Life as a Prognostic Factor in Patients After Resection of Hepatic Malignancies
	Tohme S¹, Sanin GD², Patel V³, Bess K⁴, Ahmed N⁴, Krane A⁴, Tsung A⁴, Steel JL⁴. J Surg Res. 2019 Aug 14;245:257-264. doi: 10.1016/j.jss.2019.07.061. [Epub ahead of print]

70.	Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1)
	Chen M¹, Neul C^2,3, Schaeffeler E^2,3,4, Frisch F^2,3, Winter S^2,3, Schwab M^2,4,5, Koepsell H⁶, Hu S¹, Laufer S^4,7, Baker SD¹, Sparreboom A¹, Nies AT^2,3,4. Clin Pharmacol Ther. 2019 Jul 27. doi: 10.1002/cpt.1588. [Epub ahead of print]

71.	Current and Future Systemic Therapies for Hepatocellular Carcinoma
	Bteich F^1,2, Di Bisceglie AM^1,2. Gastroenterol Hepatol (N Y). 2019 May;15(5):266-272.

72.	National Experience on Down-staging of Hepatocellular Carcinoma before Liver Transplant: Influence of Tumor Burden, AFP, and Wait Time
	Mehta N¹, Dodge JL², Grab JD², Yao FY^1,2. Hepatology. 2019 Jul 25. doi: 10.1002/hep.30879. [Epub ahead of print]

73.

Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA

Kaseb AO¹, Sánchez NS², Sen S³, Kelley RK⁴, Tan BR⁵, Bocobo AG⁶, Lim KH⁷, Abdel-Wahab R⁸, Uemura MI³, Carmagnani Pestana R⁹, Qiao W¹⁰, Xiao L¹⁰, Morris J¹⁰, Amin HM¹¹, Hassam MM⁸, Rashid A¹², Banks KC¹³, Lanman RB¹⁴, Talasaz A¹⁵, Mills Shaw KR¹⁶, George B¹⁷, Haque A¹⁸, Raghav K¹⁹, Wolf RA²⁰, Yao JC²¹, Meric-Bernstam F²², Ikeda S²³, Kurzrock R²⁴. Clin Cancer Res. 2019 Jul 30. pii: clincanres.3341.2018. doi: 10.1158/1078-0432.CCR-18-3341. [Epub ahead of print]

74.

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

Iavarone M¹, Invernizzi F¹, Czauderna C², Sanduzzi-Zamparelli M³, Bhoori S⁴, Amaddeo G⁵, Manini MA⁶, Fraile López M⁷, Anders M⁸, Pinter M⁹, Blanco Rodríguez MJ¹⁰, Romero Cristóbal M¹¹, Aballay Soteras G¹², Piñero F¹³, Villadsen GE¹⁴, Weinmann A², Crespo G¹⁵, Mazzaferro V¹⁶, Regnault H⁵, De Giorgio M⁶, González-Diéguez ML⁷, Donato MF¹, Varela M⁷, Wörns MA², Bruix J³, Lampertico P¹, Reig M³. Am J Transplant. 2019 Jul 31. doi: 10.1111/ajt.15551. [Epub ahead of print]

75.	Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
	Mahipal A¹, Tella SH², Kommalapati A³, Lim A³, Kim R⁴. Cancers (Basel). 2019 Jul 30;11(8). pii: E1078. doi: 10.3390/cancers11081078.

76.	Insights into the success and failure of systemic therapy for hepatocellular carcinoma
	Bruix J¹, da Fonseca LG², Reig M². Nat Rev Gastroenterol Hepatol. 2019 Aug 1. doi: 10.1038/s41575-019-0179-x. [Epub ahead of print]

77.

Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma

Rich NE¹, Yang JD², Perumalswami PV³, Alkhouri N⁴, Jackson W⁵, Parikh ND⁶, Mehta N⁷, Salgia R⁸, Duarte-Rojo A⁹, Kulik L¹⁰, Rakoski M¹¹, Said A¹², Oloruntoba O¹³, Ioannou GN¹⁴, Hoteit MA¹⁵, Moon AM¹⁶, Rangnekar AS¹⁷, Eswaran SL¹⁸, Zheng E¹⁹, Jou JH²⁰, Hanje J²¹, Pillai A²², Hernaez R²³, Wong R²⁴, Scaglione S²⁵, Samant H²⁶, Kapuria D²⁷, Chandna S²⁸, Rosenblatt R²⁹, Ajmera V³⁰, Frenette C³¹, Satapathy SK³², Mantry P³³, Jalal P³⁴, John BV³⁵, Fix OK³⁶, Leise M³⁷, Lindenmeyer CC³⁸, Flores A³⁹, Patel N⁴⁰, Jiang ZG⁴¹, Latt N⁴², Dhanasekaran R⁴³, Odewole M¹, Kagan S¹, Marrero JA¹, Singal AG¹. Clin Gastroenterol Hepatol. 2019 Jul 26. pii: S1542-3565(19)30786-4. doi: 10.1016/j.cgh.2019.07.042. [Epub ahead of print]

78.

Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma

Singal AG¹, Rich NE², Mehta N³, Branch A⁴, Pillai A⁵, Hoteit M⁶, Volk M⁷, Odewole M², Scaglione S⁸, Guy J⁹, Said A¹⁰, Feld JJ¹¹, John BV¹², Frenette C¹³, Mantry P¹⁴, Rangnekar AS¹⁵, Oloruntoba O¹⁶, Leise M¹⁷, Jou JH¹⁸, Bhamidimarri KR¹⁹, Kulik L²⁰, Ioannou GN²¹, Huang A³, Tran T²², Samant H²³, Dhanasekaran R²⁴, Duarte-Rojo A²⁵, Salgia R²⁶, Eswaran S²⁷, Jalal P²⁸, Flores A²⁹, Satapathy SK³⁰, Kagan S², Gopal P³¹, Wong R³², Parikh ND³³, Murphy CC². Gastroenterology. 2019 Jul 30. pii: S0016-5085(19)41137-2. doi: 10.1053/j.gastro.2019.07.040. [Epub ahead of print]

79.	Liver Imaging Reporting and Data System (LI-RADS) v2018: Impact on Categorization and Hepatocellular Carcinoma Staging
	Chernyak V¹, Flusberg M², Berman J¹, Fruitman KC¹, Kobi M¹, Fowler KJ³, Sirlin CB³. Liver Transpl. 2019 Jul 25. doi: 10.1002/lt.25614. [Epub ahead of print]

80.	Meat intake and risk of hepatocellular carcinoma in two large US prospective cohorts of women and men
	Ma Y^1,2, Yang W^2,3, Li T², Liu Y^2,4, Simon TG^5,6,7, Sui J^2,8, Wu K⁹, Giovannucci EL^2,9,10, Chan AT^2,6,7, Zhang X^2,9. Int J Epidemiol. 2019 Jul 13. pii: dyz146. doi: 10.1093/ije/dyz146. [Epub ahead of print]

81.	Immunotherapy for hepatocellular carcinoma: Current and future
	Johnston MP¹, Khakoo SI². World J Gastroenterol. 2019 Jun 28;25(24):2977-2989. doi: 10.3748/wjg.v25.i24.2977.

82.	A Phase 2 Study of Galunisertib (TGF-ß1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
	Kelley RK¹, Gane E², Assenat E³, Siebler J⁴, Galle PR⁵, Merle P⁶, Hourmand IO⁷, Cleverly A⁸, Zhao Y⁹, Gueorguieva I⁸, Lahn M⁹, Faivre S¹⁰, Benhadji KA⁹, Giannelli G¹¹. Clin Transl Gastroenterol. 2019 Jul 1. doi: 10.14309/ctg.0000000000000056. [Epub ahead of print]

83.	Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma
	Hester CA¹, Karbhari N¹, Rich NE², Augustine M¹, Mansour JC¹, Polanco PM¹, Porembka MR¹, Wang SC¹, Zeh HJ 3rd¹, Singal AG², Yopp AC¹. Cancer. 2019 Jul 12. doi: 10.1002/cncr.32336. [Epub ahead of print]

84.	Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study
	Driver RJ^1,2,3, Balachandrakumar V⁴, Burton A⁵, Shearer J², Downing A^1,3, Cross T⁴, Morris E^1,3, Rowe IA^1,2,3. BMJ Open. 2019 Jul 9;9(7):e028571. doi: 10.1136/bmjopen-2018-028571.

85.	Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma
	Chen CP¹. J Clin Transl Hepatol. 2019 Jun 28;7(2):183-190. doi: 10.14218/JCTH.2018.00060. Epub 2019 May 27.

86.	Hepatology through the crystal ball
	Williams R^1,2. Hepatol Int. 2019 Jul 4. doi: 10.1007/s12072-019-09959-y. [Epub ahead of print]

87.	Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance
	Loo N¹, Hanysak B¹, Mann J¹, Ramirez R¹, Kim J¹, Mitchell R¹, Van Frank T¹, Guerrero R¹, Hinojosa K¹, Christensen K¹, Pedicone LD², Alkhouri N¹, Wells J¹, Landaverde C¹, Rodas F¹, Lawitz E¹, Poordad F¹. Medicine (Baltimore). 2019 Jun;98(26):e16254. doi: 10.1097/MD.0000000000016254.

88.	Patterns and co-occurrence of risk factors for hepatocellular carcinoma in four Asian American communities: a cross-sectional study
	Stewart SL¹, Dang JH², Török NJ³, Chen MS Jr². BMJ Open. 2019 Jun 28;9(6):e026409. doi: 10.1136/bmjopen-2018-026409.

89.	Expression of genes that control core fucosylation in hepatocellular carcinoma: Systematic review
	Norton PA¹, Mehta AS². World J Gastroenterol. 2019 Jun 21;25(23):2947-2960. doi: 10.3748/wjg.v25.i23.2947.

90.	The changing epidemiology of primary liver cancer
	Petrick JL¹, McGlynn KA¹. Curr Epidemiol Rep. 2019 Jun;6(2):104-111. doi: 10.1007/s40471-019-00188-3. Epub 2019 May 3.

91.	A proposal for a useful algorithm to diagnose small hepatocellular carcinoma on MRI
	Coty JB¹, Paisant A², Esvan M^3,4, Lonjon J⁵, Seror O⁶, Rode A⁷, Ronot M^8,9, Lebigot J², Vilgrain V^6,8, Aubé C^2,10. Eur J Gastroenterol Hepatol. 2019 Jun 17. doi: 10.1097/MEG.0000000000001476. [Epub ahead of print]

92.	Outcomes of Liver transplantation for hepatocellular carcinoma (HCC) beyond the University of California San Francisco (UCSF) criteria: a single center experience
	Victor DW 3rd, Monsour HP Jr, Boktour M, Lunsford K, Balogh J, Graviss EA, Nguyen DT, McFadden R, Divatia MK, Heyne K, Ankoma-Sey V, Egwim C, Galati J, Duchini A, Saharia A, Mobley C, Gaber AO, Ghobrial RM. Transplantation. 2019 Jun 18. doi: 10.1097/TP.0000000000002835. [Epub ahead of print]

93.	Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents
	Kanwal F^1,2,3, Kramer JR^1,3, Asch SM^4,5, Cao Y^1,3, Li L⁶, El-Serag HB^1,2. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823. [Epub ahead of print]

94.	Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update
	Izzo F¹, Granata V², Grassi R³, Fusco R⁴, Palaia R¹, Delrio P⁵, Carrafiello G⁶, Azoulay D⁷, Petrillo A¹, Curley SA⁸. Oncologist. 2019 Jun 19. pii: theoncologist.2018-0337. doi: 10.1634/theoncologist.2018-0337. [Epub ahead of print]

95.	Dose and duration of aspirin use to reduce incidental hepatocellular carcinoma
	Fujiwara N^1,2, Singal AG¹, Hoshida Y¹. Hepatology. 2019 Jun 17. doi: 10.1002/hep.30813. [Epub ahead of print]

96.	Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis
	Bitterman DS^1,2, Sanford NN³, Niemierko A⁴, Mahal BA^1,2, Qadan M⁵, Ganguli S⁶, Blaszkowsky LS^7,8, Zhu AX⁸, Hong TS⁹, Devlin PM¹⁰, Goyal L⁸, Wo JY⁹. Am J Clin Oncol. 2019 Jun 3. doi: 10.1097/COC.0000000000000560. [Epub ahead of print]

97.	Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis
	Yau T¹, Hsu C², Kim TY³, Choo SP⁴, Kang YK⁵, Hou MM⁶, Numata K⁷, Yeo W⁸, Chopra A⁹, Ikeda M¹⁰, Kuromatsu R¹¹, Moriguchi M¹², Chao Y¹³, Zhao H¹⁴, Anderson J¹⁴, Dela Cruz C¹⁴, Kudo M¹⁵. J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300-9. doi: 10.1016/j.jhep.2019.05.014. [Epub ahead of print]

98.

Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials.

Casadei Gardini A¹, Puzzoni M², Montagnani F³, Marisi G⁴, Tamburini E⁵, Cucchetti A^6,7, Solaini L^6,7, Foschi FG⁸, Conti F⁸, Ercolani G^6,7, Cascinu S¹, Scartozzi M².

Onco Targets Ther. 2019 Apr 24;12:2981-2988. doi: 10.2147/OTT.S192572. eCollection 2019

99.	Lenvatinib mesylate to treat hepatocellular carcinoma
	Ielasi L¹, Tovoli F², Piscaglia F¹. Drugs Today (Barc). 2019 May;55(5):305-313. doi: 10.1358/dot.2019.55.5.2969817.

100.	Quality measures, all-cause mortality, and healthcare utilization in a national cohort of Veterans with cirrhosis
	Serper M^1,2,3, Kaplan DE^1,2, Shults J⁴, Reese PP^3,4,5, Beste LA^6,7,8, Taddei TH^9,10, Werner RM^1,3,11. Hepatology. 2019 May 20. doi: 10.1002/hep.30779. [Epub ahead of print]

101.	Current Trends in the Treatment of Hepatocellular Carcinoma with Transarterial Embolization: Variability in Technical Aspects
	Craig P¹, Young S², Golzarian J². Cardiovasc Intervent Radiol. 2019 May 13. doi: 10.1007/s00270-019-02232-7. [Epub ahead of print]

102.	Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort
	Sandow T¹, Pavlus J², Field D², Lacayo E², Cohen E², Lynskey G², Caridi T², Buckley D², Cardella J², Kallakury B³, Spies J², Kim AY⁴. J Vasc Interv Radiol. 2019 May 17. pii: S1051-0443(19)30027-2. doi: 10.1016/j.jvir.2018.12.736. [Epub ahead of print]

103.	Outcomes After Resection of Hepatocellular Carcinoma: Intersection of Travel Distance and Hospital Volume
	Beal EW¹, Mehta R¹, Merath K¹, Tsilimigras DI¹, Hyer JM¹, Paredes A¹, Dillhoff ME¹, Cloyd J¹, Ejaz A¹, Pawlik TM². J Gastrointest Surg. 2019 May 8. doi: 10.1007/s11605-019-04233-w. [Epub ahead of print]

104.	Telemedicine: An Evolving Field in Hepatology
	Piao C¹, Terrault NA^2,3, Sarkar S^1,4. Hepatol Commun. 2019 Mar 25;3(5):716-721. doi: 10.1002/hep4.1340. eCollection 2019 May.

105.	Hepatocellular Carcinoma Incidence is Decreasing Among Younger Adults in the United States
	Rich NE¹, Yopp AC², Singal AG³, Murphy CC⁴. Clin Gastroenterol Hepatol. 2019 Apr 28. pii: S1542-3565(19)30433-1. doi: 10.1016/j.cgh.2019.04.043. [Epub ahead of print]

106.	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers
	Tapper EB^1,2, Hao S³, Lin M³, Mafi JN^4,5, McCurdy H², Parikh ND^1,2, Lok AS^1,2. Hepatology. 2019 May 7. doi: 10.1002/hep.30695. [Epub ahead of print]

107.	Liver Disease due to Alpha-1 Antitrypsin Deficiency: Are we surprised that it is more complex than we thought?
	Di Bisceglie AM¹, Teckman J². Hepatology. 2019 May 6. doi: 10.1002/hep.30694. [Epub ahead of print]

108.	A prospective study of nut consumption and risk of primary hepatocellular carcinoma in the U.S. women and men
	Sui J¹, Yang W², Ma Y³, Li TY⁴, Simon TG⁵, Meyerhardt JA⁶, Liang G⁷, Giovannucci EL⁸, Chan AT⁹, Zhang X¹⁰. Cancer Prev Res (Phila). 2019 Apr 30. pii: canprevres.0511.2019. doi: 10.1158/1940-6207.CAPR-18-0511. [Epub ahead of print]

109.	Insurance status impacts treatment for hepatocellular carcinoma
	Sobotka LA¹, Hinton A², Conteh LF³. Ann Hepatol. 2019 Apr 12. pii: S1665-2681(19)30029-8. doi: 10.1016/j.aohep.2018.10.001. [Epub ahead of print]

110.	Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review
	Fehily SR¹, Papaluca T¹, Thompson AJ¹. Semin Liver Dis. 2019 Apr 30. doi: 10.1055/s-0039-1685538. [Epub ahead of print]

111.	Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents
	Zou WY¹, Choi K², Kramer JR^2,3, Yu X², Cao Y², El-Serag HB^2,3, Kanwal F^2,3. Dig Dis Sci. 2019 Apr 30. doi: 10.1007/s10620-019-05641-3. [Epub ahead of print]

112.	Coffee consumption by type and risk of digestive cancer: a large prospective cohort study
	Tran KT¹, Coleman HG^1,2, McMenamin ÚC¹, Cardwell CR³. Br J Cancer. 2019 May 1. doi: 10.1038/s41416-019-0465-y. [Epub ahead of print]

113.	Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab
	Adcock CS¹, Puneky LV², Campbell GS¹. Cureus. 2019 Feb 16;11(2):e4083. doi: 10.7759/cureus.4083.

114.	Lenvatinib: A Review in Hepatocellular Carcinoma
	Al-Salama ZT¹, Syed YY², Scott LJ². Drugs. 2019 Apr;79(6):665-674. doi: 10.1007/s40265-019-01116-x.

115.	Gender disparity in HCC: Is it the fat and not the sex?
	Greten TF¹. J Exp Med. 2019 Apr 18. pii: jem.20190441. doi: 10.1084/jem.20190441. [Epub ahead of print]

116.	Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
	Bonafede MM¹, Korytowsky B², Singh P², Cai Q³, Cappell K³, Jariwala-Parikh K³, Sill B², Parikh ND⁴. J Gastrointest Cancer. 2019 Apr 23. doi: 10.1007/s12029-019-00230-z. [Epub ahead of print]

117.	Hepatocellular carcinoma surveillance: An evidence-based approach
	Harris PS¹, Hansen RM¹, Gray ME², Massoud OI², McGuire BM², Shoreibah MG³. World J Gastroenterol. 2019 Apr 7;25(13):1550-1559. doi: 10.3748/wjg.v25.i13.1550.

118.	Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013
	Shiels MS¹, Engels EA¹, Yanik EL², McGlynn KA¹, Pfeiffer RM¹, O'Brien TR¹. Cancer. 2019 Apr 12. doi: 10.1002/cncr.32129. [Epub ahead of print]

119.	Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
	Grigg SE¹, Sarri GL¹, Gow PJ², Yeomans ND¹. Aliment Pharmacol Ther. 2019 Apr 15. doi: 10.1111/apt.15253. [Epub ahead of print]

120.	The Epidemiology of Hepatocellular Carcinoma in the USA
	Kim HS¹, El-Serag HB^2,3. Curr Gastroenterol Rep. 2019 Apr 11;21(4):17. doi: 10.1007/s11894-019-0681-x.

121.

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Merle P¹, Blanc JF², Phelip JM³, Pelletier G⁴, Bronowicki JP⁵, Touchefeu Y⁶, Pageaux G⁷, Gerolami R⁸, Habersetzer F⁹, Nguyen-Khac E¹⁰, Casadei-Gardini A¹¹, Borbath I¹², Tran A¹³, Wege H¹⁴, Saad AS¹⁵, Colombo M¹⁶, Abergel A¹⁷, Richou C¹⁸, Waked I¹⁹, Yee NS²⁰, Molé A²¹, Attali P²¹, Le Boulicaut J²², Vasseur B²¹; RELIVE Investigators.

Collaborators (69) Lancet Gastroenterol Hepatol. 2019 Apr 3. pii: S2468-1253(19)30040-8. doi: 10.1016/S2468-1253(19)30040-8. [Epub ahead of print]

122.	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
	Llovet JM¹, Montal R², Villanueva A³. J Hepatol. 2019 Mar 31. pii: S0168-8278(19)30075-3. doi: 10.1016/j.jhep.2019.01.028. [Epub ahead of print]

123.	Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
	Assenat E^1,2, Pageaux GP³, Thézenas S⁴, Peron JM⁵, Bécouarn Y⁶, Seitz JF⁷, Merle P⁸, Blanc JF⁹, Bouché O¹⁰, Ramdani M¹¹, Poujol S⁴, de Forges H⁴, Ychou M⁴, Boige V¹². Br J Cancer. 2019 Apr 4. doi: 10.1038/s41416-019-0443-4. [Epub ahead of print]

124.	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy
	Brown ZJ^1,2, Greten TF^1,3, Heinrich B¹. Hepatology. 2019 Mar 30. doi: 10.1002/hep.30633. [Epub ahead of print]

125.	Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma
	Fetzer DT¹, Rodgers SK², Seow JH³, Dawkins AA⁴, Joshi G⁵, Gabriel H⁶, Kamaya A⁷. Radiol Clin North Am. 2019 May;57(3):563-583. doi: 10.1016/j.rcl.2019.01.004. Epub 2019 Feb 14.

126.	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy
	Brown ZJ^1,2, Greten TF^1,3, Heinrich B¹. Hepatology. 2019 Mar 30. doi: 10.1002/hep.30633. [Epub ahead of print]

127.	The 100 most influential manuscripts on hepatocellular carcinoma: a bibliometric analysis
	Hwang JW¹, Kim H², Lee DJ³. J Int Med Res. 2019 Mar 19:300060519835974. doi: 10.1177/0300060519835974. [Epub ahead of print]

128.	Multidisciplinary Approach to HCC Management: How Can This Be Done?
	Gadsden MM^1,2, Kaplan DE^3,4. Dig Dis Sci. 2019 Mar 18. doi: 10.1007/s10620-019-05593-8. [Epub ahead of print]

129.	Three risk factors for pulmonary metastasectomy in patients with hepatocellular carcinoma
	Nakamura A^1,2, Esaki M³, Nakagawa K⁴, Asakura K⁴, Kishi Y³, Nara S³, Shimada K³, Watanabe SI⁴. Gen Thorac Cardiovasc Surg. 2019 Feb 28. doi: 10.1007/s11748-019-01082-x. [Epub ahead of print]

130.	What Comes First: Treatment of Viral Hepatitis or Liver Cancer?
	Feld JJ¹, Krassenburg LAP^2,3. Dig Dis Sci. 2019 Mar 14. doi: 10.1007/s10620-019-05518-5. [Epub ahead of print]

131.	Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?
	Lange N^1,2, Dufour JF^3,4. Dig Dis Sci. 2019 Mar 12. doi: 10.1007/s10620-019-05515-8. [Epub ahead of print]

132.	Current State of Tumor Ablation Therapies
	Bailey CW¹, Sydnor MK Jr². Dig Dis Sci. 2019 Mar 12. doi: 10.1007/s10620-019-05514-9. [Epub ahead of print]

133.	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
	Owusu Sekyere S¹, Schlevogt B^1,2, Mettke F¹, Kabbani M¹, Deterding K¹, Wirth TC¹, Vogel A¹, Manns MP^1,3,4, Falk CS^1,5, Cornberg M^1,3, Wedemeyer H^1,3,4,6. Liver Cancer. 2019 Feb;8(1):41-65. doi: 10.1159/000490360. Epub 2018 Jul 18.

134.

Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond

Kudo M¹. World J Gastroenterol. 2019 Feb 21;25(7):789-807. doi: 10.3748/wjg.v25.i7.789.

135.

Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma

Dasanu CA^1,2. J Oncol Pharm Pract. 2019 Feb 19:1078155219830166. doi: 10.1177/1078155219830166. [Epub ahead of print]

136.	Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis
	Wiltberger G¹, Wu Y², Lange U³, Hau HM³, Tapper E², Krenzien F⁴, Atanasov G⁴, Benzing C⁴, Feldbrügge L⁴, Csizmadia E², Broschewitz J², Bartels M⁵, Seehofer D², Jonas S⁶, Berg T⁷, Hessel P⁸, Ascherl R⁹, Neumann UP¹, Pratschke J⁴, Robson SC², Schmelzle M⁴. Aliment Pharmacol Ther. 2019 Mar;49(6):779-788. doi: 10.1111/apt.15089.

137.	OPTN/SRTR 2017 Annual Data Report: Liver
	Kim WR^1,2, Lake JR^1,3, Smith JM^1,4, Schladt DP¹, Skeans MA¹, Noreen SM^5,6, Robinson AM^5,6, Miller E^5,6, Snyder JJ^1,7, Israni AK^1,7,8, Kasiske BL^1,8. Am J Transplant. 2019 Feb;19 Suppl 2:184-283. doi: 10.1111/ajt.15276.

138.	Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma
	Erstad DJ¹, Tanabe KK². Ann Surg Oncol. 2019 Feb 20. doi: 10.1245/s10434-019-07227-9. [Epub ahead of print]

139.	Patterns and Predictors of Mortality after Waitlist Dropout of Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
	Gorgen A^1,2, Rosales R¹, Sadler E², Beecroft R³, Knox J⁴, Dawson LA⁵, Ghanekar A^1,2, Grant D^1,2, Greig PD^1,2, Sapisochin G^1,2. Transplantation. 2019 Feb 18. doi: 10.1097/TP.0000000000002616. [Epub ahead of print]

140.	Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center
	Kuftinec GN¹, Levy R², Kieffer DA², Medici V². Ann Hepatol. 2018 Dec 13;18(1):177-186. doi: 10.5604/01.3001.0012.7910.

141.	Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease
	Bertot LC¹, Adams LA^1,2. Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29.

142.	Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature
	Rawla P¹, Thandra KC², Vellipuram A³, Ali CDM⁴. Contemp Oncol (Pozn). 2018;22(4):209-214. doi: 10.5114/wo.2018.82641. Epub 2018 Dec 31.

143.	Association of Intake of Whole Grains and Dietary Fiber With Risk of Hepatocellular Carcinoma in US Adults
	Yang W^1,2, Ma Y^2,3, Liu Y^2,4, Smith-Warner SA^5,6, Simon TG^7,8,9, Chong DQ¹⁰, Qi Q¹¹, Meyerhardt JA¹², Giovannucci EL^2,5,6, Chan AT^2,8,9, Zhang X². JAMA Oncol. 2019 Feb 21. doi: 10.1001/jamaoncol.2018.7159. [Epub ahead of print]

144.	Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence
	Johnson BW¹, Wright GP². Am J Surg. 2019 Mar;217(3):541-545. doi: 10.1016/j.amjsurg.2018.10.018. Epub 2018 Oct 16.

145.	Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience
	Wattenberg MM¹, Damjanov N^1,2, Kaplan DE^3,4. Cancer Med. 2019 Feb 20. doi: 10.1002/cam4.2015. [Epub ahead of print]

146.	The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis
	Ahmed O¹, Liu L¹, Gayed A¹, Baadh A¹, Patel M², Tasse J¹, Turba U¹, Arslan B¹. J Clin Exp Hepatol. 2019 Jan-Feb;9(1):50-55. doi: 10.1016/j.jceh.2018.02.006. Epub 2018 Feb 16.

147.	Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
	Personeni N^1,2, Pressiani T¹, Rimassa L¹. J Hepatocell Carcinoma. 2019 Jan 31;6:31-39. doi: 10.2147/JHC.S168953. eCollection 2019.

148.	Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
	Deeks ED¹. Target Oncol. 2019 Feb 14. doi: 10.1007/s11523-019-00622-y. [Epub ahead of print]

149.	Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review
	Desai A1, Sandhu S2, Lai JP3, Sandhu DS4. World J Hepatol. 2019 Jan 27;11(1):1-18. doi: 10.4254/wjh.v11.i1.1.

150.	More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation
	McCabe P¹, Gish RG², Cheung R³, Wong RJ⁴. J Clin Gastroenterol. 2019 Feb 12. doi: 10.1097/MCG.0000000000001187. [Epub ahead of print]

151.	Improved Graft Survival after Liver Transplantation for Recipients with Hepatitis C in the Direct-acting Antiviral Era
	Cotter TG¹, Paul S¹, Sandikçi B², Couri T³, Bodzin AS⁴, Little EC⁵, Sundaram V⁶, Charlton M¹. Liver Transpl. 2019 Feb 4. doi: 10.1002/lt.25424. [Epub ahead of print]

152.

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

Carrat F¹, Fontaine H², Dorival C³, Simony M⁴, Diallo A⁵, Hezode C⁶, De Ledinghen V⁷, Larrey D⁸, Haour G³, Bronowicki JP⁹, Zoulim F¹⁰, Asselah T¹¹, Marcellin P¹¹, Thabut D¹², Leroy V¹³, Tran A¹⁴, Habersetzer F¹⁵, Samuel D¹⁶, Guyader D¹⁷, Chazouilleres O¹⁸, Mathurin P¹⁹, Metivier S²⁰, Alric L²¹, Riachi G²², Gournay J²³, Abergel A²⁴, Cales P²⁵, Ganne N²⁶, Loustaud-Ratti V²⁷, D'Alteroche L²⁸, Causse X²⁹, Geist C³⁰, Minello A³¹, Rosa I³², Gelu-Simeon M³³, Portal I³⁴, Raffi F³⁵, Bourliere M³⁶, Pol S³⁷; French ANRS CO^{22 Hepather cohort. Lancet. 2019 Feb 11. pii: S0140-6736(18)32111-1. doi: 10.1016/S0140-6736(18)32111-1. [Epub ahead of print]}

153.	Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
	Jain A¹, Miller D², Schreibman I³, Riley TR 3rd³, Krok KL³, Dohi T², Sharma R⁴, Kadry Z². Hepatol Int. 2019 Jan 24. doi: 10.1007/s12072-019-09930-x. [Epub ahead of print]

154.	Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis
	Shlomai A¹,², Leshno M³, Goldstein DA⁴,⁵. PLoS One. 2018 Nov 8;13(11):e0207132. doi: 10.1371/journal.pone.0207132. eCollection 2018.

155.	Regorafenib: a promising treatment for hepatocellular carcinoma
	Cerrito L¹, Ponziani FR¹, Garcovich M¹, Tortora A¹, Annicchiarico BE¹, Pompili M¹, Siciliano M¹, Gasbarrini A¹. Expert Opin Pharmacother. 2018 Oct 20:1-8. doi: 10.1080/14656566.2018.1534956. [Epub ahead of print]

156.	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased ?-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
	-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial~Zhu AX¹, Kang YK², Yen CJ³, Finn RS⁴, Galle PR⁵, Llovet JM⁶, Assenat E⁷, Bran

157.	Medical treatment of advanced hepatocellular carcinoma patients: the issue is not the right drug, but the right patient
	Porta C¹, Broglia C², Negri F³. Hepatology. 2019 Jan 25. doi: 10.1002/hep.30521. [Epub ahead of print]

158.	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms
	Geh D¹, Rana FA², Reeves HL¹,³. J Hepatocell Carcinoma. 2019 Jan 14;6:23-30. doi: 10.2147/JHC.S159581. eCollection 2019.

159.	Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes
	Franco RA¹, Fan Y², Jarosek S², Bae S³, Galbraith J⁴. Am J Prev Med. 2018 Nov;55(5S1):S40-S48. doi: 10.1016/j.amepre.2018.05.030.

160.	Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?
	Cabibbo G¹, Rossi M¹, Celsa C¹, Maida M², Cammà C¹. Recenti Prog Med. 2018 Dec;109(12):605-608. doi: 10.1701/3082.30746.

161.	Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association with Outcomes: Single-Center Experience
	Cowell E¹, Patel K², Heczey A³, Finegold M², Venkatramani R³, Wu H², López-Terrada D⁴, Miloh T⁵. J Pediatr Gastroenterol Nutr. 2019 Jan 21. doi: 10.1097/MPG.0000000000002285. [Epub ahead of print]

162.	National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States
	Lee BP¹, Vittinghoff E², Dodge JL³, Cullaro G¹, Terrault NA¹. JAMA Intern Med. 2019 Jan 22. doi: 10.1001/jamainternmed.2018.6536. [Epub ahead of print]

163.	Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis
	Kaplan DE¹, Serper M², Mehta R³, Fox R⁴, John B⁵, Aytaman A⁶, Baytarian M⁷, Hunt K⁸, Albrecht J⁹, Njei B³, Taddei TH³; VOCAL Study Group. Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30053-8. doi: 10.1053/j.gastro.2019.01.026. [Epub ahead of print]

164.	Ramucirumab and its use in the treatment of hepatocellular carcinoma
	Turkes F¹, Chau I¹. Future Oncol. 2019 Jan 15. doi: 10.2217/fon-2018-0822. [Epub ahead of print]

165.	Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality
	Hester D¹, Golabi P², Paik J², Younossi I³, Mishra A¹, Younossi ZM¹,². J Clin Gastroenterol. 2019 Jan 21. doi: 10.1097/MCG.0000000000001172. [Epub ahead of print]

166.	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma
	Schulte L¹, Scheiner B², Voigtländer T¹, Koch S³, Schweitzer N¹, Marhenke S¹, Ivanyi P⁴, Manns MP¹, Rodt T⁵, Hinrichs JB⁵, Weinmann A³, Pinter M², Vogel A¹, Kirstein MM¹. Liver Int. 2019 Jan 21. doi: 10.1111/liv.14048. [Epub ahead of print]

167.

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30057-5. doi: 10.1053/j.gastro.2019.01.027. [Epub ahead of print]

168.	Waist Circumference Might Be a Predictor of Primary Liver Cancer: A Population-Based Cohort Study
	Wei L¹, Li N¹, Wang G², Feng X¹, Lyu Z¹, Li X¹, Wen Y¹, Chen Y¹, Chen H¹, Chen S³, Wu S³, Dai M¹, He J¹,⁴. Front Oncol. 2018 Dec 12;8:607. doi: 10.3389/fonc.2018.00607. eCollection 2018.

169.	Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
	de Jesus VHF¹, Dettino ALA¹. J Hepatocell Carcinoma. 2018 Oct 3;5:87-90. doi: 10.2147/JHC.S171396. eCollection 2018.

170.	Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape
	Mody K¹, Abou-Alfa GK²,³. Curr Treat Options Oncol. 2019 Jan 11;20(2):3. doi: 10.1007/s11864-019-0601-1.

171.	One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation
	Robinson A¹, Ohri A¹, Liu B¹, Bhuket T¹, Wong RJ². World J Hepatol. 2018 Dec 27;10(12):956-965. doi: 10.4254/wjh.v10.i12.956.

172.	Child-Pugh Classification: Time to Abandon?
	Kok B¹, Abraldes JG¹. Semin Liver Dis. 2019 Jan 11. doi: 10.1055/s-0038-1676805. [Epub ahead of print]

173.	Statin use after diagnosis of hepatocellular carcinoma and patient survival: findings from a retrospective cohort study
	Thrift AP¹, Natarajan Y², Liu Y³, El-Serag HB². Clin Gastroenterol Hepatol. 2019 Jan 5. pii: S1542-3565(19)30019-9. doi: 10.1016/j.cgh.2018.12.046. [Epub ahead of print]

174.	Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
	Apostolidis L¹,², Pfeiffenberger J³,², Gotthardt D³,², Radeleff B⁴,², Mehrabi A⁵,², Schemmer P⁵,⁶,², Jäger D¹,², Schirmacher P⁷,², Stremmel W³,², Schulze-Bergkamen H¹,⁸,², Springfeld C¹,², Weiss KH³,². Gastrointest Tumors. 2018 Sep;5(1-2):38-46. doi: 10.1159/000487635. Epub 2018 Apr 11.

175.	Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden
	Dakhoul L¹, Gawrieh S¹, Jones KR¹, Ghabril M¹, McShane C², Orman E¹, Vilar-Gomez E¹, Chalasani N¹, Nephew L¹. Hepatol Commun. 2018 Dec 3;3(1):52-62. doi: 10.1002/hep4.1277. eCollection 2019 Jan.

176.	Increasing Awareness on Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma in the United States
	Frenette CT¹. Hepatol Commun. 2019 Jan 1;3(1):5-7. doi: 10.1002/hep4.1299. eCollection 2019 Jan.

177.	Live Donor Liver Transplantation for Patients with Hepatocellular Carcinoma Offers Increased Survival vs. Deceased Donation
	Goldaracena N¹, Gorgen A¹, Doyle A², Hansen BE³, Tomiyama K¹, Zhang W¹, Ghanekar A¹, Lilly L², Cattral M¹, Galvin Z², Selzner M¹, Bhat M², Selzner N², McGilvray I¹, Greig PD¹, Grant DR¹, Sapisochin G⁴. J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30003-0. doi: 10.1016/j.jhep.2018.12.029. [Epub ahead of print]

178.	Sorafenib: key lessons from over 10 years of experience
	Escudier B¹, Worden F², Kudo M³. Expert Rev Anticancer Ther. 2018 Dec 21:1-13. doi: 10.1080/14737140.2019.1559058. [Epub ahead of print]

179.

Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study

Baumeister SE¹, Schlesinger S², Aleksandrova K³, Jochem C⁴, Jenab M⁵, Gunter MJ⁵, Overvad K⁶, Tjønneland A⁷, Boutron-Ruault MC⁸, Carbonnel F⁹, Fournier A⁸, Kühn T¹⁰, Kaaks R¹⁰, Pischon T¹¹, Boeing H³, Trichopoulou A¹², Bamia C¹², La Vecchia C¹³, Masala G¹⁴, Panico S¹⁵, Fasanelli F¹⁶, Tumino R¹⁷, Grioni S¹⁸, de Mesquita BB¹⁹, Vermeulen R²⁰, May AM²¹, Borch KB²², Oyeyemi SO²², Ardanaz E²³, Rodríguez-Barranco M²⁴, López MDC²⁵, Felez-Nobrega M²⁶, Sonestedt E²⁷, Ohlsson B²⁸, Hemmingsson O²⁹, Werner M³⁰, Perez-Cornago A³¹, Ferrari P⁵, Stepien M⁵, Freisling H⁵, Tsilidis KK³¹, Ward H³², Riboli E³², Weiderpass E³³, Leitzmann MF⁴. J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633-3. doi: 10.1016/j.jhep.2018.12.014. [Epub ahead of print]

180.	Finally, a Minimally Invasive Option for Intrahepatic Inferior Vena Cava Invasion by Hepatocellular Carcinoma
	Soule E¹, Matteo J¹. Gastrointest Tumors. 2018 Sep;5(1-2):54-61. doi: 10.1159/000491694. Epub 2018 Aug 17.

181.	Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis
	Moran A¹, Ramos LF¹, Picado O¹, Pendola F², Sleeman D³,⁴, Dudeja V¹,⁴, Merchant N¹,⁴, Yakoub D¹,⁴. J Surg Oncol. 2018 Dec 21. doi: 10.1002/jso.25338. [Epub ahead of print]

182.	The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis
	Huang P¹,², Liu M¹, Zang F¹, Yao Y¹, Yue M³, Wang J⁴, Fan H¹, Zhuo L¹, Wu J¹, Xia X⁵, Feng Y⁵, Yu R¹,². Carcinogenesis. 2018 Dec 31;39(12):1497-1505. doi: 10.1093/carcin/bgy099.

183.	Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma
	Hosui A¹, Kimura E², Abe S³, Tanimoto T⁴, Onishi K⁵, Kusumoto Y⁶, Sueyoshi Y⁷, Matsumoto K⁸, Hirao M⁹, Yamada T¹⁰, Hiramatsu N¹¹. Nutrients. 2018 Dec 10;10(12). pii: E1955. doi: 10.3390/nu10121955.

184.	Changing Landscape of Liver Cancer in California: A Glimpse Into the Future of Liver Cancer in the United States
	Han SS¹,²,³, Kelly SP⁴, Li Y¹,⁵, Yang B¹, Nguyen M¹,², So S¹,⁶, Rosenberg PS⁴, Hsing AW¹,³,⁷. J Natl Cancer Inst. 2018 Dec 13. doi: 10.1093/jnci/djy180. [Epub ahead of print]

185.	The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report
	Han Z¹, He Z, Wang C, Wang Q. Medicine (Baltimore). 2018 Dec;97(49):e13388. doi: 10.1097/MD.0000000000013388.

186.	Trends in liver cancer mortality in the United States: Dual burden among foreign- and US-born persons
	Endeshaw M¹, Hallowell BD¹, Razzaghi H¹, Senkomago V¹, McKenna MT², Saraiya M¹. Cancer. 2018 Nov 27. doi: 10.1002/cncr.31869. [Epub ahead of print]

187.	Promising practices for the prevention of liver cancer: a review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program
	Momin B¹, Millman AJ², Nielsen DB³, Revels M³, Steele CB⁴. Cancer Causes Control. 2018 Dec 1. doi: 10.1007/s10552-018-1094-0. [Epub ahead of print]

188.	Analysis of Local Control and Pain Control Following Spine Stereotactic Radiosurgery Reveals Inferior Outcomes for Hepatocellular Carcinoma compared to other Radioresistant Histologies
	McGee HM¹, Carpenter T², Ozbek U³, Kirkwood K⁴, Tzu-Chi T¹, Blacksburg S⁵, Germano IM⁶, Green S¹, Buckstein M⁷. Pract Radiat Oncol. 2018 Dec 10. pii: S1879-8500(18)30346-1. doi: 10.1016/j.prro.2018.11.009. [Epub ahead of print]

189.	The need for complete population-based studies on the etiology of liver disease
	Pinheiro PS¹. Hepatology. 2018 Dec 6. doi: 10.1002/hep.30415. [Epub ahead of print]

190.	Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States
	Ispas S¹, So S¹, Toy M². J Community Health. 2018 Dec 11. doi: 10.1007/s10900-018-00604-7. [Epub ahead of print]

191.

Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?

Piñero F¹,²,³, Rubinstein F⁴, Marciano S⁵, Fernández N⁶, Silva J⁷, Zambelo Y⁸, Anders M⁹, Zerega A¹⁰, Ridruejo E¹¹,¹², Miguez C¹³, Ameigeiras B¹⁴, D'Amico C¹⁵, Gaite L¹⁶, Bermúdez C⁵, Rosales C⁷, Romero G¹³, McCormack L⁹, Reggiardo V⁸, Colombato L⁶, Gadano A⁵, Silva M¹¹. Dig Dis Sci. 2018 Dec 3. doi: 10.1007/s10620-018-5390-z. [Epub ahead of print]

192.	New Systemic Treatments in Advanced Hepatocellular Carcinoma.
	Sanduzzi-Zamparelli M¹, Díaz-Gonzalez Á¹, Reig M¹,². Liver Transpl. 2018 Oct 13. doi: 10.1002/lt.25354. [Epub ahead of print]

193.	Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View
	Tiniakos DG¹,², Maurício J³, Reeves HL³. Adv Exp Med Biol. 2018;1032:55-69. doi: 10.1007/978-3-319-98788-0_4.

194.	Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
	Tovoli F¹, Negrini G¹, Benevento F¹, Faggiano C¹, Goio E¹, Granito A¹. Hepat Oncol. 2018 Feb 8;5(1):HEP01. doi: 10.2217/hep-2017-0020. eCollection 2018 Jan.

195.	What FLT3 inhibitor holds the greatest promise?
	Stone RM¹. Best Pract Res Clin Haematol. 2018 Dec;31(4):401-404. doi: 10.1016/j.beha.2018.09.008. Epub 2018 Sep 20.

196.	Stereotactic radiofrequency ablation of hepatocellular carcinoma - A histopathological study in explanted livers
	Bale R¹, Schullian P¹, Eberle G¹, Putzer D¹, Zoller H², Schneeberger S³, Manzl C⁴, Moser P⁵, Oberhuber G⁵. Hepatology. 2018 Dec 5. doi: 10.1002/hep.30406. [Epub ahead of print]

197.	Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist
	Quaglia A¹. J Hepatocell Carcinoma. 2018 Nov 8;5:99-108. doi: 10.2147/JHC.S159808. eCollection 2018.

198.	Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury?
	Teschke R¹, Wolff A², Eickhoff A¹, Danan G³. JGH Open. 2018 Jun 6;2(4):152-157. doi: 10.1002/jgh3.12057. eCollection 2018 Aug.

199.	Hepatitis B virus-related hepatocellular carcinoma presenting at an advanced stage: is it preventable?
	Mules T¹, Gane E¹, Lithgow O¹, Bartlett A¹, McCall J¹. N Z Med J. 2018 Nov 30;131(1486):27-35.

200.	Advances in Genomic Hepatocellular Carcinoma Research
	Huang W¹,²,³, Skanderup AJ¹, Lee CG²,³,⁴,⁵. Gigascience. 2018 Dec 6. doi: 10.1093/gigascience/giy135. [Epub ahead of print]

201.	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
	Kang SH¹,², Cho H¹, Cho EJ¹, Lee JH¹, Yu SJ¹, Kim YJ¹, Yi NJ³, Lee KW³, Suh KS³, Yoon JH¹. J Korean Med Sci. 2018 Oct 12;33(45):e283. doi: 10.3346/jkms.2018.33.e283. eCollection 2018 Nov 5.

202.	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
	Dhanasekaran R¹, Nault JC², Roberts LR³, Zucman-Rossi J⁴. Gastroenterology. 2018 Nov 4. pii: S0016-5085(18)35210-7. doi: 10.1053/j.gastro.2018.11.001. [Epub ahead of print]

203.	Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma
	Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. J Comput Assist Tomogr. 2018 Nov 6. doi: 10.1097/RCT.0000000000000807. [Epub ahead of print]

204.	An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib
	Ielasi L¹, Sansone V¹, Granito A¹, Benevento F¹, De Lorenzo S², Tovoli F³. Drugs Today (Barc). 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176.

205.	Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma
	Chen S¹, Yu W², Zhang K¹, Liu W¹. BMC Cancer. 2018 Nov 19;18(1):1131. doi: 10.1186/s12885-018-5081-3.

206.	Systemic therapy for hepatocellular carcinoma: beyond sorafenib
	Boland P¹, Wu J². Chin Clin Oncol. 2018 Oct;7(5):50. doi: 10.21037/cco.2018.10.10.

207.	Gut microbiota, fatty liver disease, and hepatocellular carcinoma
	Chu H¹,², Williams B², Schnabl B²,³. Liver Res. 2018 Mar;2(1):43-51. doi: 10.1016/j.livres.2017.11.005. Epub 2018 Feb 21.

208.	Future Trends in Demand for Liver Transplant: Birth-Cohort Effects among Patients with NASH and HCC
	Shingina A¹,², DeWitt PE³, Dodge JL²,⁴, Biggins SW¹,², Gralla J⁵, Sprague D⁶, Bambha K¹,². Transplantation. 2018 Nov 16. doi: 10.1097/TP.0000000000002497. [Epub ahead of print]

209.	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis
	McNamara MG¹, Slagter AE², Nuttall C³, Frizziero M³, Pihlak R⁴, Lamarca A³, Tariq N⁴, Valle JW⁴, Hubner RA³, Knox JJ⁵, Amir E⁵. Eur J Cancer. 2018 Oct 29;105:1-9. doi: 10.1016/j.ejca.2018.09.031. [Epub ahead of print]

210.	Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers
	Finkelmeier F¹, Czauderna C², Perkhofer L³, Ettrich TJ³, Trojan J⁴, Weinmann A², Marquardt JU², Vermehren J⁴, Waidmann O⁴. J Cancer Res Clin Oncol. 2018 Oct 29. doi: 10.1007/s00432-018-2780-8. [Epub ahead of print]

211.	Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
	Flynn MJ¹, Sayed AA²,³, Sharma R⁴, Siddique A⁴, Pinato DJ⁴. Hepatology. 2018 Nov 1. doi: 10.1002/hep.30337. [Epub ahead of print]

212.	Functional MRI and delay discounting in patients infected with hepatitis C
	McCready H¹,²,³, Kohno M¹,²,³, Kolessar M¹,⁴, Dennis L¹,²,³, Kriz D¹, Luber H¹, Anderson R¹, Chang M¹,⁵, Sasaki A¹,⁵, Flora K⁶, Vandenbark A¹,⁷,⁸, Mitchell SH²,³,⁹, Loftis JM¹,³,⁵, Hoffman WF¹,²,³,¹⁰, Huckans M¹¹,¹²,¹³,¹⁴. J Neurovirol. 2018 Oct 8. doi: 10.1007/s13365-018-0670-0. [Epub ahead of print]

213.	Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques
	Young S¹, Craig P², Golzarian J². Eur Radiol. 2018 Oct 22. doi: 10.1007/s00330-018-5782-7. [Epub ahead of print]

214.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies

Harding JJ¹, Nandakumar S², Armenia J³, Khalil DN⁴, Albano M⁵, Ly M⁵, Shia J⁶, Hechtman JF⁶, Kundra R⁷, El Dika I⁸, Do RK⁹, Sun Y¹⁰, Kingham TP¹¹, D'Angelica MI¹², Berger MF⁷, Hyman DM¹³, Jarnagin WR¹², Klimstra DS¹⁴, Janjigian YY¹⁵, Solit DB¹⁰, Schultz N¹⁶, Abou-Alfa GK⁸. Clin Cancer Res. 2018 Oct 29. pii: clincanres.2293.2018. doi: 10.1158/1078-0432.CCR-18-2293. [Epub ahead of print]

215.	Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy
	Keane FK¹, Hong TS², Zhu AX³. Semin Radiat Oncol. 2018 Oct;28(4):332-341. doi: 10.1016/j.semradonc.2018.06.006.

216.	The Impact of HCV Eradication by Direct-acting Antivirals on the Transition of Precancerous Hepatic Nodules to HCC: a Prospective Observational Study
	Toyoda H¹, Kumada T¹, Tada T¹, Mizuno K¹, Sone Y², Akita T³, Tanaka J³, Johnson PJ⁴. Liver Int. 2018 Oct 12. doi: 10.1111/liv.13987. [Epub ahead of print]

217.	Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients
	Guss D¹, Sherigar J¹, Mohanty SR¹. Gastroenterology Res. 2018 Oct;11(5):333-339. doi: 10.14740/gr1074w. Epub 2018 Oct 1.

218.	Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma
	Toesca DAS¹, Barry A², Sapisochin G³, Beecroft R⁴, Dawson L², Owen D⁵, Mouli S⁶, Lewandowski R⁶, Salem R⁶, Chang DT⁷. Semin Radiat Oncol. 2018 Oct;28(4):295-308. doi: 10.1016/j.semradonc.2018.08.001

219.	Systemic treatment for hepatocellular carcinoma
	Aggarwal M¹,², Arain A¹,², Jin Z¹,². Chronic Dis Transl Med. 2018 Sep 17;4(3):148-155. doi: 10.1016/j.cdtm.2018.08.003. eCollection 2018 Sep.

220.	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
	Marisi G¹, Cucchetti A², Ulivi P¹, Canale M¹, Cabibbo G³, Solaini L², Foschi FG⁴, De Matteis S¹, Ercolani G², Valgiusti M⁵, Frassineti GL⁵, Scartozzi M⁶, Casadei Gardini A⁵. World J Gastroenterol. 2018 Sep 28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152.

221.	Genetic Variations Linked to Hepatocellular Carcinoma: Personalized Medicine Takes a Step Forward
	Agarwal PD¹, Lucey MR². Am J Gastroenterol. 2018 Oct 5. doi: 10.1038/s41395-018-0260-z. [Epub ahead of print]

222.	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma
	Mak LY¹, Cruz-Ramón V¹, Chinchilla-López P¹, Torres HA¹, LoConte NK¹, Rice JP¹, Foxhall LE¹, Sturgis EM¹, Merrill JK¹, Bailey HH¹, Méndez-Sánchez N¹, Yuen MF¹, Hwang JP¹. Am Soc Clin Oncol Educ Book. 2018 May 23;(38):262-279. doi: 10.1200/EDBK_200939.

223.	Nivolumab for the treatment of hepatocellular carcinoma
	Finkelmeier F¹, Waidmann O¹, Trojan J¹. Expert Rev Anticancer Ther. 2018 Oct 10. doi: 10.1080/14737140.2018.1535315. [Epub ahead of print]

224.	The impact of antiviral therapy on hepatocellular carcinoma epidemiology
	Colombo M¹,¹, Lleo A²,³,²,³. Hepat Oncol. 2018 May 10;5(1):HEP03. doi: 10.2217/hep-2017-0024. eCollection 2018 Jan.

225.	Targeted and Immune-based Therapies for Hepatocellular Carcinoma
	Greten TF¹, Lai CW², Li G³, Staveley-O'Carroll KF⁴. Gastroenterology. 2018 Oct 1. pii: S0016-5085(18)35082-0. doi: 10.1053/j.gastro.2018.09.051. [Epub ahead of print]

226.	Distinguishing Tumor from Bland Portal Vein Thrombus in Liver Transplant Candidates with Hepatocellular Carcinoma:The "A-VENA" Criteria
	Sherman CB¹, Behr S², Dodge JL³, Roberts JP³, Yao FY¹,³, Mehta N¹. Liver Transpl. 2018 Sep 24. doi: 10.1002/lt.25345. [Epub ahead of print]

227.	Burden of Liver Diseases in the World
	Asrani SK¹, Devarbhavi H², Eaton J³, Kamath PS⁴. J Hepatol. 2018 Sep 25. pii: S0168-8278(18)32388-2. doi: 10.1016/j.jhep.2018.09.014. [Epub ahead of print]

228.	Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
	Simon TG¹,²,³, Ma Y⁴,⁵, Ludvigsson JF⁶,⁷,⁸, Chong DQ⁹, Giovannucci EL⁵,¹⁰,¹¹, Fuchs CS¹², Meyerhardt JA¹³, Corey KE¹,²,⁴, Chung RT¹,², Zhang X⁵, Chan AT²,³,⁵,¹⁴,¹⁵. JAMA Oncol. 2018 Oct 4. doi: 10.1001/jamaoncol.2018.4154. [Epub ahead of print]

229.	The Role of Angiogenesis in Hepatocellular Carcinoma
	Morse MA¹, Sun W², Kim R³, He AR⁴, Abada PB⁵, Mynderse M⁶, Finn RS⁷. Clin Cancer Res. 2018 Oct 1. pii: clincanres.1254.2018. doi: 10.1158/1078-0432.CCR-18-1254. [Epub ahead of print]

230.	Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study
	Sacco R¹, Granito A², Bargellini I³, Zolfino T⁴, Saitta C⁵, Marzi L⁶, Tapete G¹, Bresci G¹, Marinelli S², Tovoli F², Attardo S⁷, Rossi M⁷, Urbani L⁸, Marchi S⁹, Buccianti P⁸, Cabibbo G⁷. Future Oncol. 2018 Aug 9. doi: 10.2217/fon-2018-0281. [Epub ahead of print]

231.	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
	Personeni N¹,², Pressiani T¹, Santoro A¹,², Rimassa L¹. Drugs Context. 2018 Jun 27;7:212533. doi: 10.7573/dic.212533. eCollection 2018. Drugs Context. 2018 Jun 27;7:212533. doi: 10.7573/dic.212533. eCollection 2018.

232.	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
	Finn RS¹, Merle P², Granito A³, Huang YH⁴, Bodoky G⁵, Pracht M⁶, Yokosuka O⁷, Rosmorduc O⁸, Gerolami R⁹, Caparello C¹⁰, Cabrera R¹¹, Chang C¹², Sun W¹³, LeBerre MA¹⁴, Baumhauer A¹⁵, Meinhardt G¹⁶, Bruix J¹⁷. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.

233.	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma
	Tovoli F¹,¹, Renzulli M²,², Granito A¹,¹, Golfieri R²,², Bolondi L¹,¹. Hepat Oncol. 2017 Oct;4(4):129-137. doi: 10.2217/hep-2017-0018. Epub 2017 Nov 17.

234.	A three-pronged epigenetic approach to the treatment of hepatocellular carcinoma
	Hlady RA¹, Robertson KD¹. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30133. [Epub ahead of print]

235.	Risk of Hepatocellular Cancer in Patients with Non-alcoholic Fatty Liver Disease
	Kanwal F¹, Kramer JR², Mapakshi S², Natarajan Y³, Chayanupatkul M³, Richardson PA², Li L⁴, Desiderio R², Thrift AP⁵, Asch SM⁶, Chu J⁷, El-Serag HB⁸. Gastroenterology. 2018 Aug 22. pii: S0016-5085(18)34889-3. doi: 10.1053/j.gastro.2018.08.024. [Epub ahead of print]

236.	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
	Chau I¹, Park JO², Ryoo BY³, Yen CJ⁴, Poon R⁵, Pastorelli D⁶, Blanc JF⁷, Kudo M⁸, Pfiffer T⁹, Hatano E¹⁰, Chung HC¹¹, Kopeckova K¹², Phelip JM¹³, Brandi G¹⁴, Ohkawa S¹⁵, Li CP¹⁶,¹⁷, Okusaka T¹⁸, Hsu Y¹⁹, Abada PB²⁰, Zhu AX²¹. Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29.

237.	Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance
	Simmons OL¹, Feng Y², Parikh ND², Singal AG³. Clin Gastroenterol Hepatol. 2018 Jul 26. pii: S1542-3565(18)30755-9. doi: 10.1016/j.cgh.2018.07.029. [Epub ahead of print]

238.	Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C
	Ioannou GN¹, Green PK², Beste LA³, Mun EJ⁴, Kerr KF⁵, Berry K². J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287-6. doi: 10.1016/j.jhep.2018.07.024. [Epub ahead of print]

239.	Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma
	Mehta AS¹, Lau DT², Wang M¹, Islam A², Nasir B², Javaid A², Poongkunran M², Block TM³,⁴. PLoS One. 2018 Aug 31;13(8):e0203149. doi: 10.1371/journal.pone.0203149. eCollection 2018.

240.	Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening
	Robinson A¹, Tavakoli H¹, Liu B¹, Bhuket T¹, Wong RJ¹. Hepatol Commun. 2018 Aug 28;2(9):1147-1155. doi: 10.1002/hep4.1236. eCollection 2018 Sep.

241.	Prevention of hepatocellular carcinoma with antiviral therapy
	Di Bisceglie AM¹. S Afr Med J. 2018 Aug 8;108(8b):47-50. doi: 10.7196/SAMJ.2018.v108i8b.13501.

242.	Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status
	Sarpel U, Heskel M, Spivack JH, Feferman Y, Ang C, Gany F. J Health Care Poor Underserved. 2018;29(3):1123-1134. doi: 10.1353/hpu.2018.0083.

243.	Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases
	Stine JG¹, Wentworth BJ², Zimmet A², Rinella ME³, Loomba R⁴, Caldwell SH¹, Argo CK¹. Aliment Pharmacol Ther. 2018 Aug 22. doi: 10.1111/apt.14937. [Epub ahead of print]

244.	Precision oncology in liver cancer
	Sullivan KM¹, Kenerson HL¹, Pillarisetty VG¹, Riehle KJ¹, Yeung RS¹. Ann Transl Med. 2018 Jul;6(14):285. doi: 10.21037/atm.2018.06.14.

245.	Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis
	Lewis RH¹, Glazer ES¹,², Bittenbinder DM¹, O'Brien T³, Deneve JL¹,², Shibata D¹,², Behrman SW¹, Vanatta JM⁴, Satapathy SK⁵, Dickson PV⁶,⁷. J Gastrointest Cancer. 2018 Aug 16. doi: 10.1007/s12029-018-0152-x. [Epub ahead of print]

246.	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA
	Hechtman JF¹, Abou Alfa GK², Stadler ZK², Mandelker DL³, Roehrl MHA³, Zehir A³, Vakiani E³, Middha S³, Klimstra DS⁴, Shia J⁵. Hum Pathol. 2018 Aug 16. pii: S0046-8177(18)30308-3. doi: 10.1016/j.humpath.2018.08.004. [Epub ahead of print]

247.

Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis

Masetti C¹, Lionetti R², Lupo M³, Siciliano M⁴, Giannelli V⁵, Ponziani FR⁶, Teti E⁷, Dell'Unto C⁸, Francioso S¹, Brega A¹, Montalbano M², Visco-Comandini U², Taibi C², Galati G⁸, Vespasiani Gentilucci U⁸, Picardi A⁸, Andreoni M⁷, Pompili M⁶, Pellicelli AM⁵, D'Offizi G², Gasbarrini A⁴, De Santis A³, Angelico M¹. J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12982. [Epub ahead of print]

248.	Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma
	Cotton RT¹, Tran Cao HS², Rana AA¹, Sada YH³,⁴, Axelrod DA⁵, Goss JA¹, Wilson MA⁶, Curley SA², Massarweh NN²,⁴. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30128. [Epub ahead of print]

249.	Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA
	Ashhab AA¹, Rodin H², Powell J¹, Debes JD¹,³. Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001212. [Epub ahead of print]

250.	Cancer Site-Specific Disparities in New York, Including the 1945-1965 Birth Cohort's Impact on Liver Cancer Patterns
	Pinheiro PS¹,², Callahan KE³, Boscoe FP⁴,⁵, Balise RR⁶,², Cobb TR³, Lee DJ⁶,⁷, Kobetz E².Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):917-927. doi: 10.1158/1055-9965.EPI-18-0194. Epub 2018 Jul 19.

251.	Cardiac Events Within the 30-Day Postoperative Period Is Associated With Increased 1-Year Mortality Among Deceased-Donor Liver Transplant Recipients
	James TW¹, Shay JES, Furfaro D, Ozseker B, Russell SD, Pustavoitau A, Rizkalla N, Saberi B, Philosophe B, Cameron AM, Gurakar A. Exp Clin Transplant. 2018 Aug 6. doi: 10.6002/ect.2017.0276. [Epub ahead of print]

252.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Abou-Alfa GK¹,², Qin S³, Ryoo BY⁴, Lu SN⁵,⁶, Yen CJ⁷, Feng YH⁸, Lim HY⁹, Izzo F¹⁰, Colombo M¹¹, Sarker D¹², Bolondi L¹³, Vaccaro G¹⁴, Harris WP¹⁵, Chen Z¹⁶, Hubner RA¹⁷, Meyer T¹⁸, Sun W¹⁹, Harding JJ¹,², Hollywood EM¹, Ma J¹, Wan PJ¹, Ly M¹, Bomalaski J²⁰, Johnston A²⁰, Lin CC²¹, Chao Y²², Chen LT⁶,²³,²⁴. Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.

253.	Review article: systemic treatment of hepatocellular carcinoma
	Pinter M¹,², Peck-Radosavljevic M³. Aliment Pharmacol Ther. 2018 Jul 23. doi: 10.1111/apt.14913. [Epub ahead of print]

254.	Molecular therapies and precision medicine for hepatocellular carcinoma
	Llovet JM¹,², Montal R³, Sia D⁴, Finn RS⁵. Nat Rev Clin Oncol. 2018 Jul 30. doi: 10.1038/s41571-018-0073-4. [Epub ahead of print]

255.	Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma
	Baxter MA¹, Glen H¹, Evans TR¹,². Future Oncol. 2018 May 22. doi: 10.2217/fon-2017-0689. [Epub ahead of print]

256.	Emerging therapies in advanced hepatocellular carcinoma
	Medavaram S¹, Zhang Y¹. Exp Hematol Oncol. 2018 Aug 3;7:17. doi: 10.1186/s40164-018-0109-6. eCollection 2018.

257.	Ultrasound for HCC Surveillance: Still Looking for the Fortune Teller
	Foerster F¹, Galle PR¹. Liver Transpl. 2018 Jul 18. doi: 10.1002/lt.25309. [Epub ahead of print]

258.	Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma
	Nakamura M¹, Xu C², Diack C³, Ohishi N¹, Lee RM², Iida S¹, Kawanishi T¹, Ohtomo T⁴, Abou-Alfa GK⁵, Chen YC². Br J Clin Pharmacol. 2018 May;84(5):944-951. doi: 10.1111/bcp.13530. Epub 2018 Mar 9.

259.	Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States
	Kim D¹, Li AA², Perumpail BJ³, Gadiparthi C⁴, Kim W⁵, Cholankeril G¹, Glenn JS¹, Harrison SA⁶, Younossi ZM⁷, Ahmed A¹. Hepatology. 2018 Jul 16. doi: 10.1002/hep.30161. [Epub ahead of print]

260.	Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance
	Tong MJ¹,², Theodoro CF³, Salvo RT¹. J Dig Dis. 2018 Jun 11. doi: 10.1111/1751-2980.12615. [Epub ahead of print]

261.	Treatment options after sorafenib failure in patients with hepatocellular carcinoma
	Dika IE¹, Abou-Alfa GK¹,². Clin Mol Hepatol. 2017 Dec;23(4):273-279. doi: 10.3350/cmh.2017.0108. Epub 2017 Nov 20.

262.	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma
	DeLeon TT¹, Ahn DH¹, Bogenberger JM¹, Anastasiadis PZ², Arora M¹, Ramanathan RK¹, Aqel BA³, Vasmatzis G⁴, Truty MJ⁵, Oklu R⁶, Bekaii-Saab TS¹, Borad MJ¹. Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20.

263.	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
	Harding JJ¹,¹, Abu-Zeinah G¹, Chou JF¹, Owen DH¹, Ly M¹, Lowery MA¹,¹, Capanu M¹, Do R¹,¹, Kemeny NE¹,¹, O'Reilly EM¹,¹, Saltz LB¹,¹, Abou-Alfa GK¹,¹. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

264.	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
	Abou-Alfa GK¹, Meyer T¹, Cheng AL¹, El-Khoueiry AB¹, Rimassa L¹, Ryoo BY¹, Cicin I¹, Merle P¹, Chen Y¹, Park JW¹, Blanc JF¹, Bolondi L¹, Klümpen HJ¹, Chan SL¹, Zagonel V¹, Pressiani T¹, Ryu MH¹, Venook AP¹, Hessel C¹, Borgman-Hagey AE¹, Schwab G¹, Kelley RK¹. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.

265.	Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?
	Baffy G¹. Adv Exp Med Biol. 2018;1061:63-77. doi: 10.1007/978-981-10-8684-7_6.

266.	Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma
	Ippolito D¹, Inchingolo R², Grazioli L³, Drago SG¹, Nardella M², Gatti M⁴, Faletti R⁴. World J Gastroenterol. 2018 Jun 21;24(23):2413-2426. doi: 10.3748/wjg.v24.i23.2413.

267.	Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review
	Young S¹, Taylor AJ¹, Sanghvi T¹. J Clin Transl Hepatol. 2018 Jun 28;6(2):189-197. doi: 10.14218/JCTH.2017.00059. Epub 2018 Feb 14.

268.	Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma
	Gordon AC¹, Gabr A¹, Riaz A¹, Uddin OM¹, Abouchaleh N¹, Ali R¹, Kallini J¹, Salem R¹,²,³, Lewandowski RJ⁴,⁵,⁶. Cardiovasc Intervent Radiol. 2018 Jun 12. doi: 10.1007/s00270-018-2008-y. [Epub ahead of print]

269.	Should we cure HCV in patients with hepatocellular carcinoma while treating cancer?
	Cabibbo G¹, Celsa C¹, Cammà C¹, Craxì A¹. Liver Int. 2018 Jun 23. doi: 10.1111/liv.13918. [Epub ahead of print]

270.	Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance
	Griffith AS¹, Hayashi PH¹, Burke LM², McRee AJ¹. J Hepatocell Carcinoma. 2018 May 31;5:55-59. doi: 10.2147/JHC.S152569. eCollection 2018.

271.	Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
	Younossi Z¹, Stepanova M², Ong JP³, Jacobson IM⁴, Bugianesi E⁵, Duseja A⁶, Eguchi Y⁷, Wong VW⁸, Negro F⁹, Yilmaz Y¹⁰, Romero-Gomez M¹¹, George J¹², Ahmed A¹³, Wong R¹⁴, Younossi I², Ziayee M², Afendy A²; Global NASH Council.. Clin Gastroenterol Hepatol. 2018 Jun 13. pii: S1542-3565(18)30611-6. doi: 10.1016/j.cgh.2018.05.057. [Epub ahead of print]

272.	Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis
	Aby E¹, Phan J¹, Truong E¹, Grotts J¹, Saab S¹,². J Clin Gastroenterol. 2018 Jun 16. doi: 10.1097/MCG.0000000000001075. [Epub ahead of print]

273.	Late Development of Hepatocellular Carcinoma After Viral Clearance in Chronic Hepatitis C Patients: A Need for Continual Surveillance
	Tong MJ¹,², Theodoro CF³, Salvo RT¹. J Dig Dis. 2018 Jun 11. doi: 10.1111/1751-2980.12615. [Epub ahead of print]

274.	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma
	Rich NE¹, Hester C², Odewole M¹, Murphy CC³, Parikh ND⁴, Marrero JA¹, Yopp AC², Singal AG⁵. Clin Gastroenterol Hepatol. 2018 May 31. pii: S1542-3565(18)30571-8. doi: 10.1016/j.cgh.2018.05.039. [Epub ahead of print]

275.	The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable
	Wallace MC¹,²,³, Knuiman M⁴, Huang Y⁵, Garas G⁶,⁵, Adams LA⁶,⁵, MacQuillan G⁶,⁵, Preen DB⁴, Jeffrey GP⁶,⁵. Dig Dis Sci. 2018 May 28. doi: 10.1007/s10620-018-5132-2. [Epub ahead of print]

276.	Hepatocellular Carcinoma: Updates to Screening and Diagnosis
	Covey AM¹. J Natl Compr Canc Netw. 2018 May;16(5S):663-665. doi: 10.6004/jnccn.2018.0052.

277.	The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome
	Black AP¹, Mehta AS². Curr Opin Pharmacol. 2018 May 14;41:74-78. doi: 10.1016/j.coph.2018.04.002. [Epub ahead of print]

278.	Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis
	Moris D¹, Tsilimigras DI², Kostakis ID³, Ntanasis-Stathopoulos I², Shah KN⁴, Felekouras E², Pawlik TM⁵. Eur J Surg Oncol. 2018 Apr 30. pii: S0748-7983(18)31024-2. doi: 10.1016/j.ejso.2018.04.018. [Epub ahead of print

279.	Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials
	Harding JJ¹,². Future Oncol. 2018 Apr 17. doi: 10.2217/fon-2018-0008. [Epub ahead of print]

280.	Liver Stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver related events in hepatitis C
	Bloom S¹, Kemp W², Nicoll A³, Roberts SK², Gow P⁴, Dev A⁵, Bell S⁶, Sood S⁷, Kronborg I⁸, Knight V⁵, Lewis D⁹, Lubel J⁹. J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32023-3. doi: 10.1016/j.jhep.2018.04.013. [Epub ahead of print]

281.	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial
	Finn RS¹, Merle P², Granito A³, Huang YH⁴, Bodoky G⁵, Pracht M⁶, Yokosuka O⁷, Rosmorduc O⁸, Gerolami R⁹, Caparello C¹⁰, Cabrera R¹¹, Chang C¹², Sun W¹³, LeBerre MA¹⁴, Baumhauer A¹⁵, Meinhardt G¹⁶, Bruix J¹⁷; RESORCE Investigators. J Hepatol. 2018 Apr 25. pii: S0168-8278(18)32018-X. doi: 10.1016/j.jhep.2018.04.010. [Epub ahead of print]

282.	Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy
	Erstad DJ¹, Fuchs BC², Tanabe KK². Cancer. 2018 Apr 17. doi: 10.1002/cncr.31257. [Epub ahead of print]

283.	A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
	Thomas MB¹,², Garrett-Mayer E¹, Anis M¹, Anderton K¹, Bentz T¹, Edwards A¹, Brisendine A¹, Weiss G³, Siegel AB⁴, Bendell J⁵, Baron A⁶, Duddalwar V⁷, El-Khoueiry A⁷. Oncology. 2018 May 2;94(6):329-339. doi: 10.1159/000485384. [Epub ahead of print]

284.	A Point-based Histologic Scoring System for Hepatocellular Carcinoma can Stratify Risk of Posttransplant Tumor Recurrence
	Roberts DE¹, Kakar S¹, Mehta N², Gill RM¹. Am J Surg Pathol. 2018 Apr 11. doi: 10.1097/PAS.0000000000001053. [Epub ahead of print]

285.	De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era
	Kwong AJ¹, Kim WR¹, Flemming JA². Hepatology. 2018 Apr 19. doi: 10.1002/hep.30045. [Epub ahead of print]

286.	Circadian misalignment and hepatocellular carcinoma incidence in the United States
	VoPham T¹, Weaver MD², Vetter C³, Hart JE⁴, Tamimi RM⁵, Laden F⁶, Bertrand KA⁷. Cancer Epidemiol Biomarkers Prev. 2018 Apr 10. pii: cebp.1052.2017. doi: 10.1158/1055-9965.EPI-17-1052. [Epub ahead of print]

287.	When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review
	Russo FP¹, Imondi A¹, Lynch EN¹, Farinati F². Dig Liver Dis. 2018 Mar 20. pii: S1590-8658(18)30232-9. doi: 10.1016/j.dld.2018.03.014. [Epub ahead of print]

288.	Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system
	Hsu CY¹,²,³, Liu PH¹,²,⁴, Ho SY¹,², Huang YH¹,⁵, Lee YH¹,², Lee RC²,⁶, Nagaria TS⁷, Hou MC¹,², Huo TI¹,²,⁸. Liver Int. 2018 Apr 2. doi: 10.1111/liv.13748. [Epub ahead of print]

289.	Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening
	Robinson A¹, Tavakoli H¹, Cheung R², Liu B¹, Bhuket T¹, Wong RJ¹. J Clin Gastroenterol. 2018 Apr 6. doi: 10.1097/MCG.0000000000001024. [Epub ahead of print]

290.	Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
	Chen S¹, Peng Z²,³, Wei M⁴, Liu W⁵, Dai Z⁴, Wang H³, Mei J³, Cheong M⁶, Zhang H⁶, Kuang M⁷,⁸. BMC Cancer. 2018 Apr 5;18(1):392. doi: 10.1186/s12885-018-4308-7.

291.	Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review
	Axley P¹, Ahmed Z¹, Ravi S¹, Singal AK². Clin Transl Hepatol. 2018 Mar 28;6(1):79-84. doi: 10.14218/JCTH.2017.00067. Epub 2017 Dec 17.

292.	Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate
	Daniel KE¹, Said A². Curr Gastroenterol Rep. 2018 Apr 5;20(5):20. doi: 10.1007/s11894-018-0626-9.

293.	Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity
	Baumann BC¹,²,³, Wei J⁴, Plastaras JP¹, Lukens JN¹, Damjanov N⁵, Hoteit M⁶, Hsu C⁶, Levine M⁷, Mondschein J⁸, Nadolski G⁸, Olthoff K⁷, Reiss KA⁵, Rosen M⁹, Siegelman E⁹, Metz JM¹, Ben-Josef E¹. Am J Clin Oncol. 2018 Mar 16. doi: 10.1097/COC.0000000000000435. [Epub ahead of print]

294.	Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
	Schietroma I¹, Scheri GC¹, Pinacchio C¹, Statzu M², Petruzziello A³, Vullo V¹. Open Virol J. 2018 Feb 28;12:16-25. doi: 10.2174/1874357901812010016. eCollection 2018.

295.	Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey
	Gill J¹, Baiceanu A², Clark PJ³, Langford A⁴, Latiff J⁵, Yang PM⁶, Yoshida EM⁷, Kanavos P¹. Future Oncol. 2018 Mar 15. doi: 10.2217/fon-2017-0715. [Epub ahead of print]

296.

Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study

Romano A¹, Angeli P¹, Piovesan S², Noventa F², Anastassopoulos G², Chemello L¹, Cavalletto L¹, Gambato M³, Russo FP³, Burra P³, Vincenzi V⁴, Scotton PG⁵, Panese S⁶, Tempesta D⁷, Bertin T⁸, Carrara M⁹, Carlotto A¹⁰, Capra F¹¹, Carolo G¹², Scroccaro G¹³, Alberti A¹⁴. J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172-7. doi: 10.1016/j.jhep.2018.03.009. [Epub ahead of print]

297.	Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma
	Petruzziello A¹. Open Virol J. 2018 Feb 28;12:26-32. doi: 10.2174/1874357901812010026. eCollection 2018.

298.	Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data-a pilot study
	McNamara MM¹, Thomas JV², Alexander LF³, Little MD², Bolus DN², Li YE⁴, Morgan DE². Abdom Radiol (NY). 2018 Mar 3. doi: 10.1007/s00261-018-1535-y. [Epub ahead of print]

299.	Managing the Burden of Non-NASH NAFLD
	Danford CJ¹, Sanchez JE², Corey KE³. Curr Hepatol Rep. 2017 Dec;16(4):326-334. doi: 10.1007/s11901-017-0371-9. Epub 2017 Oct 27.

300.	Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?
	Tan CHN¹,², Yu Y³, Tan YRN³, Lim BLK⁴,², Iyer SG¹,², Madhavan K¹,², Kow AWC¹,². Ann Hepatobiliary Pancreat Surg. 2018 Feb;22(1):27-35. doi: 10.14701/ahbps.2018.22.1.27. Epub 2018 Feb 26.

301.	Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors
	Baecker A¹, Liu X¹,², La Vecchia C³, Zhang ZF¹,⁴,⁵. Eur J Cancer Prev. 2018 Feb 27. doi: 10.1097/CEJ.0000000000000428. [Epub ahead of print]

302.

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

Chow PKH¹, Gandhi M¹, Tan SB¹, Khin MW¹, Khasbazar A¹, Ong J¹, Choo SP¹, Cheow PC¹, Chotipanich C¹, Lim K¹, Lesmana LA¹, Manuaba TW¹, Yoong BK¹, Raj A¹, Law CS¹, Cua IHY¹, Lobo RR¹, Teh CSC¹, Kim YH¹, Jong YW¹, Han HS¹, Bae SH¹, Yoon HK¹, Lee RC¹, Hung CF¹, Peng CY¹, Liang PC¹, Bartlett A¹, Kok KYY¹, Thng CH¹, Low AS¹, Goh ASW¹, Tay KH¹, Lo RHG¹, Goh BKP¹, Ng DCE¹, Lekurwale G¹, Liew WM¹, Gebski V¹, Mak KSW¹, Soo KC¹; Asia-Pacific Hepatocellular CarcinomaTrials Group. J Clin Oncol. 2018 Mar 2:JCO2017760892. doi: 10.1200/JCO.2017.76.0892. [Epub ahead of print]

303.	Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy
	Fritsche MR¹, Watchmaker JM¹, Lipnik AJ², Baker JC¹, Geevarghese S³, Banovac F¹, Omary RA¹, Brown DB⁴. J Vasc Interv Radiol. 2018 Feb 23. pii: S1051-0443(17)31038-2. doi: 10.1016/j.jvir.2017.11.018. [Epub ahead of print]

304.	Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan
	Younossi ZM¹,², Tanaka A³, Eguchi Y⁴, Henry L⁵, Beckerman R⁶, Mizokami M⁷. J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886. [Epub ahead of print]

305.	Ablation approach for primary liver tumors: Peri-operative outcomes
	Berger NG¹, Herren JL¹, Liu C¹, Burrow RH¹, Silva JP¹, Tsai S¹, Christians KK¹, Gamblin TC¹. J Surg Oncol. 2018 Feb 26. doi: 10.1002/jso.25019. [Epub ahead of print]

306.	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma
	DeLeon TT¹, Ahn DH¹, Bogenberger JM¹, Anastasiadis PZ², Arora M¹, Ramanathan RK¹, Aqel BA³, Vasmatzis G⁴, Truty MJ⁵, Oklu R⁶, Bekaii-Saab TS¹, Borad MJ¹. Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20.

307.	Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular CarcinomaRecurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout
	Huang AC¹, Mehta N¹, Dodge JL², Yao FY¹,², Terrault NA¹,². Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855. [Epub ahead of print]

308.	Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
	Sun W¹,², Cabrera R³. J Gastrointest Cancer. 2018 Feb 17. doi: 10.1007/s12029-018-0065-8. [Epub ahead of print]

309.	The impact of treatment of hepatitis C with DAAs on the occurrence of HCC
	Roche B¹,²,³,⁴, Coilly A¹,²,³,⁴, Duclos-Vallee JC¹,²,³,⁴, Samuel D¹,²,³,⁴. Liver Int. 2018 Feb;38 Suppl 1:139-145. doi: 10.1111/liv.13659.

310.	Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma
	Tong MJ¹,², Rosinski AA¹, Huynh CT¹, Raman SS³, Lu DSK³. Hepatol Commun. 2017 Jun 21;1(7):595-608. doi: 10.1002/hep4.1047. eCollection 2017 Sep.

311.	Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review
	Walker AJ¹,², Peacock CJ¹, Pedergnana V³; STOP-HCV Consortium, Irving WL¹. J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871. [Epub ahead of print]

312.	Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System
	Tayob N¹, Richardson P²,³, White DL²,³, Yu X⁴, Davila JA²,³, Kanwal F²,³, Feng Z⁵, El-Serag HB²,³. BMC Med Res Methodol. 2018 Jan 4;18(1):1. doi: 10.1186/s12874-017-0458-6.

313.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

Harms MH¹, Lammers WJ¹, Thorburn D²,³, Corpechot C⁴, Invernizzi P⁵, Janssen HLA⁶, Battezzati PM⁷, Nevens F⁸, Lindor KD⁹,¹⁰, Floreani A¹¹, Ponsioen CY¹², Mayo MJ¹³, Dalekos GN¹⁴, Bruns T¹⁵, Parés A¹⁶, Mason AL¹⁷, Verhelst X¹⁸, Kowdley KV¹⁹, Goet JC¹, Hirschfield GM²⁰, Hansen BE¹,⁶, van Buuren HR¹. Am J Gastroenterol. 2017 Dec 12. doi: 10.1038/ajg.2017.440. [Epub ahead of print]

314.	Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study
	Richter G¹, Radeleff B², Stroszczynski C³, Pereira P⁴, Helmberger T⁵, Barakat M⁶, Huppert P⁷. Cardiovasc Intervent Radiol. 2017 Nov 22. doi: 10.1007/s00270-017-1839-2. [Epub ahead of print]

315.	Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study
	Kaplan DE¹,², Mehta R³,⁴, D'Addeo K³,⁴, Valderrama A⁵, Taddei TH³,⁴; Sorafenib for Hepatocellular carcinomA in VEterans (SHAVE) Study Investigators. Medicine (Baltimore). 2018 Jan;97(4):e9757. doi: 10.1097/MD.0000000000009757.

316.	Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function
	Benjamin AJ¹, Baker TB¹, Talamonti MS², Bodzin AS¹, Schneider AB¹, Winschester DJ², Roggin KK¹, Bentrem DJ³, Suss NR², Baker MS⁴. Surgery. 2018 Jan 19. pii: S0039-6060(17)30866-8. doi: 10.1016/j.surg.2017.12.005. [Epub ahead of print]

317.	Hypoalbuminemia is Associated With Significantly Higher Liver Transplant Waitlist Mortality and Lower Probability of Receiving Liver Transplant
	Ahn J¹, Sundaram V², Ayoub WS², Frenette C³, Wong RJ⁴. J Clin Gastroenterol. 2018 Jan 19. doi: 10.1097/MCG.0000000000000984. [Epub ahead of print]

318.	Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease
	Backus LI¹, Belperio PS¹, Shahoumian TA¹, Mole LA¹. Hepatology. 2018 Jan 29. doi: 10.1002/hep.29811. [Epub ahead of print]

319.	Report from the International Conference on Viral Hepatitis - 2017
	Soriano V¹, Young B², Reau N³. AIDS Rev. 2018 Jan 25;20(1). [Epub ahead of print]

320.

Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

Vitale A¹, Lai Q², Farinati F¹, Bucci L³, Giannini EG⁴, Napoli L⁵, Ciccarese F⁶, Rapaccini GL⁷, Di Marco M⁸, Caturelli E⁹, Zoli M⁵, Borzio F¹⁰, Sacco R¹¹, Cabibbo G¹², Virdone R¹³, Marra F¹⁴, Felder M¹⁵, Morisco F¹⁶, Benvegnù L¹⁷, Gasbarrini A¹⁸, Svegliati-Baroni G¹⁹, Foschi FG²⁰, Missale G²¹, Masotto A²², Nardone G²³, Colecchia A²⁴, Bernardi M³, Trevisani F³, Pawlik TM²⁵; Italian Liver Cancer (ITA.LI.CA) group. J Gastrointest Surg. 2018 Jan 19. doi: 10.1007/s11605-018-3688-y. [Epub ahead of print]

321.	Downstaging for hepatocellular cancer: harm or benefit?
	Bryce K¹, Tsochatzis EA¹. Transl Gastroenterol Hepatol. 2017 Dec 12;2:106. doi: 10.21037/tgh.2017.11.18. eCollection 2017.

322.	Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests
	Colombo M¹,², Boccaccio V². J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862. [Epub ahead of print]

323.	Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis
	Shang J1, Xu S2, Zhang J3, Ran X4, Bai L1, Tang H1. Oncotarget. 2017 Sep 28;8(65):109723-109731. doi: 10.18632/oncotarget.21299. eCollection 2017 Dec 12.

324.	Laparoscopic liver resection for hepatocellular carcinoma in early and advanced cirrhosis
	Beard RE1, Wang Y2, Khan S2, Marsh JW3, Tsung A2, Geller DA2. HPB (Oxford). 2018 Jan 6. pii: S1365-182X(17)31165-6. doi: 10.1016/j.hpb.2017.11.011. [Epub ahead of print]

325.	Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma
	Wang Y1, Attar BM2, Fuentes HE1, Jaiswal P1, Tafur AJ3. J Gastrointest Oncol. 2017 Dec;8(6):1065-1071. doi: 10.21037/jgo.2017.09.06.

326.	Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage: A Contemporary Appraisal of the Milan Criteria
	Ecker BL1, Hoteit MA2, Forde KA2,3, Hsu CC2, Reddy KR2, Furth EE4, Siegelman ES5, Habibollahi P5, Ben-Josef E6, Porrett PM1, Abt PL1, Shaked A1, Olthoff KM1, Levine MH1. Transplantation. 2018 Jan 10. doi: 10.1097/TP.0000000000002056. [Epub ahead of print]

327.	Hepatocellular carcinoma
	Forner A1, Reig M2, Bruix J2. Lancet. 2018 Jan 4. pii: S0140-6736(18)30010-2. doi: 10.1016/S0140-6736(18)30010-2. [Epub ahead of print]

328.	HCC Risk Scores: Useful or Not?
	Sherman M1. Semin Liver Dis. 2017 Nov;37(4):287-295. doi: 10.1055/s-0037-1607452. Epub 2017 Dec 22.

329.	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
	Harding JJ1,1, Abu-Zeinah G1, Chou JF1, Owen DH1, Ly M1, Lowery MA1,1, Capanu M1, Do R1,1, Kemeny NE1,1, O'Reilly EM1,1, Saltz LB1,1, Abou-Alfa GK1,1. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

330.	Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation
	Rubinstein MM1, Kaubisch A1, Kinkhabwala M2, Reinus J2, Liu Q1, Chuy JW1. J Gastrointest Oncol. 2017 Dec;8(6):1051-1055. doi: 10.21037/jgo.2017.08.11.

331.	Trans-arterial radio-embolization: a new chance for patients with hepatocellularcancer to access liver transplantation, a world review
	Levi Sandri GB1, Ettorre GM1, Giannelli V2, Colasanti M1, Sciuto R3, Pizzi G4, Cianni R5, D'Offizi G6, Antonini M7, Vennarecci G1, Lucatelli P8. Transl Gastroenterol Hepatol. 2017 Nov 27;2:98. doi: 10.21037/tgh.2017.11.11. eCollection 2017.

332.	Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening
	Tillman BG1, Gorman JD1, Hru JM1, Lee MH1, King MC1, Sirlin CB2, Marks RM3. Clin Radiol. 2017 Dec 12. pii: S0009-9260(17)30532-9. doi: 10.1016/j.crad.2017.11.013. [Epub ahead of print]

333.	Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation
	Rosenblatt RE1, Tafesh ZH1, Halazun KJ2. Transl Gastroenterol Hepatol. 2017 Nov 21;2:95. doi: 10.21037/tgh.2017.10.04. eCollection 2017.

334.	Benefits of laparoscopic liver resection in patients with hepatocellular carcinomaand portal hypertension: a case-matched study
	Molina V1, Sampson-Dávila J1, Ferrer J1, Fondevila C1, Díaz Del Gobbo R1, Calatayud D1, Bruix J2,3, García-Valdecasas JC1, Fuster J4,5,6. Surg Endosc. 2017 Dec 7. doi: 10.1007/s00464-017-5930-1. [Epub ahead of print]

335.	Childhood Liver Cancer Treatment (PDQ®): Patient Version.
	PDQ Pediatric Treatment Editorial Board.

336.	An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas
	Cicalese L1, Raun L2, Shirafkan A1, Campos L2, Zorzi D1, Montalbano M1, Rhoads C1, Gazis V1, Ensor K2, Rastellini C1,3. Liver Cancer. 2017 Nov;6(4):287-296. doi: 10.1159/000475776. Epub 2017 Aug 29.

337.	Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States
	Parsons HM1, Chu Q2, Karlitz JJ3, Stevens JL4, Harlan LC5. Liver Cancer. 2017 Jun;6(3):216-226. doi: 10.1159/000473862. Epub 2017 Apr 28.

338.	Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature
	Tapper EB1, Kanwal F2,3,4, Asrani SK5, Ho C6, Ovchinsky N7, Poterucha J8, Flores A9, Smith JE10, Ankoma-Sey V11, Luxon B12, Volk M13. Hepatology. 2017 Dec 22. doi: 10.1002/hep.29756. [Epub ahead of print]

339.	Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma
	Rudnick SR1, Russo MW2. Expert Rev Gastroenterol Hepatol. 2017 Dec 12. doi: 10.1080/17474124.2018.1417035. [Epub ahead of print]

340.	The utility of biomarkers in hepatocellular carcinoma: review of urine-based 1H-NMR studies - what the clinician needs to know
	Cartlidge CR1, U MRA2, Alkhatib AMA2, Taylor-Robinson SD1. Int J Gen Med. 2017 Nov 27;10:431-442. doi: 10.2147/IJGM.S150312. eCollection 2017.

341.	Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular CarcinomaRecurrence in a 5-year Transplant Cohort
	Sandow TA1, Arndt SE1, Albar AA1, DeVun DA1, Kirsch DS1, Gimenez JM1, Bohorquez HE1, Gilbert PJ1, Thevenot PT1, Nunez KG1, Galliano GA1, Cohen AJ1, Kay D1, Gulotta PM1. Radiology. 2017 Dec 4:170731. doi: 10.1148/radiol.2017170731. [Epub ahead of print]

342.	The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib
	Conroy G1, Salleron J2, Belle A1, Bensenane M1, Nani A1, Ayav A3, Peiffert D4, Lopez A1, Baumann C5, Barraud H1, Bronowicki JP1. Oncotarget. 2017 Sep 30;8(56):95853-95864. doi: 10.18632/oncotarget.21401. eCollection 2017 Nov 10.

343.	Histological Grading of Hepatocellular Carcinoma-A Systematic Review of Literature
	Martins-Filho SN1,2, Paiva C1, Azevedo RS1, Alves VAF1,2. Front Med (Lausanne). 2017 Nov 10;4:193. doi: 10.3389/fmed.2017.00193. eCollection 2017.

344.	Survival of children after liver transplantation for hepatocellular carcinoma
	Baumann U1, Adam R2, Duvoux C3, Mikolajczyk R4,5, Karam V2, D'Antiga L6, Chardot C7, Coker A8, Colledan M9, Erizon BG10, Line PD11, Hadzic N12, Isoniemi H13, Klempnauer JL14, Reding R15, McKiernan PJ16, McLin V17, Paul A18, Salizzoni M19, Furtado ESB20, Schneeberger S21, Karch A4,5. Liver Transpl. 2017 Dec 9. doi: 10.1002/lt.24994. [Epub ahead of print]

345.	Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma: History, Current Status, and Opportunities
	Meyer J1, Singal AG2. Liver Transpl. 2017 Dec 5. doi: 10.1002/lt.24991. [Epub ahead of print]

346.	Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions
	Ray EM1, Sanoff HK1. J Hepatocell Carcinoma. 2017 Nov 8;4:131-138. doi: 10.2147/JHC.S124366. eCollection 2017.

347.	Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies
	Simon TG1,2,3,4, King LY5, Chong DQ6, Nguyen L1,2,3,4, Ma Y3,7,8, VoPham T3,9,8, Giovannucci EL3,9,10,8, Fuchs CS11, Meyerhardt JA3,12, Corey KE1,2,3,4, Khalili H2,3,4, Chung RT1,2,3, Zhang X3,8, Chan AT2,3,4,8. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29660. [Epub ahead of print]

348.	Treatment options after sorafenib failure in patients with hepatocellular carcinoma
	Dika IE1, Abou-Alfa GK1,2. Clin Mol Hepatol. 2017 Nov 20. doi: 10.3350/cmh.2017.0108. [Epub ahead of print]

349.	Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
	Gerbes A1, Zoulim F2,3, Tilg H4, Dufour JF5,6, Bruix J7, Paradis V8, Salem R9, Peck-Radosavljevic M10, Galle PR11, Greten TF12,13, Nault JC14,15,16, Avila MA17. Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068. [Epub ahead of print]

350.	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen
	Innes H1, Barclay ST2, Hayes PC3, Fraser A4, Dillon JF5, Stanley A2, Bathgate A3, McDonald SA1, Goldberg D6, Valerio H1, Fox R7, Kennedy N8, Bramley P9, Hutchinson SJ1. J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429-7. doi: 10.1016/j.jhep.2017.10.033. [Epub ahead of print]

351.	Treatment options after sorafenib failure in patients with hepatocellular carcinoma
	Dika IE1, Abou-Alfa GK1,2. Clin Mol Hepatol. 2017 Nov 20. doi: 10.3350/cmh.2017.0108. [Epub ahead of print]

352.	Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
	Gerbes A1, Zoulim F2,3, Tilg H4, Dufour JF5,6, Bruix J7, Paradis V8, Salem R9, Peck-Radosavljevic M10, Galle PR11, Greten TF12,13, Nault JC14,15,16, Avila MA17. Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068. [Epub ahead of print]

353.	Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies
	Simon TG1,2,3,4, King LY5, Chong DQ6, Nguyen L1,2,3,4, Ma Y3,7,8, VoPham T3,9,8, Giovannucci EL3,9,10,8, Fuchs CS11, Meyerhardt JA3,12, Corey KE1,2,3,4, Khalili H2,3,4, Chung RT1,2,3, Zhang X3,8, Chan AT2,3,4,8. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29660. [Epub ahead of print]

354.	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen
	Innes H1, Barclay ST2, Hayes PC3, Fraser A4, Dillon JF5, Stanley A2, Bathgate A3, McDonald SA1, Goldberg D6, Valerio H1, Fox R7, Kennedy N8, Bramley P9, Hutchinson SJ1. J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429-7. doi: 10.1016/j.jhep.2017.10.033. [Epub ahead of print]

355.	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?
	Margetts J1,2, Ogle LF2, Chan SL3,4, Chan AWH5, Chan KCA6, Jamieson D2, Willoughby CE2, Mann DA7, Wilson CL7, Manas DM8, Yeo W3, Reeves HL1,9. Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.386. [Epub ahead of print]

356.	Should we undertake surveillance for HCC in patients with NAFLD?
	Younes R1, Bugianesi E2. J Hepatol. 2017 Nov 6. pii: S0168-8278(17)32353-X. doi: 10.1016/j.jhep.2017.10.006. [Epub ahead of print]

357.	Hepatocellular carcinoma in the era of immunotherapy
	Sim HW1, Knox J2. Curr Probl Cancer. 2017 Nov 14. pii: S0147-0272(17)30110-1. doi: 10.1016/j.currproblcancer.2017.10.007. [Epub ahead of print]

358.	Pilot study of living donor liver transplantation for patients with HCC exceeding Milan criteria (BCLC extended criteria)
	Llovet JM1,2,3, Pavel M4, Rimola J1, Diaz MA5, Colmenero J4,6, Saavedra D4, Fondevila C4, Ayuso C1, Fuster J1,4, Ginès P4,6, Bruix J1,6, Garcia Valdecasas JC4. Liver Transpl. 2017 Nov 15. doi: 10.1002/lt.24977. [Epub ahead of print]

359.	Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma
	Mokdad AA1, Murphy CC2, Pruitt SL2, Mansour JC1, Marrero JA3, Singal AG3, Yopp AC1. Cancer. 2017 Oct 26. doi: 10.1002/cncr.31066. [Epub ahead of print]

360.	Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review
	Moris D1, Chakedis J1, Sun SH1, Spolverato G1, Tsilimigras DI2, Ntanasis-Stathopoulos I2, Spartalis E3, Pawlik TM1. J Surg Oncol. 2017 Nov 8. doi: 10.1002/jso.24869. [Epub ahead of print]

361.	Epigenetic reprogramming in liver fibrosis and cancer
	Wilson CL1, Mann DA2, Borthwick LA3. Adv Drug Deliv Rev. 2017 Oct 25. pii: S0169-409X(17)30235-1. doi: 10.1016/j.addr.2017.10.011. [Epub ahead of print]

362.	Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?
	Adam LC1, Murali N1, Chapiro J1, Geschwind JF1. Radiology. 2017 Nov;285(2):333-335. doi: 10.1148/radiol.2017171527.

363.	Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma
	Ahmed AF1, Samreen N2,3, Grajo JR2, Zendejas I4, Sistrom CL2, Collinsworth A5, Esnakula A5, Shah JL2, Cabrera R6, Geller BS2, Toskich BB2,7. Abdom Radiol (NY). 2017 Oct 20. doi: 10.1007/s00261-017-1354-6. [Epub ahead of print]

364.	The Liver in Oncology
	Dhanasekaran R1, Kwo PY2. Clin Liver Dis. 2017 Nov;21(4):697-707. doi: 10.1016/j.cld.2017.06.003. Epub 2017 Jul 26.

365.	Nonstandardized Terminology to Describe Focal Liver Lesions in Patients at Risk for Hepatocellular Carcinoma: Implications Regarding Clinical Communication
	Corwin MT1,2,3, Lee AY1,2,3, Fananapazir G1,2,3, Loehfelm TW1,2,3, Sarkar S1,2,3, Sirlin CB1,2,3. AJR Am J Roentgenol. 2017 Oct 12:1-6. doi: 10.2214/AJR.17.18416. [Epub ahead of print]

366.	Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System
	Fetzer DT1, Rodgers SK2, Harris AC3, Kono Y4, Wasnik AP5, Kamaya A6, Sirlin C7. Radiol Clin North Am. 2017 Nov;55(6):1197-1209. doi: 10.1016/j.rcl.2017.06.012.

367.

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients With Unresectable Hepatocellular Carcinoma Lesions

Tak WY1, Lin SM2, Wang Y3, Zheng J4, Vecchione A5, Park SY6, Chen MH7, Wong S8, Xu R9, Peng CY10, Chiou YY11, Huang GT12, Cai J13, Abdullah BJ14, Lee JS15, Lee JY16, Choi JY17, Gopez-Cervantes J18, Sherman M19, Finn RS20, Omata M21, O'Neal M22, Makris L23, Borys N24, Poon R25, Lencioni R26. Clin Cancer Res. 2017 Oct 10. pii: clincanres.2433.2016. doi: 10.1158/1078-0432.CCR-16-2433. [Epub ahead of print]

368.	Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma
	Riordan JD1, Feddersen CR1, Tschida BR2, Jackson P2, Keng VW3, Linden MA4, Amin K4, Stipp CS5, Largaespada DA2, Dupuy AJ1. Hepatology. 2017 Sep 29. doi: 10.1002/hep.29565. [Epub ahead of print]

369.	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting
	Thein HH1,2, Qiao Y1, Zaheen A3, Jembere N1, Sapisochin G4, Chan KKW3,5,6, Yoshida EM7, Earle CC2,6,8,9. PLoS One. 2017 Oct 10;12(10):e0185198. doi: 10.1371/journal.pone.0185198. eCollection 2017.

370.	Minimally Invasive Approaches for Surgical Management of Primary Liver Cancers
	Beard RE1, Tsung A1. Cancer Control. 2017 Jul-Sep;24(3):1073274817729234. doi: 10.1177/1073274817729234.

371.	The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer
	Shiani A1, Narayanan S1, Pena L2, Friedman M2. Cancer Control. 2017 Jul-Sep;24(3):1073274817729240. doi: 10.1177/1073274817729240.

372.	Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma
	Eatrides J1, Wang E1, Kothari N1, Kim R1. Cancer Control. 2017 Jul-Sep;24(3):1073274817729243. doi: 10.1177/1073274817729243.

373.	Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma
	Estevez J1,2, Chen VL3,4, Podlaha O5, Li B5, Le A1, Vutien P1,6, Chang ET7, Rosenberg-Hasson Y8, Jiang Z5, Pflanz S5, Ge D5, Gaggar A5, Nguyen MH9. Sci Rep. 2017 Sep 19;7(1):11867. doi: 10.1038/s41598-017-11975-7.

374.	Feasibility and outcomes of percutaneous thermal ablation of hepatocellular carcinoma in a transplanted allograft
	Welch BT1,2,3,4, Schmitz JJ5, Kurup AN5, Atwell TD5, Callstrom MR5, Frey G6, Paz-Fumagalli R6, Allen A7, Watt K7, Heimbach J8, Schmit GD5. Abdom Radiol (NY). 2017 Sep 21. doi: 10.1007/s00261-017-1323-0. [Epub ahead of print]

375.	Management of Incidental Liver Lesions on CT: A White Paper of the ACR Incidental Findings Committee
	Gore RM1, Pickhardt PJ2, Mortele KJ3, Fishman EK4, Horowitz JM5, Fimmel CJ6, Talamonti MS7, Berland LL8, Pandharipande PV9. J Am Coll Radiol. 2017 Sep 16. pii: S1546-1440(17)30889-X. doi: 10.1016/j.jacr.2017.07.018. [Epub ahead of print]

376.	Venous invasion by hepatic tumors: imaging appearance and implications for management
	Thompson SM1, Wells ML2, Andrews JC2, Ehman EC2, Menias CO3, Hallemeier CL4, Roberts LR5, Venkatesh SK2. Abdom Radiol (NY). 2017 Sep 19. doi: 10.1007/s00261-017-1298-x. [Epub ahead of print]

377.	A Subset of Well Differentiated Hepatocellular Carcinomas are Arginase-1 Negative
	Clark I1, Shah SS2, Moreira R2, Graham RP2, Wu TT2, Torbenson MS2, Chandan V3. Hum Pathol. 2017 Sep 29. pii: S0046-8177(17)30352-0. doi: 10.1016/j.humpath.2017.09.007. [Epub ahead of print]

378.	US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma
	Morgan TA1, Maturen KE2, Dahiya N3, Sun MRM4, Kamaya A5; American College of Radiology Ultrasound Liver Imaging and Reporting Data System (US LI-RADS) Abdom Radiol (NY). 2017 Sep 21. doi: 10.1007/s00261-017-1317-y. [Epub ahead of print] Working Group.

379.	Quality of life as a prognostic factor for survival in hepatocellular carcinoma
	Sternby Eilard M1, Hagström H2, Mortensen KE3, Wilsgaard T4, Vagnildhaug OM5, Dajani O6, Stål P2, Rizell M1. Liver Int. 2017 Sep 20. doi: 10.1111/liv.13593. [Epub ahead of print]

380.	Long-Term Follow-Up of Clinical Trial Patients Treated for Chronic HCV Infection with Daclatasvir-Based Regimens
	Reddy KR1, Pol S2, Thuluvath PJ3, Kumada H4, Toyota J5, Chayama K6, Levin J7, Lawitz EJ8, Gadano A9, Ghesquiere W10, Gerken G11, Brunetto MR12, Peng CY13, Silva M14, Strasser SI15, Heo J16, McPhee F17, Liu Z18, Yang R17, Linaberry M19, Noviello S19. Liver Int. 2017 Sep 21. doi: 10.1111/liv.13596. [Epub ahead of print]

381.	An Update on Randomized Clinical Trials in Hepatocellular Carcinoma
	Sim HW1, Knox J1, Dawson LA2. Surg Oncol Clin N Am. 2017 Oct;26(4):647-666. doi: 10.1016/j.soc.2017.05.006. Epub 2017 Aug 4.

382.	Coffee Consumption and Prevention of Cirrhosis - In Support of the Caffeine Hypothesis
	Dranoff J1. Gene Expr. 2017 Sep 11. doi: 10.3727/105221617X15046391179559. [Epub ahead of print]

383.	Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms
	Lee YS1, Seo YS1, Kim JH1, Lee J2, Kim HR1, Yoo YJ1, Kim TS3, Kang SH1, Suh SJ1, Joo MK1, Jung YK1, Lee BJ1, Yim HJ1, Yeon JE1, Kim JS1, Park JJ1, Um SH1, Bak YT1, Byun KS1. Gut Liver. 2017 Sep 7. doi: 10.5009/gnl17040. [Epub ahead of print]

384.	Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection
	Mittal S1, Kramer JR2, Omino R3, Chayanupatkul M3, Richardson PA2, El-Serag HB4, Kanwal F4. Clin Gastroenterol Hepatol. 2017 Sep 1. pii: S1542-3565(17)31050-9. doi: 10.1016/j.cgh.2017.08.042. [Epub ahead of print]

385.	Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy for Patients With Chronic Hepatitis C Virus Infection
	Grandhe S1, Frenette CT1. Gastroenterol Hepatol (N Y). 2017 Jul;13(7):421-425.

386.	Treatment at a high-volume center is associated with improved survival among patients with non-metastatic hepatocellular carcinoma
	Holliday EB1, Allen PK2, Elhalawani H1, Abdel-Rahman O3. Liver Int. 2017 Aug 29. doi: 10.1111/liv.13561. [Epub ahead of print]

387.	Hepatitis C virus-related complications are increasing in women veterans: A national cohort study
	Kramer JR1,2, El-Serag HB1,3, Taylor TJ4, White DL1,3,2, Asch SM4, Frayne SM4, Cao Y1, Smith DL1, Kanwal F1,3. J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728. [Epub ahead of print]

388.	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
	Sacco R1, Tapete G1, Simonetti N1, Sellitri R1, Natali V1, Melissari S1, Cabibbo G2, Biscaglia L3, Bresci G1, Giacomelli L4. J Hepatocell Carcinoma. 2017 Jul 27;4:105-110. doi: 10.2147/JHC.S103661. eCollection 2017.

389.	Role of exosomes in treatment of hepatocellular carcinoma
	Moris D1, Beal EW1, Chakedis J1, Burkhart RA2, Schmidt C1, Dillhoff M1, Zhang X1, Theocharis S3, Pawlik TM4. Surg Oncol. 2017 Sep;26(3):219-228. doi: 10.1016/j.suronc.2017.04.005. Epub 2017 Apr 25.

390.	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era
	Millman AJ1, Nelson NP1, Vellozzi C1. Curr Epidemiol Rep. 2017 Jun;4(2):174-185. doi: 10.1007/s40471-017-0108-x. Epub 2017 Apr 20.

391.	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma
	Tavakoli H1, Robinson A1, Liu B2, Bhuket T2, Younossi Z3, Saab S4, Ahmed A5, Wong RJ6. Dig Dis Sci. 2017 May 4. doi: 10.1007/s10620-017-4595-x. [Epub ahead of print]

392.	Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database
	Hammad AY1, Robbins JR2, Turaga KK1, Christians KK1, Gamblin TC1, Johnston FM3. Ann Palliat Med. 2016 Nov 22. pii: apm.2016.11.02. doi: 10.21037/apm.2016.11.02. [Epub ahead of print]

393.	Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions
	Chapman WC1, Garcia-Aroz S2, Vachharajani N2, Fowler K3, Saad N3, Lin Y2, Wellen J2, Tan B4, Khan AS2, Doyle M2. J Am Coll Surg. 2017 Jan 6. pii: S1072-7515(16)31724-0. doi: 10.1016/j.jamcollsurg.2016.12.020. [Epub ahead of print]

394.	Treatment of Non-Alcoholic Fatty Liver Disease
	Scherer A1, Dufour JF. Dig Dis. 2016;34 Suppl 1:27-31. doi: 10.1159/000447278. Epub 2016 Aug 22.

395.	Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy
	Byrne TJ1, Rakela J1. World J Transplant. 2016 Jun 24;6(2):306-13. doi: 10.5500/wjt.v6.i2.306.

396.	Patients with Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-stage Liver Disease
	Goldberg D1, French B2, Newcomb C3, Liu Q3, Sahota G4, Wallace AE4, Forde KA5, Lewis JD6, Halpern SD7. Clin Gastroenterol Hepatol. 2016 Jun 29. pii: S1542-3565(16)30366-4. doi: 10.1016/j.cgh.2016.06.019. [Epub ahead of print]

397.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir)

Ganne-Carrié N1,2,3, Layese R4, Bourcier V1, Cagnot C5, Marcellin P6, Guyader D7, Pol S8, Larrey D9, de Lédinghen V10, Ouzan D11, Zoulim F12, Roulot D2,13, Tran A14, Bronowicki JP15, Zarski JP16, Riachi G17, Calès P18, Péron JM19, Alric L20, Bourlière M21, Mathurin P22, Blanc JF23, Abergel A24, Serfaty L25, Mallat A26, Grangé JD27, Attali P28, Bacq Y29, Wartelle C30, Dao T31, Benhamou Y32, Pilette C33, Silvain C34, Christidis C35, Capron D36, Bernard-Chabert B37, Zucman D38, Di Martino V39, Trinchet JC1,2,3, Nahon P1,2,3, Roudot-Thoraval F4; ANRS CO12 CirVir study group. Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702. [Epub ahead of print]

398.	Older Patients With Hepatocellular Carcinoma Have More Advanced Disease, Lower Rates of Treatment, and Lower Survival
	Yan M1, Ha J, Aguilar M, Liu B, Frenette CT, Bhuket T, Wong RJ. J Clin Gastroenterol. 2016 Jul 1. [Epub ahead of print]

399.	The use of ?-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis
	Herrera I1, Pascual S, Zapater P, Carnicer F, Bellot P, María Palazón J. Eur J Gastroenterol Hepatol. 2016 Jun 10. [Epub ahead of print]

400.	The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma
	Wirth TC1, Manns MP2. Ann Oncol. 2016 May 25. pii: mdw219. [Epub ahead of print]

401.	Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
	Sanoff HK1, Chang Y2, Lund JL3, O'Neil BH4, Dusetzina SB5. Oncologist. 2016 May 16. pii: theoncologist.2015-0478. [Epub ahead of print]

402.	Current Status of Liver Allocation in the United States
	Elwir S1, Lake J1. Gastroenterol Hepatol (N Y). 2016 Mar;12(3):166-70. Gastroenterol Hepatol (N Y). 2016 Mar;12(3):166-70.

403.	Randomized, Open-Label Phase 2 Study Comparing Frontline Dovitinib vs Sorafenib in Patients With Advanced Hepatocellular Carcinoma
	Cheng AL1, Thongprasert S2, Lim HY3, Sukeepaisarnjaroen W4, Yang TS5, Wu CC6, Chao Y7, Chan SL8, Kudo M9, Ikeda M10, Kang YK11, Pan H12, Numata K13, Han G14, Balsara B15, Zhang Y15, Rodriguez AM16, Zhang Y15, Wang Y15, Poon RT17. Hepatology. 2016 Apr 15. doi: 10.1002/hep.28600. [Epub ahead of print]

404.	Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis
	Bush DA1, Smith JC2, Slater JD3, Volk ML4, Reeves ME5, Cheng J4, Grove R3, de Vera ME4. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):477-82. doi: 10.1016/j.ijrobp.2016.02.027. Epub 2016 Feb 13.

405.	Disentangling the effects of race and socioeconomic factors on liver transplantation rates for hepatocellular carcinoma
	Sarpel U1, Suprun M2, Sofianou A3, Berger Y1, Tedjasukmana A4, Sekendiz Z5, Bagiella E2, Schwartz ME6. Clin Transplant. 2016 Mar 30. doi: 10.1111/ctr.12739. [Epub ahead of print]

406.	Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer
	Ryerson AB1, Eheman CR1, Altekruse SF2, Ward JW3, Jemal A4, Sherman RL5, Henley SJ1, Holtzman D3, Lake A6, Noone AM2, Anderson RN7, Ma J4, Ly KN3, Cronin KA2, Penberthy L2, Kohler BA5. Cancer. 2016 Mar 9. doi: 10.1002/cncr.29936. [Epub ahead of print]

407.	Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
	Granito A1, Marinelli S2, Negrini G2, Menetti S2, Benevento F2, Bolondi L2. Therap Adv Gastroenterol. 2016 Mar;9(2):240-9. doi: 10.1177/1756283X15618129.

408.	Hepatocellular carcinoma: Where are we?
	Mazzanti R1, Arena U1, Tassi R1. World J Exp Med. 2016 Feb 20;6(1):21-36. doi: 10.5493/wjem.v6.i1.21. eCollection 2016.

409.	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD
	Reeves HL1, Zaki MY2, Day CP3. Dig Dis Sci. 2016 Feb 26. [Epub ahead of print]

410.	Strengthening the Fight Against HCC
	Berlin J. Tex Med. 2016 Mar 1;112(3):53-8.

411.	A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
	Takami Y1,2, Eguchi S3, Tateishi M4, Ryu T5, Mikagi K6, Wada Y7, Saitsu H8. Hepatol Int. 2016 Feb 4. [Epub ahead of print]

412.	Aspirin use is associated with lower indices of liver fibrosis among adults in the United States
	Jiang ZG1, Feldbrügge L1, Tapper EB1, Popov Y1, Ghaziani T1, Afdhal N1, Robson SC1, Mukamal KJ2. Aliment Pharmacol Ther. 2016 Jan 7. doi: 10.1111/apt.13515. [Epub ahead of print]

413.	Follow-up of patients with chronic hepatitis C and a sustained viral response
	Serfaty L1,2. Liver Int. 2016 Jan;36 Suppl 1:67-71. doi: 10.1111/liv.13016.

414.	Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review
	Dyal HK1, Aguilar M2, Bartos G3, Holt EW4, Bhuket T5, Liu B6, Cheung R7,8, Wong RJ9. Dig Dis Sci. 2015 Dec 24. [Epub ahead of print]

415.	Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care
	McMahon B1, Block J2, Block T1, Cohen C1, Evans AA1, Hosangadi A1, London WT1, Sherman M1; 2015 Princeton HCC Workshop participants. J Natl Cancer Inst. 2015 Nov 30;108(4). pii: djv359. doi: 10.1093/jnci/djv359. Print 2016 Apr.

416.	Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
	Park JG1. Clin Mol Hepatol. 2015 Sep;21(3):287-94. doi: 10.3350/cmh.2015.21.3.287. Epub 2015 Sep 30.

417.	Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition
	Schmidt B1, Wei L1, DePeralta DK1, Hoshida Y2, Tan P2,3, Sun X2, Sventek JP1, Lanuti M4, Tanabe KK1, Fuchs BC1. Int J Cancer. 2015 Oct 20. doi: 10.1002/ijc.29893. [Epub ahead of print]

418.	General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan
	Kudo M1, Kitano M, Sakurai T, Nishida N. Dig Dis. 2015 Oct;33(6):765-70. doi: 10.1159/000439101. Epub 2015 Oct 21.

419.	Hepatocellular Carcinoma and Lifestyles
	Saran U1, Humar B2, Kolly P1, Dufour JF3. J Hepatol. 2015 Sep 1. pii: S0168-8278(15)00600-5. doi: 10.1016/j.jhep.2015.08.028. [Epub ahead of print]

420.	The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes
	Younossi ZM1,2, Stepanova M1,2, Saab S3, Ahmed A4, Lam B1, Srishord M1,2, Venkatesan C1, Wai H1, Henry L1,2. J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12449. [Epub ahead of print]

421.	Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009
	Younossi ZM1,2,3, Otgonsuren M3, Henry L1,3, Venkatesan C2, Mishra A1, Erario M2, Hunt S1. Hepatology. 2015 Aug 14. doi: 10.1002/hep.28123. [Epub ahead of print]

422.	Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival
	Yang XD1, Pan LH, Wang L, Ke Y, Cao J, Yang C, Zhong JH, Luo W, Guo J, Li LQ. Asian Pac J Cancer Prev. 2015;16(13):5541-5547.

423.	Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment of Recurrent Hepatocellular Carcinoma after Initial Resection: a Systematic Review and Meta-analysis
	Wang DY1, Liu L, Qi XS, Su CP, Chen X, Liu X, Chen J, Li HY, Guo XZ. Asian Pac J Cancer Prev. 2015;16(13):5573-5578.

424.	Hepatocellular Carcinoma in the Absence of Cirrhosis in US Veterans is Associated with Non-Alcoholic Fatty Liver Disease
	Mittal S1, El-Serag HB2, Sada YH3, Kanwal F2, Duan Z3, Temple S3, May SB3, Kramer JR3, Richardson PA3, Davila JA3. Clin Gastroenterol Hepatol. 2015 Jul 18. pii: S1542-3565(15)00978-7. doi: 10.1016/j.cgh.2015.07.019. [Epub ahead of print]

425.	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
	Kim WR1, Loomba R2, Berg T3, Aguilar Schall RE4, Yee LJ4, Dinh PV4, Flaherty JF4, Martins EB4, Therneau TM5, Jacobson I6, Fung S7, Gurel S8, Buti M9, Marcellin P10. Cancer. 2015 Jul 15. doi: 10.1002/cncr.29537. [Epub ahead of print]

426.	Development and performance of an algorithm to estimate the Child-Turcotte-Pugh Score from a national electronic healthcare database
	Kaplan DE1, Dai F2, Aytaman A3, Baytarian M4, Fox R5, Hunt K6, Knott A7, Pedrosa M4, Pocha C7, Mehta R2, Duggal M2, Skanderson M8, Valderrama A9, Taddei T2; VOCAL Study Group. Clin Gastroenterol Hepatol. 2015 Jul 15. pii: S1542-3565(15)00966-0. doi: 10.1016/j.cgh.2015.07.010. [Epub ahead of print]

427.	Hepatocellular carcinoma: Where there is unmet need
	Bupathi M1, Kaseb A2, Meric-Bernstam F1, Naing A3. Mol Oncol. 2015 Jun 25. pii: S1574-7891(15)00129-5. doi: 10.1016/j.molonc.2015.06.005. [Epub ahead of print]

428.	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study
	Daniele B1, Croitoru A2, Papandreou C3, Bronowicki JP4, Mathurin P5, Serejo F6, Stål P7, Turnes J8, Ratziu V9, Bodoky G10. Future Oncol. 2015 Jul 9:1-10. [Epub ahead of print]

429.	Hepatocellular carcinoma: From diagnosis to treatment
	Waghray A1, Murali AR1, Menon KN1. World J Hepatol. 2015 May 18;7(8):1020-9. doi: 10.4254/wjh.v7.i8.1020.

430.	Tivozanib: status of development
	Jamil MO1, Hathaway A, Mehta A. Curr Oncol Rep. 2015 Jun;17(6):451. doi: 10.1007/s11912-015-0451-3.

431.	Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results
	Cosgrove DP1, Reyes DK1, Pawlik TM1, Feng AL1, Kamel IR1, Geschwind JF1. Radiology. 2015 Jun 11:142481. [Epub ahead of print]

432.	Development and Internal Validation of a Model for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis
	Patel J1, Yopp A, Waljee A, Singal AG. J Clin Gastroenterol. 2015 Jun 25. [Epub ahead of print]

433.

Dietary Fat, Fat Subtypes and Hepatocellular Carcinoma in a Large European Cohort

Laursen AS7, Hansen L8, Overvad K7, Tjønneland A8, Boutron-Ruault MC9,10, Fagherazzi G9,10, His M9,10, Boeing H3, Katzke V11, Kühn T11, Trichopoulou A6,12, Valanou E4,12, Kritikou M12, Masala G13, Panico S14, Sieri S15, Ricceri F16,17, Tumino R18, Bueno-de-Mesquita HB19,20,21,22, Peeters PH21,23, Hjartåker A24, Skeie G25, Weiderpass E25,26,27,28, Ardanaz E29,30, Bonet C31, Chirlaque MD30,32, Dorronsoro M33, Quirós JR34, Johansson I35, Ohlsson B36, Sjöberg K36,37, Wennberg M38, Khaw KT39, Travis RC40, Wareham N41, Ferrari P1, Freisling H1, Romieu I1, Cross AJ42, Gunter M42, Lu Y42, Jenab M1. Int J Cancer. 2015 Jun 16. doi: 10.1002/ijc.29643. [Epub ahead

434.	Nonalcoholic fatty liver disease: a systematic review
	Rinella ME1. JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.

435.	Advances in targeted therapies for hepatocellular carcinoma in the genomic era
	Llovet JM1, Villanueva A1, Lachenmayer A2, Finn RS3. Nat Rev Clin Oncol. 2015 Jun 9. doi: 10.1038/nrclinonc.2015.103. [Epub ahead of print]

436.	Current systemic treatment of hepatocellular carcinoma: A review of the literature
	Chen KW1, Ou TM1, Hsu CW1, Horng CT1, Lee CC1, Tsai YY1, Tsai CC1, Liou YS1, Yang CC1, Hsueh CW1, Kuo WH1. World J Hepatol. 2015 Jun 8;7(10):1412-20. doi: 10.4254/wjh.v7.i10.1412.

437.	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin
	Ampuero J1, Romero-Gomez M1. World J Hepatol. 2015 May 18;7(8):1105-11. doi: 10.4254/wjh.v7.i8.1105.

438.	A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma
	Del Poggio P1, Olmi S, Ciccarese F, Mazzoleni M, Jazzetti M, Jamoletti C, Mattiello M, Del Poggio A, Portugali V, Stroffolini T. Eur J Gastroenterol Hepatol. 2015 Jun 5. [Epub ahead of print]

439.	A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014
	Wen Y1, Zheng YX1, Tan de M1. Hepat Mon. 2015 May 23;15(5):e27181. doi: 10.5812/hepatmon.15(5)2015.27181. eCollection 2015.

440.	Relationship between Obesity, Gut Microbiome and Hepatocellular Carcinoma Development
	Hara E1. Dig Dis. 2015;33(3):346-50. doi: 10.1159/000371679. Epub 2015 May 27.

441.	Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment
	Clark T1, Maximin S2, Meier J3, Pokharel S3, Bhargava P2. Curr Probl Diagn Radiol. 2015 Apr 16. pii: S0363-0188(15)00059-6. doi: 10.1067/j.cpradiol.2015.04.004. [Epub ahead of print]

442.	Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma
	Wang CH1, Wey KC, Mo LR, Chang KK, Lin RC, Kuo JJ. Asian Pac J Cancer Prev. 2015;16(9):3595-3604.

443.	Systematic Review of Catheter-Based Intraarterial Therapies in Hepatocellular Carcinoma: State of the Art and Future Directions
	Duran R1, Chapiro J, Schernthaner RE, Geschwind JF. Br J Radiol. 2015 May 15:20140564. [Epub ahead of print]

444.	I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis
	Feld JJ1, Lavoie ÉG2, Michel F2, Dranoff JA2. F1000Res. 2015 Apr 21;4:95. doi: 10.12688/f1000research.6368.1. eCollection 2015.

445.	Biphenotypic hepatic tumors: imaging findings and review of literature
	Wells ML1, Venkatesh SK, Chandan VS, Fidler JL, Fletcher JG, Johnson GB, Hough DM, Roberts LR. Abdom Imaging. 2015 May 8. [Epub ahead of print]

446.	Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial
	Hoffmann K1, Ganten T2, Gotthardtp D3, Radeleff B4, Settmacher U5, Kollmar O6, Nadalin S7, Karapanagiotou-Schenkel I8, von Kalle C9, Jäger D10, Büchler MW11, Schemmer P12,13. BMC Cancer. 2015 May 11;15(1):392. [Epub ahead of print]

447.	Elevated Alpha-Fetoprotein: Differential Diagnosis - Hepatocellular Carcinoma and Other Disorders
	Wong RJ1, Ahmed A2, Gish RG3. Clin Liver Dis. 2015 May;19(2):309-323. doi: 10.1016/j.cld.2015.01.005. Epub 2015 Feb 27.

448.	Classification and Staging of Hepatocellular Carcinoma: An Aid to Clinical Decision-Making
	Addissie BD1, Roberts LR2. Clin Liver Dis. 2015 May;19(2):277-294. doi: 10.1016/j.cld.2015.01.011.

449.	Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease
	Wensheng L1, Baker SS, Baker RD, Zhu L. Curr Drug Targets. 2015 Apr 27. [Epub ahead of print]

450.	Effects of statins on the risk of hepatocellular carcinoma
	Mansourian PG1, Yoneda M1, Krishna Rao M1, Martinez FJ1, Thomas E1, Schiff ER1. Gastroenterol Hepatol (N Y). 2014 Jul;10(7):417-26.

451.	Anatomic Pathology of Hepatocellular Carcinoma: Histopathology Using Classic and New Diagnostic Tools
	Pittman ME1, Brunt EM2. Clin Liver Dis. 2015 May;19(2):239-259. doi: 10.1016/j.cld.2015.01.003. Epub 2015 Mar 10.

452.	Global Epidemiology of Hepatocellular Carcinoma: An Emphasis on Demographic and Regional Variability
	McGlynn KA1, Petrick JL2, London WT3. Clin Liver Dis. 2015 May;19(2):223-238. doi: 10.1016/j.cld.2015.01.001. Epub 2015 Feb 26.

453.	Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation
	Faitot F1, Allard MA, Pittau G, Ciacio O, Adam R, Castaing D, Sa Cunha A, Pelletier G, Cherqui D, Samuel D, Vibert E. Hepatology. 2015 Apr 24. doi: 10.1002/hep.27864. [Epub ahead of print]

454.	NAFLD: A multisystem disease
	Byrne CD1, Targher G2. J Hepatol. 2015 Apr;62(1S):S47-S64. doi: 10.1016/j.jhep.2014.12.012.

455.	Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation
	Scatton O1, Goumard C, Cauchy F, Fartoux L, Perdigao F, Conti F, Calmus Y, Boelle PY, Belghiti J, Rosmorduc O, Soubrane O. J Surg Oncol. 2015 Apr 28. doi: 10.1002/jso.23916. [Epub ahead of print]

456.	Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study
	Shaw CM1, Eisenbrey JR2, Lyshchik A1, O'Kane PL1, Merton DA1, Machado P1, Pino L1, Brown DB1, Forsberg F1. J Ultrasound Med. 2015 May;34(5):278-4297. doi: 10.7863/ultra.34.5.859.

457.	Tivozanib: status of development
	Jamil MO1, Hathaway A, Mehta A. Curr Oncol Rep. 2015 Jun;17(6):451. doi: 10.1007/s11912-015-0451-3.

458.	The Race to Liver Transplantation: A Comparison of Patients With and Without Hepatocellular Carcinoma from Listing to Post-Transplantation
	Patel MS1, Kohn R2, Kratz JR3, Shah JA1, Markmann JF1, Vagefi PA4. J Am Coll Surg. 2015 Jan 21. pii: S1072-7515(15)00031-9. doi: 10.1016/j.jamcollsurg.2014.12.050. [Epub ahead of print]

459.	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
	Lee IC1, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Medicine (Baltimore). 2015 Apr;94(14):e688. doi: 10.1097/MD.0000000000000688.

460.	Associations between Pre-S Deletion Mutation of Hepatitis B Virus and Risk of Hepatocellular Carcinoma in the Asian Population: A Meta-Analysis
	Wang C1, Teng Z2, Zhu Y2, Zhao AZ1, Sun C3. Med Sci Monit. 2015 Apr 14;21:1072-7. doi: 10.12659/MSM.894058.

461.	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
	Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Hepatol Res. 2015 Apr;45(4):363-77. doi: 10.1111/hepr.12511.

462.	Management of hepatocellular carcinoma with portal vein thrombosis
	Quirk M1, Kim YH1, Saab S1, Lee EW1. World J Gastroenterol. 2015 Mar 28;21(12):3462-3471.

463.	The evolving epidemiology of hepatocellular carcinoma: a global perspective
	Wallace MC1, Preen D, Jeffrey GP, Adams LA. Expert Rev Gastroenterol Hepatol. 2015 Apr 1:1-15. [Epub ahead of print]

464.	Overexpression of C-reactive Protein as a Poor Prognostic Marker of Resectable Hepatocellular Carcinomas
	Shin JH1, Kim CJ1, Jeon EJ1, Sung CO1, Shin HJ1, Choi J1, Yu E1. J Pathol Transl Med. 2015 Mar;49(2):105-11. doi: 10.4132/jptm.2015.01.19. Epub 2015 Mar 12.

465.	Analysis of prognostic factors for survival after hepatectomy for hepatocellular carcinoma based on a bayesian network
	Cai ZQ1, Si SB2, Chen C3, Zhao Y4, Ma YY3, Wang L3, Geng ZM3. PLoS One. 2015 Mar 31;10(3):e0120805. doi: 10.1371/journal.pone.0120805. eCollection 2015.

466.	Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does ?-fetoprotein still have a role?
	Webb GJ1, Wright KV2, Harrod EC3, Gorard DA4, Collier JD5, Evans AK6. Clin Med. 2015 Apr;15(2):139-44. doi: 10.7861/clinmedicine.15-2-139.

467.	Liver Transplantation for Hepatocellular Carcinoma: Analysis of Factors Predicting Outcome in 1074 Patients in OPTN Region 5
	Macdonald B1, Sewell JL, Harper AM, Roberts JP, Yao FY. Clin Transplant. 2015 Mar 17. doi: 10.1111/ctr.12542. [Epub ahead of print]

468.	CEUS in Hepatocellular Carcinoma and Intrahepatic Cholangiocellular Carcinoma in 320 Patients - Early or Late Washout Matters: A Subanalysis of the DEGUM Multicenter Trial
	Wildner D1, Bernatik T2, Greis C3, Seitz K4, Neurath MF1, Strobel D1. Ultraschall Med. 2015 Mar 26. [Epub ahead of print]

469.	Lenvatinib: First Global Approval
	Scott LJ1. Drugs. 2015 Mar 21. [Epub ahead of print]

470.	Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective
	Willatt J1, Hannawa KK1, Ruma JA1, Frankel TL1, Owen D1, Barman PM1. World J Hepatol. 2015 Feb 27;7(2):235-44. doi: 10.4254/wjh.v7.i2.235.

471.	Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
	Park JW1, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Liver Int. 2015 Mar 5. doi: 10.1111/liv.12818. [Epub ahead of print]

472.	Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know
	Reynolds AR1, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT, Tublin ME. Radiographics. 2015 Mar-Apr;35(2):371-386.

473.

Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project

McGlynn KA1, Sahasrabuddhe VV1, Campbell PT2, Graubard BI1, Chen J1, Schwartz LM1, Petrick JL1, Alavanja MC1, Andreotti G1, Boggs DA3, Buring JE4, Chan AT5, Freedman ND1, Gapstur SM2, Hollenbeck AR6, Hou L7, King LY5, Koshiol J1, Linet M1, Palmer JR3, Poynter JN8, Purdue M1, Robien K9, Schairer C1, Sesso HD4, Sigurdson A1, Wactawski-Wende J10, Zeleniuch-Jacquotte A11. Br J Cancer. 2015 Mar 5. doi: 10.1038/bjc.2015.58. [Epub ahead of print]

474.

Fruit and vegetable consumption in relation to hepatocellular carcinoma in a multi-centre, European cohort study

Bamia C1, Lagiou P2, Jenab M3, Aleksandrova K4, Fedirko V5, Trichopoulos D6, Overvad K7, Tjønneland A8, Olsen A8, Clavel-Chapelon F9, Boutron-Ruault MC9, Kvaskoff M9, Katzke VA10, Kühn T10, Boeing H4, Nöthlings U11, Palli D12, Sieri S13, Panico S14, Tumino R15, Naccarati A16, Bueno-de-Mesquita HA17, Peeters PH18, Weiderpass E19, Skeie G20, Quirós JR21, Agudo A22, Chirlaque MD23, Sanchez MJ24, Ardanaz E25, Dorronsoro M26, Ericson U27, Nilsson LM28, Wennberg M29, Khaw KT30, Wareham N31, Key TJ32, Travis RC32, Ferrari P3, Stepien M3, Duarte-Salles T3, Norat T33, Murphy N33, Riboli E33, Trichopoulou A34. Br J Cancer. 2015 Mar 5. doi: 10.1038/bjc.2014.654. [Epub ahead of print]

475.	Surgical Treatment of Hepatocellular Carcinoma in North America: Can Hepatic Resection Still Be Justified?
	Chapman WC1, Klintmalm G2, Hemming A3, Vachharajani N4, Majella Doyle MB4, DeMatteo R5, Zaydfudim V6, Chung H4, Cavaness K2, Goldstein R2, Zendajas I7, Melstrom LG8, Nagorney D9, Jarnagin W5. J Am Coll Surg. 2015 Jan 6. pii: S1072-7515(14)01927-9. doi: 10.1016/j.jamcollsurg.2014.12.030. [Epub ahead of print]

476.	Liver Transplantation for Hepatocellular Carcinoma
	Rude MK1, Crippin JS. Curr Gastroenterol Rep. 2015 Mar;17(3):435.

477.	Tuberculosis reactivation in hepatocellular carcinoma: association with transarterial chemoembolization
	Laake AM1, Liappis AP, Guy E, Kerr G, Benator DA. Infect Dis (Lond). 2015 Feb 17:1-4. [Epub ahead of print]

478.	Sorafenib or 90Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?
	Garin E1, Rolland Y, Edeline J. Liver Int. 2015 Feb 18. doi: 10.1111/liv.12811. [Epub ahead of print]

479.	Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
	Ren Z1, Zhu K1, Kang H1, Lu M1, Qu Z1, Lu L1, Song T1, Zhou W1, Wang H1, Yang W1, Wang X1, Yang Y1, Shi L1, Bai Y1, Guo X1, Ye SL2. J Clin Oncol. 2015 Feb 9. pii: JCO.2013.52.9651. [Epub ahead of print]

480.	MELDEQ : An alternative MELD score for patients with hepatocellular carcinoma
	Marvin MR1, Ferguson N, Cannon RM, Jones C, Brock GN. Liver Transpl. 2015 Feb 18. doi: 10.1002/lt.24098. [Epub ahead of print]

481.	Risk factors for the Long-Term Efficacy, Recurrence, and Metastasis in Small Hepatocellular Carcinomas
	Chen Y1, Gao SG, Chen JM, Wang GP, Wang ZF, Zhou B, Jin CH, Yang YT, Feng XS. Cell Biochem Biophys. 2015 Feb 8. [Epub ahead of print]

482.	Emerging role of microRNA in hepatocellular carcinoma (Review)
	Gong J1, He XX1, Tian A1. Oncol Lett. 2015 Mar;9(3):1027-1033. Epub 2014 Dec 19.

483.	Cigarette smoking increases risk of early morbidity after hepatic resection in patients with hepatocellular carcinoma
	Lv Y1, Liu C1, Wei T2, Zhang JF1, Liu XM1, Zhang XF3. Eur J Surg Oncol. 2015 Jan 26. pii: S0748-7983(15)00027-X. doi: 10.1016/j.ejso.2015.01.015. [Epub ahead of print]

484.	Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes
	Yang W1, Yan K1, Wu GX1, Wu W1, Fu Y1, Lee JC1, Zhang ZY1, Wang S1, Chen MH1. World J Gastroenterol. 2015 Feb 7;21(5):1554-66. doi: 10.3748/wjg.v21.i5.1554.

485.	Glutamate dehydrogenase and alkaline phosphatase as very early predictors of hepatocellular carcinoma recurrence after liver transplantation
	Piras-Straub K1, Khairzada K, Gerken G, Saner F, Treckmann J, Paul A, Canbay A, Herzer K. Digestion. 2015;91(2):117-27. doi: 10.1159/000370212. Epub 2015 Jan 30.

486.	Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review
	Kalogeridi MA1, Zygogianni A1, Kyrgias G1, Kouvaris J1, Chatziioannou S1, Kelekis N1, Kouloulias V1. World J Hepatol. 2015 Jan 27;7(1):101-12. doi: 10.4254/wjh.v7.i1.101.

487.	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis
	Kim MN1, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song KJ, Park YN, Han KH. Hepatology. 2015 Jan 30. doi: 10.1002/hep.27735. [Epub ahead of print]

488.	Clinical trial watch: reports from the Liver Meeting (American Association for the Study of Liver Diseases), Boston, November 2014
	Londoño MC1, Abraldes JG2, Altamirano J3, Deacens T4, Forns X5. J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00059-8. doi: 10.1016/j.jhep.2015.01.028. [Epub ahead of print]

489.	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma
	Kim BK1, Kim SU2, Kim KA3, Chung YE4, Kim MJ4, Park MS4, Park JY1, Kim DY1, Ahn SH5, Kim MD4, Park SI4, Won JY4, Lee DY4, Han KH5. J Hepatol. 2015 Jan 28. pii: S0168-8278(15)00053-7. doi: 10.1016/j.jhep.2015.01.022. [Epub ahead of print]

490.	Hepatitis C screening
	Joshi SN1. Ochsner J. 2014 Winter;14(4):664-8.

491.	The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 cases
	Hu S1, Zhao L2, Yang J1, Hu M1. Meta Gene. 2013 Oct 30;1:126-37. doi: 10.1016/j.mgene.2013.09.010. eCollection 2013.

492.	From minimal to maximal surgery in the treatment of hepatocarcinoma: A review
	Perini MV1, Starkey G1, Fink MA1, Bhandari R1, Muralidharan V1, Jones R1, Christophi C1. World J Hepatol. 2015 Jan 27;7(1):93-100. doi: 10.4254/wjh.v7.i1.93.

493.	Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization
	Ray CE Jr1, Brown AC, Green TJ, Winston H, Curran C, Kreidler SM, Glueck DH, Rochon PJ. AJR Am J Roentgenol. 2015 Feb;204(2):440-7. doi: 10.2214/AJR.14.12844.

494.	USP7 accelerates p14ARF degradation by deubiquitinating TRIP12 and promotes HCC progression
	Cai JB1, Shi GM, Dong ZR, Ke AW, Ma HH, Gao Q, Shen ZZ, Huang XY, Chen H, Yu DD, Liu LX, Zhang PF, Zhang C, Hu MY, Yang LX, Shi YH, Wang XY, Ding ZB, Qiu SJ, Sun HC, Zhou J, Shi YG, Fan J. Hepatology. 2014 Dec 29. doi: 10.1002/hep.27682. [Epub ahead of print]

495.	Comparison of improved prognosis between hepatitis B- and hepatitis C- related hepatocellular carcinoma
	Minami T1, Tateishi R, Shiina S, Nakagomi R, Kondo M, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Koike K. Hepatol Res. 2015 Jan 6. doi: 10.1111/hepr.12468. [Epub ahead of print]

496.	Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal?
	Cabibbo G1, Antonucci M, Sacco R, Sciarrino E. Expert Rev Anticancer Ther. 2015 Jan 6:1-4. [Epub ahead of print]

497.	Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies
	Oda K1, Uto H, Mawatari S, Ido A. Clin J Gastroenterol. 2015 Jan 10. [Epub ahead of print]

498.	Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
	Hollebecque A1, Malka D2, Ferté C2, Ducreux M2, Boige V3. Eur J Cancer. 2015 Jan 2. pii: S0959-8049(14)01165-4. doi: 10.1016/j.ejca.2014.12.005. [Epub ahead of print]

499.	Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI
	Nojiri S1, Fujiwara K1, Shinkai N1, Endo M1, Joh T1. World J Hepatol. 2014 Dec 27;6(12):930-8. doi: 10.4254/wjh.v6.i12.930.

500.	Current and future HCV therapy: do we still need other anti-HCV drugs?
	Petta S1, Craxì A. Liver Int. 2015 Jan;35 Suppl 1:4-10. doi: 10.1111/liv.12714.

501.	Optimal Methods for Measuring Eligibility for Liver Transplant in Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization
	Kim H1, Shim JH2, Kim G3, Shin YM4, Yu E5, Lee S6, Lee D3, Kim KM3, Lim Y3, Lee HC3, Chung Y3, Lee YS3. J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00934-9. doi: 10.1016/j.jhep.2014.12.013. [Epub ahead of print]

502.	Treatment of hepatocellular carcinoma: beyond international guidelines
	Colombo M1, Sangiovanni A. Liver Int. 2015 Jan;35 Suppl 1:129-38. doi: 10.1111/liv.12713.

503.	Non-hypervascular Hepatobiliary phase Hypointense Nodules on Gadoxetic Acid-enhanced MRI: Risk of HCC Recurrence after Radiofrequency Ablation
	Lee DH1, Lee JM2, Lee JY3, Kim SH3, Kim JH3, Yoon JH4, Kim YJ4, Lee J4, Yu SJ4, Han JK3, Choi BI3. J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00936-2. doi: 10.1016/j.jhep.2014.12.015. [Epub ahead of print]

504.	Liver Resection For Hepatocellular Carcinoma in 313 Western Patients: Tumor Biology and Underlying Liver Rather than Tumor Size Drive Prognosis
	Kluger MD1, Salceda JA2, Laurent A2, Tayar C2, Duvoux C3, Decaens T3, Luciani A4, Van Nhieu JT5, Azoulay D2, Cherqui D6. J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00939-8. doi: 10.1016/j.jhep.2014.12.018. [Epub ahead of print]

505.	Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation
	Kim JH1, Sohn BH2, Lee HS2, Kim SB2, Yoo JE3, Park YY4, Jeong W5, Lee SS6, Park ES7, Kaseb A8, Kim BH9, Kim WB10, Yeon JE11, Byun KS11, Chu IS12, Kim SS13, Wang XW14, Thorgeirsson SS15, Luk JM16, Kang KJ17, Heo J18, Park YN3, Lee JS19. PLoS Med. 2014 Dec 23;11(12):e1001770. doi: 10.1371/journal.pmed.1001770. eCollection 2014.

506.	Portal Vein Thrombosis Is Not Associated With Increased Mortality Among Patients With Cirrhosis
	Berry K1, Taylor J2, Liou IW2, Ioannou GN3. Clin Gastroenterol Hepatol. 2014 Oct 18. pii: S1542-3565(14)01501-8. doi: 10.1016/j.cgh.2014.10.010. [Epub ahead of print]

507.	Systemic Therapy for Hepatocellular Carcinoma and Cholangiocarcinoma
	Chung V. Surg Oncol Clin N Am. 2015 Jan;24(1):187-198. doi: 10.1016/j.soc.2014.09.009. Epub 2014 Oct 12.

508.	Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants
	Pais R1, Lebray P1, Rousseau G2, Charlotte F3, Esselma G1, Savier E2, Thabut D1, Rudler M1, Eyraud D4, Vezinet C4, Siksik JM2, Vaillant JC2, Hannoun L2, Poynard T1, Ratziu V5.

509.	An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma
	Peng S1, Zhao Y1, Xu F1, Jia C1, Xu Y1, Dai C1. PLoS One. 2014 Dec 2;9(12):e112530. doi: 10.1371/journal.pone.0112530. eCollection 2014.

510.	Reports from the International Liver Cancer Association (ILCA) congress 2014
	Nault JC1. J Hepatol. 2014 Nov 22. pii: S0168-8278(14)00859-9. doi: 10.1016/j.jhep.2014.11.015. [Epub ahead of print]

511.	Development of risk scoring system for stratifying population for hepatocellular-carcinoma screening
	Hung YC1, Lin CL, Liu CJ, Hung H, Lin SM, Lee SD, Chen PJ, Chuang SC, Yu MW. Hepatology. 2014 Nov 21. doi: 10.1002/hep.27610. [Epub ahead of print]

512.	Hepatitis C Virus-Associated Cancer
	Lin MV1, King LY, Chung RT. Annu Rev Pathol. 2014 Nov 5. [Epub ahead of print]

513.	Treatment of hepatocellular carcinoma with child-pugh C cirrhosis
	Nouso K1, Kokudo N, Tanaka M, Kuromatsu R, Nishikawa H, Toyoda H, Oishi N, Kuwaki K, Kusanaga M, Sakaguchi T, Morise Z, Kitai S, Kudo M. Oncology. 2014;87 Suppl 1:99-103. doi: 10.1159/000368152. Epub 2014 Nov 22.

514.	Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis
	Cai H1, Kong W, Zhou T, Qiu Y. Medicine (Baltimore). 2014 Nov;93(22):e122. doi: 10.1097/MD.0000000000000122.

515.	Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib
	Arizumi T1, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Dig Dis. 2014;32(6):705-10. doi: 10.1159/000368006. Epub 2014 Oct 29.

516.	Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection
	Yamada R1, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T; the Osaka Liver Forum. J Gastroenterol. 2014 Nov 11. [Epub ahead of print]

517.	Metformin does not improve survival in patients with hepatocellular carcinoma
	Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. World J Gastroenterol. 2014 Nov 14;20(42):15750-5. doi: 10.3748/wjg.v20.i42.15750.

518.	Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0-B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
	Feng X1, Xu R2, Du X3, Dou K4, Qin X5, Xu J6, Jia W7, Wang Z8, Zhao H9, Yang S10, Guo C11, Liu T12, Ma K1. Am J Gastroenterol. 2014 Nov 18. doi: 10.1038/ajg.2014.343. [Epub ahead of print]

519.	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST
	Reig M1, Darnell A2, Forner A1, Rimola J3, Ayuso C3, Bruix J1. Semin Liver Dis. 2014 Nov;34(4):444-55. doi: 10.1055/s-0034-1394143. Epub 2014 Nov 4.

520.	Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage - a hospital based linkage study
	Huang Y1, de Boer WB, Adams LA, MacQuillan G, Bulsara MK, Jeffrey GP. Intern Med J. 2014 Nov 5. doi: 10.1111/imj.12626. [Epub ahead of print]

521.	Chronic Hepatitis B and Liver Cancer Risks among Asian Immigrants in New York City: Results from a Large, Community-Based Screening, Evaluation, and Treatment Program
	Pollack HJ1, Kwon SC2, Wang SH3, Wyatt LC2, Trinh-Shevrin C2; AAHBP Coalition. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2229-39. doi: 10.1158/1055-9965.EPI-14-0491.

522.	Hepatocellular carcinoma screening and diagnosis
	Sherman M1, Colombo M2. Semin Liver Dis. 2014 Nov;34(4):389-97. doi: 10.1055/s-0034-1394139. Epub 2014 Nov 4.

523.	Adjuvant therapy for hepatocellular carcinoma after curative treatment
	Jeng WJ1, Lin CC, Chen WT, Sheen IS, Lin CY, Lin SM. Dig Dis. 2014;32(6):747-54. doi: 10.1159/000368017. Epub 2014 Oct 29.

524.	Review article: the management of cirrhosis in women
	Allen AM1, Hay JE. Aliment Pharmacol Ther. 2014 Sep 28. doi: 10.1111/apt.12974. [Epub ahead of print]

525.

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study

Curry MP1, Forns X2, Chung RT3, Terrault NA4, Brown R Jr5, Fenkel JM6, Gordon F7, O'Leary J8, Kuo A9, Schiano T10, Everson G11, Schiff E12, Befeler A13, Gane E14, Saab S15, McHutchison JG16, Subramanian GM16, Symonds WT16, Denning J16, McNair L16, Arterburn S16, Svarovskaia E16, Moonka D17, Afdhal N18. Gastroenterology. 2014 Sep 24. pii: S0016-5085(14)01145-7. doi: 10.1053/j.gastro.2014.09.023. [Epub ahead of print]

526.	Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice
	Choi GH1, Han S, Shim JH, Ryu MH, Ryoo BY, Kang YK, Kim KM, Lim YS, Lee HC. Am J Clin Oncol. 2014 Sep 29. [Epub ahead of print]

527.	Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension
	Zhong JH1, Li H2, Xiao N3, Ye XP4, Ke Y1, Wang YY1, Ma L1, Chen J1, You XM1, Zhang ZY1, Lu SD1, Li LQ1. PLoS One. 2014 Sep 30;9(9):e108755. doi: 10.1371/journal.pone.0108755. eCollection 2014.

528.	Effects of Mutations of 3 Amino Acids on Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
	Lin LL1, Wang W2, Chang J1, Song X2, Yu R1, Qiu DM3. Technol Cancer Res Treat. 2014 Sep 26. pii: 1533034614547455. [Epub ahead of print]

529.	Hepatocellular carcinoma tumour markers: Current role and expectations
	Rich N1, Singal AG2. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):843-853. doi: 10.1016/j.bpg.2014.07.018. Epub 2014 Aug 22.

530.	Prognosis prediction and staging
	Forner A1, Díaz-González A2, Liccioni A2, Vilana R3. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):855-865. doi: 10.1016/j.bpg.2014.08.002. Epub 2014 Aug 23.

531.	Magnetic Resonance Imaging with Gadoxetic Acid Disodium for the Detection of Hepatocellular Carcinoma: A Meta-analysis of 18 Studies
	Chen L1, Zhang L2, Liang M2, Bao J3, Zhang J2, Xia Y4, Huang X2, Wang J5. Acad Radiol. 2014 Sep 25. pii: S1076-6332(14)00310-9. doi: 10.1016/j.acra.2014.08.003. [Epub ahead of print]

532.	Prognostic value of enzymatic liver function for the estimation of short-term survival of liver transplant candidates: a prospective study with the LiMAx test
	Jara M1, Malinowski M, Lüttgert K, Schott E, Neuhaus P, Stockmann M. Transpl Int. 2014 Sep 2. doi: 10.1111/tri.12441. [Epub ahead of print]

533.	Comparison of standard-dose and half?dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis
	Nishikawa H1, Osaki Y1, Endo M1, Takeda H1, Tsuchiya K2, Joko K3, Ogawa C4, Taniguchi H5, Orito E6, Uchida Y7, Izumi N2. Int J Oncol. 2014 Sep 16. doi: 10.3892/ijo.2014.2654. [Epub ahead of print]

534.	Role of antiviral treatment for HCC prevention
	Colombo M1, Iavarone M2. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):771-781. doi: 10.1016/j.bpg.2014.07.017. Epub 2014 Aug 23.

535.	Surveillance for hepatocellular carcinoma
	Sherman M. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):783-793. doi: 10.1016/j.bpg.2014.08.008. Epub 2014 Aug 23.

536.	Radiofrequency Ablation versus Laser Ablation for the Treatment of Small Hepatocellular Carcinoma in Cirrhosis: a Randomized Trial
	Di Costanzo GG1, Tortora R, D Adamo G, De Luca M, Lampasi F, Addario L, Galeota Lanza A, Picciotto FP, Tartaglione MT, Cordone G, Imparato M, Mattera S, Pacella CM. J Gastroenterol Hepatol. 2014 Sep 24. doi: 10.1111/jgh.12791. [Epub ahead of print]

537.	Hepatocellular carcinoma epidemiology
	Bosetti C1, Turati F2, La Vecchia C3. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):753-770. doi: 10.1016/j.bpg.2014.08.007. Epub 2014 Aug 23.

538.	A meta-analysis of Cinobufacini combined with transcatheterarterial chemoembolization in the treatment of advanced hepatocellular carcinoma
	Wu T, Sun R, Wang Z, Yang W, Shen S, Zhao Z1. J Cancer Res Ther. 2014 Aug;10 Suppl:C60-4. doi: 10.4103/0973-1482.139763.

539.	Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation
	Bian H1, Zheng JS1, Nan G1, Li R1, Chen C1, Hu CX1, Zhang Y1, Sun B1, Wang XL1, Cui SC1, Wu J1, Xu J1, Wei D1, Zhang X1, Liu H1, Yang W1, Ding Y1, Li J1, Chen ZN2. J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju239. doi: 10.1093/jnci/dju239. Print 2014 Aug.

540.	Detecting patients with cirrhosis in primary care
	Keane MG, Lai C, Pereira SP. Practitioner. 2014 Jul-Aug;258(1773):15-20, 2-3.

541.	Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: A meta-analysis
	Fu F, Wan Y1; Mulati, Wu T. J Cancer Res Ther. 2014 Aug;10 Suppl:C38-41. doi: 10.4103/0973-1482.139753.

542.	Dietary Supplement Use Among Patients With Hepatocellular Carcinoma
	Lee V1, Goyal A1, Hsu CC1, Jacobson JS1, Rodriguez RD1, Siegel AB2. Integr Cancer Ther. 2014 Sep 15. pii: 1534735414550038. [Epub ahead of print]

543.

Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: Multi-centre, prospective cohort study

Bamia C1, Lagiou P, Jenab M, Trichopoulou A, Fedirko V, Aleksandrova K, Pischon T, Overvad K, Olsen A, Tjønneland A, Boutron-Ruault MC, Fagherazzi G, Racine A, Kuhn T, Boeing H, Floegel A, Benetou V, Palli D, Grioni S, Panico S, Tumino R, Vineis P, Bueno-De-Mesquita HB, Dik VK, Bhoo-Pathy N, Uiterwaal CS, Weiderpass E, Lund E, Quirós JR, Zamora-Ros R, Molina-Montes E, Chirlaque MD, Ardanaz E, Dorronsoro M, Lindkvist B, Wallström P, Nilsson LM, Sund M, Khaw KT, Wareham N, Bradbury KE, Travis RC, Ferrari P, Duarte-Salles T, Stepien M, Gunter M, Murphy N, Riboli E, Trichopoulos D. Int J Cancer. 2014 Sep 15. doi: 10.1002/ijc.29214. [Epub ahead of print]

544.	Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses
	Thiele M1, Gluud LL2, Fialla AD1, Dahl EK1, Krag A1. PLoS One. 2014 Sep 16;9(9):e107177. doi: 10.1371/journal.pone.0107177. eCollection 2014.

545.	Portal hypertension on the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis
	Berzigotti A1, Reig M, Abraldes JG, Bosch J, Bruix J. Hepatology. 2014 Sep 12. doi: 10.1002/hep.27431. [Epub ahead of print]

546.	Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: A meta-analysis
	Zheng Z1, Liang W, Wang D, Schroder PM, Ju W, Wu L, Zheng Z, Shang Y, Guo Z, He X. Int J Cancer. 2014 Sep 10. doi: 10.1002/ijc.29203. [Epub ahead of print]

547.	No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up
	van Meer S1, de Man RA, van den Berg AP, Houwen RH, Linn FH, van Oijen MG, Siersema PD, van Erpecum KJ. J Gastroenterol Hepatol. 2014 Aug 26. doi: 10.1111/jgh.12716. [Epub ahead of print]

548.	Hepatocellular carcinoma: systemic therapies and future perspectives
	Mikhail S1, Cosgrove D, Zeidan A. Expert Rev Anticancer Ther. 2014 Sep 9:1-14. [Epub ahead of print]

549.	The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma
	Kinoshita A1, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M. Ann Surg Oncol. 2014 Sep 5. [Epub ahead of print]

550.	The Effect of a Regional Hepatopancreaticobiliary Surgical Program on Clinical Volume, Quality of Cancer Care, and Outcomes in the Veterans Affairs System
	Lau K1, Salami A1, Barden G2, Khawja S1, Castillo DL1, Poppelaars V3, Artinyan A4, Awad SS5, Berger DH5, Albo D6, Anaya DA5. JAMA Surg. 2014 Sep 10. doi: 10.1001/jamasurg.2014.1711. [Epub ahead of print]

551.	Persistent hypoglycemia as an early, atypical presentation of hepatocellular carcinoma: A case report and systematic review of the literature
	Tsai CY1, Chou SC1, Liu HT2, Lin JD3, Lin YC4. Oncol Lett. 2014 Oct;8(4):1810-1814. Epub 2014 Jul 18.

552.

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey

Santini D1, Pantano F1, Riccardi F2, Di Costanzo GG3, Addeo R4, Guida FM1, Ceruso MS1, Barni S5, Bertocchi P6, Marinelli S7, Marchetti P8, Russo A9, Scartozzi M10, Faloppi L10, Santoni M10, Cascinu S10, Maiello E11, Silvestris F12, Tucci M12, Ibrahim T13, Masi G14, Gnoni A15, Comandone A16, Fazio N17, Conti A18, Imarisio I19, Pisconti S20, Giommoni E21, Cinieri S22, Catalano V23, Palmieri VO24, Infante G25, Aieta M26, Trogu A27, Gadaleta CD28, Brunetti AE29, Lorusso V29, Silvestris N29. PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014.

553.	Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans
	El-Serag HB1, Kramer J2, Duan Z2, Kanwal F1. Am J Gastroenterol. 2014 Jul 29. doi: 10.1038/ajg.2014.214. [Epub ahead of print]

554.	Serum autoantibody measurement for the detection of hepatocellular carcinoma
	Middleton CH1, Irving W2, Robertson JF1, Murray A3, Parsy-Kowalska CB3, Macdonald IK3, McElveen J3, Allen J3, Healey GF3, Thomson BJ2, Ryder SJ2, Holdenrieder S4, Chapman CJ1. PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.

555.	The combination of TACE (transcatheter arterial chemombolization) and sorafenib is well-tolerated and effective in Asian Patients with hepatocellular carcinoma: Final results of the START trial
	Chao Y1, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY. Int J Cancer. 2014 Aug 5. doi: 10.1002/ijc.29126. [Epub ahead of print]

556.	Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality
	Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J. BMC Gastroenterol. 2014 Aug 7;14(1):137. [Epub ahead of print]

557.	Ischemia time impacts recurrence of hepatocellular carcinoma following liver transplantation
	Nagai S1, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, Florman SS. Hepatology. 2014 Aug 7. doi: 10.1002/hep.27358. [Epub ahead of print]

558.	Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer
	Wang Y1, Luo Q2, Li Y3, Wang H4, Deng S5, Wei S5, Li X3. PLoS One. 2014 Aug 8;9(8):e103939. doi: 10.1371/journal.pone.0103939. eCollection 2014.

559.	Clinical outcome of small hepatocellular carcinoma after different treatments: A meta-analysis
	Dong W, Zhang T, Wang ZG, Liu H. World J Gastroenterol. 2014 Aug 7;20(29):10174-82. doi: 10.3748/wjg.v20.i29.10174.

560.	Health-related quality of life as a prognostic factor in patients with advanced cancer
	Steel JL1, Geller DA, Robinson TL, Savkova AY, Brower DS, Marsh JW, Tsung A. Cancer. 2014 Aug 7. doi: 10.1002/cncr.28902. [Epub ahead of print]

561.	The Role of Bridge Therapy Prior to Orthotopic Liver Transplantation
	Prasad MA, Kulik LM. J Natl Compr Canc Netw. 2014 Aug;12(8):1183-1191.

562.	Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma
	Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. J Gastrointest Oncol. 2014 Aug;5(4):259-64. doi: 10.3978/j.issn.2078-6891.2014.036.

563.	Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance
	Singal AG1, Li X2, Tiro J3, Kandunoori P4, Adams-Huet B2, Nehra MS4, Yopp A5. Am J Med. 2014 Aug 9. pii: S0002-9343(14)00665-2. doi: 10.1016/j.amjmed.2014.07.027. [Epub ahead of print]

564.	Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer.
	Ravi S1, Singal AK2. Core Evid. 2014 Jul 17;9:81-7. doi: 10.2147/CE.S48626. eCollection 2014.

565.	Suboptimal Knowledge of and Surveillance for Hepatocellular Carcinoma by Primary Care Providers
	McGowan CE1, Edwards TP2, Luong MU1, Hayashi PH3. Clin Gastroenterol Hepatol. 2014 Aug 9. pii: S1542-3565(14)01141-0. doi: 10.1016/j.cgh.2014.07.056. [Epub ahead of print]

566.	Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma
	Tsuchiya K, Asahina Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Izumi N. Liver Transpl. 2014 Mar;20(3):291-7.

567.	Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma
	Furtado R1, Crawford M, Sandroussi C. Ann Surg Oncol. 2014 Apr 18. [Epub ahead of print]

568.	Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites
	Lutz P1, Parcina M2, Bekeredjian-Ding I2, Nischalke HD1, Nattermann J1, Sauerbruch T3, Hoerauf A2, Strassburg CP1, Spengler U1. PLoS One. 2014 Apr 8;9(4):e93909. doi: 10.1371/journal.pone.0093909. eCollection 2014.

569.	Adjuvant Intraarterial Lipiodol or 131I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial
	Dumortier J1, Decullier E, Hilleret MN, Bin-Dorel S, Valette PJ, Boillot O, Partensky C, Letoublon C, Ducerf C, Leroy V, Vuillez JP, Borson-Chazot F. J Nucl Med. 2014 Apr 10. [Epub ahead of print]

570.	Psychometric properties of a brief, clinically relevant measure of pain in patients with hepatocellular carcinoma
	Butt Z1, Lai JS, Beaumont JL, Kaiser K, Mallick R, Cella D, Steel JL. Qual Life Res. 2014 Apr 20. [Epub ahead of print]

571.	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use
	Giannini EG1, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) Group. Cancer. 2014 Apr 10. doi: 10.1002/cncr.28706. [Epub ahead of print]

572.	Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
	Okita K1, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. J Gastroenterol. 2014 Apr 13. [Epub ahead of print]

573.	Expanded criteria for hepatocellular carcinoma after liver transplantation: a 20-year evolution
	Lai Q, Nudo F, Mennini G, Spoletini G, Morabito V, Levi SG, Melandro F, Guglielmo N, Berloco PB, Rossi M. Hepatogastroenterology. 2013 Nov-Dec;60(128):2039-41.

574.	Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis
	Guo Z1, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Ann Surg Oncol. 2014 Apr 12. [Epub ahead of print]

575.	Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?
	Lee YA1, Friedman SL2.Antiviral Res. 2014 Apr 9. pii: S0166-3542(14)00086-2. doi: 10.1016/j.antiviral.2014.03.012. [Epub ahead of print]

576.	Anatomic versus non-anatomic liver resection for hepatocellular carcinoma: a systematic review
	Tang YH, Wen TF, Chen X. Hepatogastroenterology. 2013 Nov-Dec;60(128):2019-25.

577.	Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model
	Fox R1, Berhane S2, Teng M3, Cox T4, Tada T5, Toyoda H5, Kumada T5, Kagebayashi C6, Satomura S6, Johnson PJ7. Br J Cancer. 2014 Apr 1. doi: 10.1038/bjc.2014.130. [Epub ahead of print]

578.	Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
	Liu L1, Chen H1, Wang M2, Zhao Y3, Cai G4, Qi X1, Han G1. PLoS One. 2014 Mar 20;9(3):e91124. doi: 10.1371/journal.pone.0091124. eCollection 2014.

579.	Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
	Ronot M1, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Oncologist. 2014 Mar 20. [Epub ahead of print]

580.	Improved Survival Outcomes in Patients with Nonalcoholic Steatohepatitis and Alcoholic Liver Disease Following Liver Transplantation: An Analysis of 2002-2012 UNOS Data
	Wong RJ1, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Clin Transplant. 2014 Mar 22. doi: 10.1111/ctr.12364. [Epub ahead of print]

581.	Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients
	D'Amico G1, Pasta L, Morabito A, D'Amico M, Caltagirone M, Malizia G, Tinè F, Giannuoli G, Traina M, Vizzini G, Politi F, Luca A, Virdone R, Licata A, Pagliaro L. Aliment Pharmacol Ther. 2014 Mar 24. doi: 10.1111/apt.12721. [Epub ahead of print]

582.	Clinical value of circulating liver cancer cells for the diagnosis of hepatocellular carcinoma: A meta-analysis
	Jin T1, Peng H1, Wu H2. Biomed Rep. 2013 Sep;1(5):731-736. Epub 2013 Jul 18.

583.	Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib
	Takeda H, Nishikawa H, Iguchi E, Ohara Y, Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, Komekado H, Kita R, Kimura T, Osaki Y. Mol Clin Oncol. 2013 Mar;1(2):241-248. Epub 2012 Dec 3.

584.	Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria
	Lim KC1, Wang VW, Siddiqui FJ, Shi LM, Chan SY, Oh HC, Tan SB, Chow PK. Hepatology. 2014 Mar 18. doi: 10.1002/hep.27135. [Epub ahead of print]

585.	Influence of Clinically Significant Portal Hypertension on Hepatectomy for Hepatocellular Carcinoma: a Meta-analysis
	Tang YH1, Zhu WJ, Wen TF. Asian Pac J Cancer Prev. 2014;15(4):1649-54.

586.	Is BCLC algorithm useful in clinical practice? Study on 164 HCC patients
	Trovato MA, Pesce A, Sofia M, Montineri A, Basile A, Palermo F, Fatuzzo F, Nigro L, Puleo S. Hepatogastroenterology. 2013 Oct;60(127):1742-5.

587.	Surveillance and Interpretation of Trends in US Age-Specific Incidence Rates for Primary Liver Cancer, in Relation to the Epidemic of Hepatitis C Infection
	Polednak AP. J Registry Manag. 2013 Fall;40(3):115-21.

588.	Is Previous Exposure to Hepatitis B a Risk Factor for Pancreatic Cancer or Hepatocellular Carcinoma?
	Tang J1, Sharma R, Lamerato L, Sheehan M, Krajenta R, Gordon SC. J Clin Gastroenterol. 2014 Mar 10. [Epub ahead of print]

589.	Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease
	Stinton LM1, Loomba R. Minerva Gastroenterol Dietol. 2014 Mar;60(1):5-13.

590.	Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience
	Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatogastroenterology. 2013 Oct;60(127):1611-23.

591.	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group
	Leoni S1, Piscaglia F2, Serio I2, Terzi E2, Pettinari I2, Croci L2, Marinelli S2, Benevento F2, Golfieri R3, Bolondi L2. Dig Liver Dis. 2014 Mar 14. pii: S1590-8658(14)00244-8. doi: 10.1016/j.dld.2014.02.012. [Epub ahead of print]

592.	The diagnosis and treatment of hepatocellular carcinoma
	Malek NP1, Schmidt S, Huber P, Manns MP, Greten TF. Dtsch Arztebl Int. 2014 Feb 14;111(7):101-6. doi: 10.3238/arztebl.2014.0101.

593.	Prognosis of Unresectable Hepatocellular Carcinoma: Comparison of Seven Staging Systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese Cohort
	Zhang JF1, Shu ZJ2, Xie CY3, Li Q4, Jin XH5, Gu W6, Jiang FJ1, Ling CQ6. PLoS One. 2014 Mar 7;9(3):e88182. doi: 10.1371/journal.pone.0088182. eCollection 2014.

594.	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease
	Cho JY1, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Gut. 2014 Mar 10. doi: 10.1136/gutjnl-2013-306409. [Epub ahead of print]

595.

Dairy products and risk of hepatocellular carcinoma: The European Prospective Investigation into Cancer and Nutrition (EPIC)

Duarte-Salles T1, Fedirko V, Stepien M, Trichopoulou A, Bamia C, Lagiou P, Lukanova A, Trepo E, Overvad K, Tjønneland A, Halkjaer J, Boutron-Ruault MC, Racine A, Cadeau C, Kühn T, Aleksandrova K, Trichopoulos D, Tsiotas K, Boffetta P, Palli D, Pala V, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita HB, Dik VK, Peeters PH, Weiderpass E, Gram IT, Hjartåker A, Quirós JR, Fonseca-Nunes A, Molina-Montes E, Dorronsoro M, Navarro Sanchez C, Barricarte A, Lindkvist B, Sonestedt E, Johansson I, Wennberg M, Khaw KT, Wareham N, Travis RC, Romieu I, Riboli E, Jenab M. Int J Cancer. 2014 Feb 26. doi: 10.1002/ijc.28812. [Epub ahead of print]

596.	α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation
	Zhang Q1, Shang L, Zang Y, Chen X, Zhang L, Wang Y, Wang L, Liu Y, Mao S, Shen Z. Eur J Gastroenterol Hepatol. 2014 Mar 7. [Epub ahead of print]

597.	Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective
	Walko CM1, Grande C2. Semin Oncol. 2014 Feb;41 Suppl 2:S17-28. doi: 10.1053/j.seminoncol.2014.01.002. Epub 2014 Jan 9.

598.	Management of Sorafenib-Related Adverse Events: A Clinician's Perspective
	Brose MS1, Frenette CT2, Keefe SM3, Stein SM4. Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. Epub 2014 Jan 9.

599.	Nutrition and metabolism in hepatocellular carcinoma
	Smith RJ. Hepatobiliary Surg Nutr. 2013 Apr;2(2):89-96.

600.	Quantification of liver iron with MRI: State of the art and remaining challenges
	Hernando D1, Levin YS, Sirlin CB, Reeder SB. J Magn Reson Imaging. 2014 Mar 3. doi: 10.1002/jmri.24584. [Epub ahead of print]

601.	Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
	Llovet JM1, Hernandez-Gea V. Clin Cancer Res. 2014 Mar 3. [Epub ahead of print]

602.	Repeatability of Diagnostic Features and Scoring Systems for Hepatocellular Carcinoma by Using MR Imaging
	Davenport MS1, Khalatbari S, Liu PS, Maturen KE, Kaza RK, Wasnik AP, Al-Hawary MM, Glazer DI, Stein EB, Patel J, Somashekar DK, Viglianti BL, Hussain HK. Radiology. 2014 Feb 18:131963. [Epub ahead of print]

603.	Systemic and Targeted Therapy for Biliary Tract Tumors and Primary Liver Tumors
	Thomas MB. Surg Oncol Clin N Am. 2014 Apr;23(2):369-381. doi: 10.1016/j.soc.2013.11.004. Epub 2013 Dec 31.

604.	Palliation: Treating Patients with Inoperable Biliary Tract and Primary Liver Tumors
	Amini A1, Gamblin TC2. Surg Oncol Clin N Am. 2014 Apr;23(2):383-397. doi: 10.1016/j.soc.2013.10.008. Epub 2013 Dec 27.

605.	Secondary use of existing public microarray data to predict outcome for hepatocellular carcinoma
	Wray CJ1, Ko TC2, Tan FK3. J Surg Res. 2014 Jan 6. pii: S0022-4804(13)02178-1. doi: 10.1016/j.jss.2013.12.013. [Epub ahead of print]

606.	Hepatocellular Carcinoma: Diagnosis, Management, and Prognosis
	Page AJ1, Cosgrove DC2, Philosophe B1, Pawlik TM3. Surg Oncol Clin N Am. 2014 Apr;23(2):289-311. doi: 10.1016/j.soc.2013.10.006. Epub 2013 Dec 7.

607.	Nonsurgical treatment for localized hepatocellular carcinoma
	Kennedy AS, Sangro B. Curr Oncol Rep. 2014 Mar;16(3):373. doi: 10.1007/s11912-013-0373-x.

608.	Multimodality Therapy and Liver Transplantation for Hepatocellular Carcinoma: A 14-Year Prospective Analysis of Outcomes
	Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP, Fisher RA. Transplantation. 2014 Feb 5. [Epub ahead of print]

609.	Bland- versus Chemo-Embolization of Hepatocellular Carcinoma Prior to Transplantation
	Kluger K, Halazun K, Barroso R, Fox A, Olsen S, Madoff D, Siegel A, Weintraub J, Susman J, Brown R, Cherqui D, Emond J. Liver Transpl. 2014 Feb 3. doi: 10.1002/lt.23846. [Epub ahead of print]

610.	Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma
	Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A; HOVAS Group (Hepatocellular Carcinoma Treatment Outcome at VA San Francisco). HPB (Oxford). 2014 Jan 28. doi: 10.1111/hpb.12214. [Epub ahead of print]

611.	Clinical and Economical Impact of 2010 AASLD Guidelines for the Diagnosis of Hepatocellular Carcinoma
	Manini MA1, Sangiovanni A2, Fornari F3, Piscaglia F4, Biolato M5, Fanigliulo L3, Ravaldi E4, Grieco A5, Colombo M1; on behalf of the Study Participants. J Hepatol. 2014 Jan 21. pii: S0168-8278(14)00049-X. doi: 10.1016/j.jhep.2014.01.006. [Epub ahead of print]

612.	The Role of Bridging Therapy in Hepatocellular Carcinoma
	Galuppo R, McCall A, Gedaly R. Int J Hepatol. 2013;2013:419302. Epub 2013 Dec 19.

613.

Inflammatory and metabolic biomarkers and risk of liver and bilary tract cancer

Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V, Kaaks R, Lukanova A, Trichopoulou A, Trichopoulos D, Boffetta P, Trepo E, Westhpal S, Duarte-Salles T, Stepien M, Overvad K, Tjønneland A, Halkjaer J, Boutron-Ruault MC, Dossus L, Racine A, Lagiou P, Bamia C, Benetou V, Agnoli C, Palli D, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita B, Peeters PH, Gram IT, Lund E, Weiderpass E, Quirós JR, Agudo A, Sánchez MJ, Gavrila D, Barricarte A, Dorronsoro M, Ohlsson B, Lindkvist B, Johansson A, Sund M, Khaw KT, Wareham N, Travis RC, Riboli E, Pischon T. Hepatology. 2014 Jan 17. doi: 10.1002/hep.27016. [Epub ahead of print]

614.	Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S
	Wong RJ, Cheung R, Ahmed A. Hepatology. 2013 Dec 25. doi: 10.1002/hep.26986. [Epub ahead of print]

615.	The Association Between Metabolic Syndrome and Hepatocellular Carcinoma: Systemic Review and Meta-analysis
	Jinjuvadia R, Patel S, Liangpunsakul S. J Clin Gastroenterol. 2014 Feb;48(2):172-7. doi: 10.1097/MCG.0b013e3182a030c4.

616.	Analysis of National Data on Liver Transplantation and Organ Allocation for Patients with Hepatopulmonary Syndrome
	Goldberg DS1, Krok K2, Batra S3, Trotter JF4, Kawut SM5, Fallon MB3. Gastroenterology. 2014 Jan 8. pii: S0016-5085(14)00015-8. doi: 10.1053/j.gastro.2014.01.005. [Epub ahead of print]

617.	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis
	Singal AG1, Manjunath H2, Yopp AC3, Beg MS2, Marrero JA1, Gopal P4, Waljee AK5. Am J Gastroenterol. 2014 Jan 21. doi: 10.1038/ajg.2013.476. [Epub ahead of print]

618.	Hepatocellular carcinoma and cholangiocarcinoma: an update
	Yazici C, Niemeyer DJ, Iannitti DA, Russo MW. Expert Rev Gastroenterol Hepatol. 2014 Jan;8(1):63-82. doi: 10.1586/17474124.2014.852468.

619.	Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma
	Nakagawa S, Beppu T, Okabe H, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Hayashi H, Sakamoto Y, Hashimoto D, Chikamoto A, Ishiko T, Watanabe M, Baba H. Hepatol Res. 2013 Nov 19. doi: 10.1111/hepr.12277. [Epub ahead of print]

620.	Clinical Presentation and Survival of Asian and Non-Asian Patients with HCV-Related Hepatocellular Carcinoma
	Yip B, Wantuck JM, Kim LH, Wong RJ, Ahmed A, Garcia G, Nguyen MH. Dig Dis Sci. 2014 Jan;59(1):192-200. doi: 10.1007/s10620-013-2948-7. Epub 2013 Nov 27.

621.	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
	Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. PLoS One. 2013 Nov 11;8(11):e80276. doi: 10.1371/journal.pone.0080276.

622.	Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study
	Kaiser K, Mallick R, Butt Z, Mulcahy MF, Benson AB, Cella D. Support Care Cancer. 2013 Nov 21. [Epub ahead of print]

623.	The impact of obesity on liver histology
	Goodman ZD. Clin Liver Dis. 2014 Feb;18(1):33-40. doi: 10.1016/j.cld.2013.09.010. Epub 2013 Oct 25.

624.	Clin Liver Dis. 2014 Feb;18(1):73-89. doi: 10.1016/j.cld.2013.09.005. Epub 2013 Oct 24.
	Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G.

625.	Non-alcoholic fatty liver disease: factors associated with its presence and onset
	Miyake T, Kumagi T, Furukawa S, Tokumoto Y, Hirooka M, Abe M, Hiasa Y, Matsuura B, Onji M. J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:71-8. doi: 10.1111/jgh.12251.

626.	Characteristics and diagnosis of NAFLD/NASH
	Hashimoto E, Taniai M, Tokushige K. J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70. doi: 10.1111/jgh.12271.

627.	Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update
	Vivarelli M, Montalti R, Risaliti A. World J Gastroenterol. 2013 Nov 14;19(42):7316-26. doi: 10.3748/wjg.v19.i42.7316.

628.	Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors
	Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, Kudo M. Dig Dis. 2013;31(5-6):472-9. doi: 10.1159/000355248. Epub 2013 Nov 21.

629.	Standardizing management of hepatocellular carcinoma in China: devising evidence-based clinical practice guidelines
	Song P. Biosci Trends. 2013 Oct;7(5):250-2.

630.	Long-term outcome of elderly patients (75 years or older) with hepatocellular carcinoma
	Hori M, Tanaka M, Ando E, Sakata M, Simose S, Ohno M, Yutani S, Kuraoka K, Kuromatsu R, Sumie S, Sata M. Hepatol Res. 2013 Nov 21. doi: 10.1111/hepr.12279. [Epub ahead of print]

631.	Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma
	Jiang G, Xu X, Ren S, Wang L. Tumour Biol. 2013 Nov 26. [Epub ahead of print]

632.	CD34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma
	Tsuji N, Ishiguro S, Sasaki Y, Kudo M. Dig Dis. 2013;31(5-6):467-71. doi: 10.1159/000355246. Epub 2013 Nov 21.

633.	Update on Biomarkers of Hepatocellular Carcinoma
	Chaiteerakij R1, Addissie BD2, Roberts LR3. Clin Gastroenterol Hepatol. 2013 Nov 23. pii: S1542-3565(13)01789-8. doi: 10.1016/j.cgh.2013.10.038. [Epub ahead of print]

634.	Significant impact of patient age on outcome after liver resection for HCC in cirrhosis
	Faber W, Stockmann M, Schirmer C, Möllerarnd A, Denecke T, Bahra M, Klein F, Schott E, Neuhaus P, Seehofer D. Eur J Surg Oncol. 2013 Nov 5. pii: S0748-7983(13)00866-4. doi: 10.1016/j.ejso.2013.10.018. [Epub ahead of print]

635.	Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies
	van Meer S, de Man RA, Siersema PD, van Erpecum KJ. World J Gastroenterol. 2013 Oct 28;19(40):6744-56. doi: 10.3748/wjg.v19.i40.6744.

636.	Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib
	Nagai H, Kanekawa T, Kobayashi K, Mukozu T, Matsui D, Matsui T, Kanayama M, Wakui N, Momiyama K, Shinohara M, Ishii K, Igarashi Y, Sumino Y. Cancer Chemother Pharmacol. 2013 Nov 13. [Epub ahead of print]

637.	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy
	Wong GL, Wong VW. World J Gastroenterol. 2013 Oct 21;19(39):6515-22. doi: 10.3748/wjg.v19.i39.6515.

638.	Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis
	Zhao ZH, Fan YC, Yang Y, Wang K. World J Gastroenterol. 2013 Nov 7;19(41):7189-96. doi: 10.3748/wjg.v19.i41.7189.

639.	Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis
	Testino G, Borro P. World J Hepatol. 2013 Oct 27;5(10):521-527.

640.	Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma
	Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. World J Virol. 2012 Dec 12;1(6):174-183.

641.	Hepatocellular Carcinoma Incidence in Noncirrhotic Patients With Chronic Hepatitis B and Patients With Cirrhosis of All Etiologies
	Do AL, Wong CR, Nguyen LH, Nguyen VG, Trinh H, Nguyen MH. J Clin Gastroenterol. 2013 Nov 6. [Epub ahead of print]

642.	The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib
	Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y, Hu BS. Asian Pac J Cancer Prev. 2013;14(9):5527-31.

643.	Mediterranean diet and hepatocellular carcinoma
	Turati F, Trichopoulos D, Polesel J, Bravi F, Rossi M, Talamini R, Franceschi S, Montella M, Trichopoulou A, La Vecchia C, Lagiou P. J Hepatol. 2013 Nov 14. pii: S0168-8278(13)00797-6. doi: 10.1016/j.jhep.2013.10.034. [Epub ahead of print]

644.

Long term results of liver transplantation for Wilson's disease: Experience in France

Guillaud O1, Dumortier J2, Sobesky R3, Debray D4, Wolf P5, Vanlemmens C6, Durand F7, Calmus Y8, Duvoux C9, Dharancy S10, Kamar N11, Boudjema K12, Bernard PH13, Pageaux GP14, Salamé E15, Gugenheim J16, Lachaux A17, Habes D18, Radenne S19, Hardwigsen J20, Chazouillères O21, Trocello JM22, Woimant F22, Ichai P3, Branchereau S18, Soubrane O23, Castaing D3, Jacquemin E18, Samuel D3, Duclos-Vallée JC3. J Hepatol. 2013 Nov 6. pii: S0168-8278(13)00751-4. doi: 10.1016/j.jhep.2013.10.025. [Epub ahead of print]

645.	HIV/Hepatitis C Virus-Coinfected Patients and Cirrhosis: How to Diagnose It and What to Do Next?
	Martel-Laferrière V, Wong M, Dieterich DT. Clin Infect Dis. 2013 Nov 22. [Epub ahead of print]

646.	Coffee and Non-Alcoholic Fatty Liver Disease: Brewing evidence for hepatoprotection?
	Chen S, Teoh NC, Chitturi S, Farrell GC. J Gastroenterol Hepatol. 2013 Nov 7. doi: 10.1111/jgh.12422. [Epub ahead of print]

647.	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers
	Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S. Cancer Epidemiol Biomarkers Prev. 2013 Dec 26. [Epub ahead of print]

648.	Clinical Appraisal of the Recently Proposed Barcelona Clinic Liver Cancer Stage B Subclassification by Survival Analysis
	Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. J Gastroenterol Hepatol. 2013 Nov 13. doi: 10.1111/jgh.12452. [Epub ahead of print]

649.	Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization
	Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, Wong J, Ma B, Lai P, Mok T, Yeo W. Radiology. 2013 Oct 14. [Epub ahead of print]

650.	Molecular targeted therapy for hepatocellular carcinoma: current and future
	Shin JW, Chung YH. World J Gastroenterol. 2013 Oct 7;19(37):6144-55. doi: 10.3748/wjg.v19.i37.6144.

651.	Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma
	Ishikawa T. World J Gastroenterol. 2013 Oct 7;19(37):6127-30. doi: 10.3748/wjg.v19.i37.6127.

652.	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B
	Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. J Hepatol. 2013 Oct 12. pii: S0168-8278(13)00695-8. doi: 10.1016/j.jhep.2013.09.029. [Epub ahead of print]

653.	Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy
	Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. J Gastroenterol Hepatol. 2014 Jan;29(1):137-43. doi: 10.1111/jgh.12401.

654.	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials
	Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. Int J Cancer. 2013 Oct 11. doi: 10.1002/ijc.28544. [Epub ahead of print]

655.	Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma
	Chan DL, Alzahrani NA, Morris DL, Chua TC. J Gastroenterol Hepatol. 2014 Jan;29(1):31-41. doi: 10.1111/jgh.12399.

656.	Advanced ultrasonography technologies to assess the effects of radiofrequency ablation on hepatocellular carcinoma.
	Toshikuni N, Shiroeda H, Ozaki K, Matsue Y, Minato T, Nomura T, Hayashi N, Arisawa T, Tsutsumi M.

657.	Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data
	Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, Hamza S, Corradini SG, Burza MA, Guyot E, Donati B, Spengler U, Hillon P, Toniutto P, Henrion J, Franchimont D, Devière J, Mathurin P, Moreno C, Romeo S, Deltenre P. Hepatology. 2013 Oct 1. doi: 10.1002/hep.26767. [Epub ahead of print]

658.	Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: A Western perspective
	Sullivan KM, Groeschl RT, Turaga KK, Tsai S, Christians KK, White SB, Rilling WS, Pilgrim CH, Gamblin TC. J Surg Oncol. 2013 Oct 4. doi: 10.1002/jso.23448. [Epub ahead of print]

659.	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding
	Reverter E1, Tandon P2, Augustin S3, Turon F4, Casu S4, Bastiampillai R2, Keough A2, Llop E4, González A3, Seijo S4, Berzigotti A4, Ma M2, Genescà J5, Bosch J1, García-Pagán JC1, Abraldes JG6. Gastroenterology. 2013 Oct 19. pii: S0016-5085(13)01492-3. doi: 10.1053/j.gastro.2013.10.018. [Epub ahead of print]

660.	Liver Transplantation Versus Liver Resection in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies
	Zheng Z, Liang W, Milgrom DP, Zheng Z, Schroder PM, Kong NS, Yang C, Guo Z, He X. Transplantation. 2013 Oct 17. [Epub ahead of print]

661.	Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?
	Yu LH, Li N, Shi J, Guo WX, Wu MC, Cheng SQ. Ann Surg Oncol. 2013 Oct 12. [Epub ahead of print]

662.	Family history of hepatocellulcar carcinoma is not associated with its patients' prognosis after hepatectomy
	Huang J, Zhang Y, Chen M, Huang J, Xu L, Chen M. World J Surg Oncol. 2013 Oct 18;11(1):280. [Epub ahead of print]

663.	Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis
	Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M. J Gastroenterol. 2013 Oct 18. [Epub ahead of print]

664.	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir
	Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. Hepatology. 2013 Oct 1. doi: 10.1002/hep.26739. [Epub ahead of print]

665.	Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis
	Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. J Med Virol. 2014 Jan;86(1):131-8. doi: 10.1002/jmv.23790. Epub 2013 Oct 12.

666.	Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer
	Zhao J, Lawless MW. Cytokine. 2013 Dec;64(3):626-37. doi: 10.1016/j.cyto.2013.09.009. Epub 2013 Oct 11.

667.	Hepatocellular carcinoma: illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the Study of Liver Diseases
	McEvoy SH, McCarthy CJ, Lavelle LP, Moran DE, Cantwell CP, Skehan SJ, Gibney RG, Malone DE. Radiographics. 2013 Oct;33(6):1653-68. doi: 10.1148/rg.336125104.

668.	Intraoperative Ultrasound in Patients with Hepatocellular Carcinoma: From Daily Practice to Future Trends
	Donadon M, Torzilli G. Liver Cancer. 2013 Jan;2(1):16-24.

669.	Perspectives on the Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted Therapy
	Hsu C, Po-Ching-Liang, Morita S, Hu FC, Cheng AL. Liver Cancer. 2012 Nov;1(3-4):168-176.

670.	Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy
	Shindoh J, Kaseb A, Vauthey JN. Liver Cancer. 2013 Jan;2(1):47-54.

671.	Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma
	Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. PLoS One. 2013 Oct 14;8(10):e77240. doi: 10.1371/journal.pone.0077240.

672.	Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity
	Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, Lartigau E, Mirabel X. PLoS One. 2013 Oct 11;8(10):e77472. doi: 10.1371/journal.pone.0077472.

673.	Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma
	Jihye C, Jinsil S. Liver Cancer. 2012 Nov;1(3-4):216-225.

674.	Therapeutic Efficacy of Percutaneous Radiofrequency Ablation versus Microwave Ablation for Hepatocellular Carcinoma
	Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. PLoS One. 2013 Oct 17;8(10):e76119. doi: 10.1371/journal.pone.0076119.

675.	Treatment of Hepatocellular Carcinoma: A Systematic Review
	Lin S, Hoffmann K, Schemmer P. Liver Cancer. 2012 Nov;1(3-4):144-158.

676.	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition
	Finn RS. Liver Cancer. 2012 Nov;1(3-4):247-256.

677.	Liver Transplantation Versus Liver Resection in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies
	Zheng Z, Liang W, Milgrom DP, Zheng Z, Schroder PM, Kong NS, Yang C, Guo Z, He X. Transplantation. 2013 Oct 17. [Epub ahead of print]

678.	Liver Transplantation for Hepatocellular Carcinoma: An Appraisal of Current Controversies
	Lee Cheah Y, K H Chow P. Liver Cancer. 2012 Nov;1(3-4):183-189.

679.	Long-term survival outcomes for living donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma
	Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Park CS, Park YH, Kang SH, Jung BH, Lee SG. Transplant Proc. 2013 Oct;45(8):3032-4. doi: 10.1016/j.transproceed.2013.08.027.

680.	Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation
	Hwang S, Moon DB, Ahn CS, Kim KH, Ha TY, Song GW, Jung DH, Park GC, Lee HC, Lee YS, Chung YH, Abdulkarim BA, Lee SG. Transplant Proc. 2013 Oct;45(8):3076-84. doi: 10.1016/j.transproceed.2013.08.068.

681.	Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma
	Park SY, Han J, Kim JB, Yang MG, Kim YJ, Lim HJ, An SY, Kim JH. Eur J Cancer. 2013 Oct 22. pii: S0959-8049(13)00896-4. doi: 10.1016/j.ejca.2013.09.021. [Epub ahead of print]

682.	Is the genotype 3 of the hepatitis C virus the new villain?
	Goossens N, Negro F. Hepatology. 2013 Oct 24. doi: 10.1002/hep.26905. [Epub ahead of print]

683.	Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma
	Bota S, Piscaglia F, Marinelli S, Pecorelli A, Terzi E, Bolondi L. Liver Cancer. 2012 Nov;1(3-4):190-200.

684.	Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review
	Nishikawa H, Kimura T, Kita R, Osaki Y. J Cancer. 2013 Sep 14;4(8):635-643.

685.	Assessing variation in the costs of care among patients awaiting liver transplantation
	Axelrod DA, Dzebisashvili N, Lentine K, Segev DL, Dickson R, Tuttle-Newhall E, Freeman R, Schnitzler M. Am J Transplant. 2014 Jan;14(1):70-8. doi: 10.1111/ajt.12494. Epub 2013 Oct 28.

686.	Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China
	Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Liver Cancer. 2013 Jan;2(1):31-39.

687.	Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?
	Shao YY, Hsu CH, Cheng AL. Liver Cancer. 2013 Apr;2(2):93-107.

688.	Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis
	Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M. J Gastroenterol. 2013 Oct 18. [Epub ahead of print]

689.	Vascular Invasion in Hepatocellular Carcinoma: Prevalence, Determinants and Prognostic Impact
	Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CW, Lin HC, Huo TI. J Clin Gastroenterol. 2013 Oct 4. [Epub ahead of print]

690.	Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients
	Guan HT, Wang J, Yang M, Song L, Tong XQ, Zou YH. Chin Med J (Engl). 2013;126(19):3651-5.

691.	Systemic therapies in hepatocellular carcinoma: present and future
	Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Future Oncol. 2013 Oct;9(10):1533-48. doi: 10.2217/fon.13.171.

692.	Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma
	Ishikawa T. World J Gastroenterol. 2013 Oct 7;19(37):6127-30. doi: 10.3748/wjg.v19.i37.6127.

693.	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B
	Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. J Hepatol. 2013 Oct 12. pii: S0168-8278(13)00695-8. doi: 10.1016/j.jhep.2013.09.029. [Epub ahead of print]

694.	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
	Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Cancer. 2013 Oct 7. doi: 10.1002/cncr.28384. [Epub ahead of print]

695.	A systematic review of sorafenib in Child-Pugh a patients with unresectable hepatocellular carcinoma
	Shen A, Tang C, Wang Y, Chen Y, Yan X, Zhang C, Liu R, Wei X, Zhu Y, Zhang H, Wu Z. J Clin Gastroenterol. 2013 Nov-Dec;47(10):871-80. doi: 10.1097/MCG.0b013e3182a87cfd.

696.	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials
	Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. Int J Cancer. 2013 Oct 11. doi: 10.1002/ijc.28544. [Epub ahead of print]

697.	Tumour size and differentiation predict survival after liver resection for hepatocellular carcinoma arising from non-cirrhotic and non-fibrotic liver: A case-controlled study
	Yip VS, Gomez D, Tan CY, Staettner S, Terlizzo M, Fenwick S, Malik HZ, Ghaneh P, Poston G. Int J Surg. 2013;11(10):1078-82. doi: 10.1016/j.ijsu.2013.10.001. Epub 2013 Oct 12.

698.	Systematic Review of Efficacy and Outcomes of Salvage Liver Transplantation After Primary Hepatic Resection for Hepatocellular Carcinoma
	Chan DL, Alzahrani NA, Morris DL, Chua TC. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12399. [Epub ahead of print]

699.	Hepatocellular carcinoma: illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the Study of Liver Diseases
	McEvoy SH, McCarthy CJ, Lavelle LP, Moran DE, Cantwell CP, Skehan SJ, Gibney RG, Malone DE. Radiographics. 2013 Oct;33(6):1653-68. doi: 10.1148/rg.336125104.

700.	The Impact of PNPLA3 Polymorphisms on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection
	Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. Hepatol Res. 2013 Oct 11. doi: 10.1111/hepr.12258. [Epub ahead of print]

701.	Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: A Western perspective
	Sullivan KM, Groeschl RT, Turaga KK, Tsai S, Christians KK, White SB, Rilling WS, Pilgrim CH, Gamblin TC. J Surg Oncol. 2013 Oct 4. doi: 10.1002/jso.23448. [Epub ahead of print]

702.	Medical treatment of hepatocellular carcinoma
	Germano D, Tinessa V, Barletta E, Cannella L, Daniele B. Minerva Med. 2013 Oct;104(5):545-61.

703.	Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C
	Khokhar N, Niazi TK, Qureshi MO. J Coll Physicians Surg Pak. 2013 Oct;23(10):699-702. doi: 10.2013/JCPSP.699702.

704.	Hepatocellular carcinoma: beyond the boundaries of age
	Di Benedetto F, Tarantino G, Quintini C, Tirelli U, Berretta M. Anticancer Agents Med Chem. 2013 Nov;13(9):1371-7.

705.	Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis
	Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C, Ma J. J Cancer Res Clin Oncol. 2013 Sep 29. [Epub ahead of print]

706.	Long-term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia
	Ogata T, Okuda K, Sato T, Hirakawa Y, Yasunaga M, Horiuchi H, Nomura Y, Kage M, Ide T, Kuromatsu R, Kinoshita H, Tanaka H. Kurume Med J. 2013 Sep 20. [Epub ahead of print]

707.	Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib
	Shin SY, Lee YJ. Int J Clin Pharmacol Ther. 2013 Nov;51(11):837-46. doi: 10.5414/CP201907.

708.	Size discrepancy between sonographic and computed tomographic/magnetic resonance imaging measurement of hepatocellular carcinoma: the necessity of tumor size measurement standardization
	Cha MJ, Lee MW, Cha DI, Kim JH, Rhim H, Cho YK, Kim YJ, Choi D, Kim YS, Lim HK. J Ultrasound Med. 2013 Oct;32(10):1703-9. doi: 10.7863/ultra.32.10.1703.

709.	Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients
	Ni JY, Xu LF, Sun HL, Zhou JX, Chen YT, Luo JH. J Cancer Res Clin Oncol. 2013 Dec;139(12):2021-33. doi: 10.1007/s00432-013-1530-1. Epub 2013 Sep 26.

710.	Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study
	Sarvari J, Mojtahedi Z, Taghavi SA, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, Nakamura K. Hepat Mon. 2013 Jul 3;13(7):e8351. doi: 10.5812/hepatmon.8351.

711.	Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
	Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Clin Gastroenterol Hepatol. 2013 Sep 25. pii: S1542-3565(13)01428-6. doi: 10.1016/j.cgh.2013.09.023. [Epub ahead of print]

712.	Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review
	Liccardo D, Alisi A, Porta G, Nobili V. Expert Rev Gastroenterol Hepatol. 2013 Sep;7(7):601-4. doi: 10.1586/17474124.2013.827483.

713.	Primary hepatocellular carcinoma and metabolic syndrome: An update
	Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA.

714.	Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma
	Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, Takada Y, Uemoto S. Surgery. 2013 Nov;154(5):1053-60. doi: 10.1016/j.surg.2013.04.056. Epub 2013 Sep 24.

715.	Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis
	Zhuang L, Zeng X, Yang Z, Meng Z. PLoS One. 2013 Sep 17;8(9):e61361. doi: 10.1371/journal.pone.0061361.

716.	Donor Factors Similarly Impact Survival Outcome After Liver Transplantation in Hepatocellular Carcinoma and Non-hepatocellular Carcinoma Patients
	Salgia RJ, Goodrich NP, Marrero JA, Volk ML. Dig Dis Sci. 2013 Sep 28. [Epub ahead of print]

717.	Body mass index in childhood and adult risk of primary liver cancer
	Berentzen TL, Gamborg M, Holst C, Sørensen TI, Baker JL. J Hepatol. 2013 Sep 26. pii: S0168-8278(13)00675-2. doi: 10.1016/j.jhep.2013.09.015. [Epub ahead of print]

718.	Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection
	Deng B, Zhang XF, Zhu XC, Huang H, Jia HL, Ye QH, Dong QZ, Qin LX. Oncol Rep. 2013 Dec;30(6):2795-803. doi: 10.3892/or.2013.2737. Epub 2013 Sep 19.

719.	Adjuvant systemic drug therapy and recurrence of hepatocellular carcinoma following curative resection
	Zhong YS, Liu B, Deng MH, Xu RY. Drug Discov Ther. 2013 Aug;7(4):164-6.

720.	Absence of Viable HCC in the Native Liver Is an Independent Protective Factor of Tumor Recurrence After Liver Transplantation
	Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N, Ballarin R, Spaggiari M, Tarantino G, D'Amico G, De Santis M, De Pietri L, Troisi RI, Gerunda GE, Di Benedetto F. Transplantation. 2013 Sep 19. [Epub ahead of print]

721.	Multispecialist Care and Mortality in Hepatocellular Carcinoma
	Chirikov VV, Mullins CD, Hanna N, Breunig IM, Seal B, Shaya FT. Am J Clin Oncol. 2013 Sep 21. [Epub ahead of print]

722.	Living-Donor Liver Transplantation Associated with Higher Incidence of Hepatocellular Carcinoma Recurrence Than Deceased-Donor Liver Transplantation
	Park MS, Lee KW, Suh SW, You T, Choi Y, Kim H, Hong G, Yi NJ, Kwon CH, Joh JW, Lee SK, Suh KS. Transplantation. 2013 Sep 19. [Epub ahead of print]

723.	Decreased expression of interleukin-36? correlates with poor prognosis in hepatocellular carcinoma
	Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC. Cancer Immunol Immunother. 2013 Nov;62(11):1675-85. doi: 10.1007/s00262-013-1471-1. Epub 2013 Sep 6.

724.	A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma
	Jiang S, Liu Y, Wang L, Duan C, Liu M. World J Surg Oncol. 2013 Sep 24;11(1):240. doi: 10.1186/1477-7819-11-240.

725.	Downstaging Disease in Patients with Hepatocellular Carcinoma Outside of Milan Criteria: Strategies Using Drug-eluting Bead Chemoembolization
	Green TJ, Rochon PJ, Chang S, Ray CE Jr, Winston H, Ruef R, Kreidler SM, Glueck DH, Shulman BC, Brown AC, Durham J. J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20.

726.	Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?
	Thiele M, Wiest R, Gluud LL, Albillos A, Krag A. Med Hypotheses. 2013 Nov;81(5):871-4. doi: 10.1016/j.mehy.2013.08.026. Epub 2013 Sep 4.

727.	High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
	Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. J Gastroenterol. 2013 Sep 23. [Epub ahead of print]

728.	Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study
	Hyder O, Dodson RM, Nathan H, Herman JM, Cosgrove D, Kamel I, Geschwind JF, Pawlik TM. J Am Coll Surg. 2013 Nov;217(5):896-906. doi: 10.1016/j.jamcollsurg.2013.07.007. Epub 2013 Sep 13.

729.	Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature
	Abdel-Rahman O, Elsayed ZA. Dig Dis Sci. 2013 Dec;58(12):3389-96. doi: 10.1007/s10620-013-2872-x. Epub 2013 Sep 18.

730.	Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma
	Li Y, Zheng YB, Zhao W, Liu B, Hu BS, He X, Huang JW, Lu LG. Med Oncol. 2013 Dec;30(4):730. doi: 10.1007/s12032-013-0730-5. Epub 2013 Sep 19.

731.	Systemic Cytotoxic Chemotherapy of Patients With Advanced Hepatocellular Carcinoma in the Era of Sorafenib Nonavailability
	Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS. J Clin Gastroenterol. 2013 Sep 16. [Epub ahead of print]

732.	Computed tomographic-guided radiofrequency ablation of recurrent or residual hepatocellular carcinomas around retained iodized oil after transarterial chemoembolization
	Koh YH, Choi JI, Kim HB, Kim MJ. Korean J Radiol. 2013 Sep-Oct;14(5):733-42. doi: 10.3348/kjr.2013.14.5.733. Epub 2013 Aug 30.

733.	Pretreatment evaluation with contrast-enhanced ultrasonography for percutaneous radiofrequency ablation of hepatocellular carcinomas with poor conspicuity on conventional ultrasonography
	Kim AY, Lee MW, Rhim H, Cha DI, Choi D, Kim YS, Lim HK, Cho SW. Korean J Radiol. 2013 Sep-Oct;14(5):754-63. doi: 10.3348/kjr.2013.14.5.754. Epub 2013 Aug 30.

734.	Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis
	Liu TC, Vachharajani N, Chapman WC, Brunt EM. Mod Pathol. 2013 Sep 20. doi: 10.1038/modpathol.2013.148. [Epub ahead of print]

735.	Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease
	Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ. Dig Dis Sci. 2013 Sep 19. [Epub ahead of print]

736.	Met as a therapeutic target in HCC: Facts and hopes
	Giordano S, Columbano A. J Hepatol. 2013 Sep 14. pii: S0168-8278(13)00661-2. doi: 10.1016/j.jhep.2013.09.009. [Epub ahead of print]

737.	Liver Masses: A Clinical, Radiologic, and Pathologic Perspective
	Venkatesh SK, Chandan V, Roberts LR. Clin Gastroenterol Hepatol. 2013 Sep 18. pii: S1542-3565(13)01324-4. doi: 10.1016/j.cgh.2013.09.017. [Epub ahead of print]

738.	Lack of Association between Hsa-miR-149 rs2292832 Polymorphism and Cancer Risk: A Meta-Analysis of 12 Studies
	Xu L, Zhou X, Qiu MT, Yin R, Wu YQ, Xu L. PLoS One. 2013 Sep 5;8(9):e73762. doi: 10.1371/journal.pone.0073762.

739.	Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma
	Yu YL, Su KJ, Hsieh YH, Lee HL, Chen TY, Hsiao PC, Yang SF. PLoS One. 2013 Sep 10;8(9):e74870. doi: 10.1371/journal.pone.0074870.

740.	Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009: An Analysis of 1066 Cases of a German HCC Registry
	Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, Hansen T, Pitton MB, Düber C, Otto G, Schuchmann M, Galle PR, Wörns MA. J Clin Gastroenterol. 2013 Sep 25. [Epub ahead of print]

741.	Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies
	Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Rev Assoc Med Bras. 2013 September - October;59(5):514-524. doi: 10.1016/j.ramb.2013.03.005. Epub 2013 Sep 14.

742.	Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma
	Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K; Okayama Liver Cancer Group. Br J Cancer. 2013 Oct 15;109(8):2072-8. doi: 10.1038/bjc.2013.554. Epub 2013 Sep 17.

743.	Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma
	Kim MJ, Jang JW, Oh BS, Kwon JH, Chung KW, Jung HS, Jekarl DW, Lee S. Cytokine. 2013 Nov;64(2):516-22. doi: 10.1016/j.cyto.2013.07.021. Epub 2013 Sep 12.

744.	Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma
	Heng-Jun G, Yao-Jun Z, Min-Shan C, Mei-Xian C, Jun-Ting H, Li X, Lau WY. Liver Int. 2013 Aug 12. doi: 10.1111/liv.12307. [Epub ahead of print]

745.	Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma
	Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, Nishie A, Yamanaka T. Br J Surg. 2013 Oct;100(11):1523-30. doi: 10.1002/bjs.9258.

746.	Efficacy and long-term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma
	Yamazaki H, Tsuji K, Nagai K, Tomonari A, Matsui T, Kang JH, Kodama Y, Sakurai Y, Maguchi Hepatol Res. 2013 Sep 3. doi: 10.1111/hepr.12233. [Epub ahead of print]

747.	Role of microRNAs in hepatocellular carcinoma: a clinical perspective
	Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Onco Targets Ther. 2013 Sep 2;6:1167-1178

748.	Hepatocellular carcinoma from an immunological perspective
	Greten TF, Duffy AG, Korangy F. Clin Cancer Res. 2013 Sep 12. [Epub ahead of print]

749.	Epigenetics of hepatocellular carcinoma: role of microRNA
	Khare S, Zhang Q, Ibdah JA. World J Gastroenterol. 2013 Sep 7;19(33):5439-45. doi: 10.3748/wjg.v19.i33.5439.

750.	Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma
	Singal AG, Waljee AK, Patel N, Chen EY, Tiro JA, Marrero JA, Yopp AC J Natl Compr Canc Netw. 2013 Sep 1;11(9):1101-8.

751.

Branched-chain Amino Acids Prevent Hepatocarcinogenesis and Prolong Survival of Patients With Cirrhosis

Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, Iwasa M, Tokumoto Y, Endo R, Kawamura NH, Shiraki M, Habu D, Tsuruta S, Miwa Y, Kawaguchi A, Kakuma T, Sakai H, Kawada N, Hanai T, Takahashi SI, Kato A, Onji M, Takei Y, Kohgo Y, Seki T, Tamano M, Katayama K, Mine T, Sata M, Moriwaki H, Suzuki K. Clin Gastroenterol Hepatol. 2013 Sep 10. pii: S1542-3565(13)01312-8. doi: 10.1016/j.cgh.2013.08.050. [Epub ahead of print]

752.	Prognosis of Patients with Advanced Hepatocellular Carcinoma Who Failed First-Line Systemic Therapy
	Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, Hsu CH, Cheng AL. J Hepatol. 2013 Sep 11. pii: S0168-8278(13)00653-3. doi: 10.1016/j.jhep.2013.08.027. [Epub ahead of print]

753.	TNF-α, HGF and Macrophage in Peritumoural Liver Tissue Relate to Major Risk Factors of HCC Recurrence
	Liu XL, Li FQ, Liu LX, Li B, Zhou ZP. Hepatogastroenterology. 2013 Jul;60(125):1121-6. doi: 10.5754/hge12982.

754.	Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients
	Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Von Roenn NM, Berkes JL, Cotler SJ. Ann Hepatol. 2013 Sep-Oct;12(5):766-73.

755.	Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: Current state-of-the science
	Sahin IH, Hassan MM, Garrett CR. Cancer Lett. 2013 Sep 7. pii: S0304-3835(13)00644-7. doi: 10.1016/j.canlet.2013.09.001. [Epub ahead of print]

756.	Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma
	Mallick R, Cai J, Wogen J. Curr Med Res Opin. 2013 Sep 27. [Epub ahead of print]

757.	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease
	Tian Y, Wong VW, Chan HL, Cheng AS. Semin Cancer Biol. 2013 Sep 7. pii: S1044-579X(13)00086-2. doi: 10.1016/j.semcancer.2013.08.010. [Epub ahead of print]

758.	A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma
	Huang TS, Shyu YC, Chen HY, Yuan SS, Shih JN, Chen PJ. J Viral Hepat. 2013 Oct;20(10):729-43. doi: 10.1111/jvh.12096. Epub 2013 Apr 16.

759.	HCC Patients Suffer Less From Geographic Differences in Organ Availability
	Schuetz C, Dong N, Smoot E, Elias N, Schoenfeld DA, Markmann JF, Yeh Am J Transplant. 2013 Nov;13(11):2989-95. doi: 10.1111/ajt.12441. Epub 2013 Sep 6.

760.	Genome-Wide Methylation Analysis and Epigenetic Unmasking Identify Tumor Suppressor Genes in Hepatocellular Carcinoma
	Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, Llovet JM, Powers S. Gastroenterology. 2013 Sep 5. pii: S0016-5085(13)01275-4. doi: 10.1053/j.gastro.2013.08.055. [Epub ahead of print]

761.	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE
	Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. J Hepatol. 2013 Sep 3. pii: S0168-8278(13)00617-X. doi: 10.1016/j.jhep.2013.08.022. [Epub ahead of print]

762.	Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study
	Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. J Clin Oncol. 2013 Oct 10;31(29):3647-55. doi: 10.1200/JCO.2012.48.5896. Epub 2013 Sep 3.

763.	Usefulness of contrast-enhanced ultrasonography in the diagnosis of ruptured hepatocellular carcinoma
	Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Ishii K, Igarashi Y, Sumino Y. Clin J Gastroenterol. 2013;6:334-337. Epub 2013 Jun 25.

764.	Targeted Therapies in Hepatocellular Carcinoma
	Bronte F, Bronte G, Cusenza S, Fiorentino E, Rolfo C, Cicero G, Bronte E, Di Marco V, Angarano G, Fontana T, Russo A. Curr Med Chem. 2013 Aug 23. [Epub ahead of print]

765.	Comparison of the Number of Image Acquisitions and Procedural Time Required for Transarterial Chemoembolization of Hepatocellular Carcinoma with and without Tumor-Feeder Detection Software
	Iwazawa J, Ohue S, Hashimoto N, Mitani T. Radiol Res Pract. 2013;2013:580839. doi: 10.1155/2013/580839. Epub 2013 Jul 29.

766.	Percutaneous radiofrequency ablation of hepatocellular lesions in segment II of the liver: a risk factor for cardiac tamponade
	Silverman ER, Lai YH, Osborn IP, Yudkowitz FS. J Clin Anesth. 2013 Aug 26. pii: S0952-8180(13)00221-3. doi: 10.1016/j.jclinane.2013.04.014. [Epub ahead of print]

767.	Prevention of hepatitis C virus infection and liver cancer
	Lim EJ, Torresi J. Recent Results Cancer Res. 2014;193:113-33. doi: 10.1007/978-3-642-38965-8_7.

768.	Treatment Options and Surveillance Strategies After Therapy for Hepatocellular Carcinoma
	Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Ann Surg Oncol. 2013 Sep 5. [Epub ahead of print]

769.	The oncogenic role of hepatitis C virus
	Koike K. Recent Results Cancer Res. 2014;193:97-111. doi: 10.1007/978-3-642-38965-8_6.

770.	Safety of hepatic resection for hepatocellular carcinoma in obese patients with cirrhosis
	Tanaka S, Iimuro Y, Hirano T, Hai S, Suzumura K, Nakamura I, Kondo Y, Fujimoto J. Surg Today. 2013 Nov;43(11):1290-7. doi: 10.1007/s00595-013-0706-2. Epub 2013 Aug 31.

771.	Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma
	Hernandez BY, Zhu X, Kwee S, Chan OT, Tsai N, Okimoto G, Horio D, McGlynn KA, Altekruse S, Wong LL. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2016-23. doi: 10.1158/1055-9965.EPI-13-0397. Epub 2013 Aug 27.

772.	Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation
	Li C, Wen TF, Yan LN, Li B, Yang JY, Xu MQ, Wang WT, Wei YG. PLoS One. 2013 Aug 21;8(8):e72235. doi: 10.1371/journal.pone.0072235.

773.	Epidemiology of virus infection and human cancer
	Chen CJ, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL. Recent Results Cancer Res. 2014;193:11-32. doi: 10.1007/978-3-642-38965-8_2.

774.	Evaluation of a method for improving the detection of hepatocellular carcinoma
	Bendik E, Noël PB, Münzel D, Fingerle AA, Henninger M, Markus C, Vlassenbroek A, Rummeny EJ, Dobritz M. Eur Radiol. 2013 Sep 3. [Epub ahead of print]

775.	Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring
	Wang L, Yao M, Dong Z, Zhang Y, Yao D. Tumour Biol. 2013 Sep 5. [Epub ahead of print]

776.	Biomarker Discovery for Early Detection of Hepatocellular Carcinoma (HCC)in Hepatitis C (HCV) Infected Patients
	Mustafa GM, Petersen JR, Ju H, Cicalese L, Snyder N, Haidacher SJ, Denner L, Elferink C. Mol Cell Proteomics. 2013 Sep 5. [Epub ahead of print]

777.	Anti-viral treatment and cancer control
	Shih WL, Fang CT, Chen PJ. Recent Results Cancer Res. 2014;193:269-90. doi: 10.1007/978-3-642-38965-8_14.

778.	Hepatocellular carcinoma vascularization: From the most common to the lesser known arteries
	Cazejust J, Bessoud B, Colignon N, Garcia-Alba C, Planché O, Menu Y. Diagn Interv Imaging. 2013 Aug 23. pii: S2211-5684(13)00156-3. doi: 10.1016/j.diii.2013.04.015. [Epub ahead of print]

779.	One-off Complete Radiofrequency Ablation of Hepatocellular Carcinoma Adjacent to the Gallbladder by a Novel Laparoscopic Technique Without Gallbladder Isolation
	Jiang K, Su M, Zhao X, Chen Y, Zhang W, Wang J, Dong J, Huang Z. Cell Biochem Biophys. 2013 Aug 27. [Epub ahead of print]

780.	Prognostic Value of Hepatocyte Nuclear Factors 4? and 1? Identified by Tissue Microarray in Resectable Hepatocellular Carcinoma
	Shim JH, Kang HJ, Han S, Lee YJ, Lee SG, Yu E, Lee HC. J Gastroenterol Hepatol. 2013 Aug 23. doi: 10.1111/jgh.12371. [Epub ahead of print]

781.	TMT-HCC: A tool for text mining the biomedical literature for hepatocellular carcinoma (HCC) biomarkers identification
	Seoud RA, Mabrouk MS. Comput Methods Programs Biomed. 2013 Dec;112(3):640-8. doi: 10.1016/j.cmpb.2013.07.014. Epub 2013 Aug 23.

782.	Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization
	Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, Aal AK, Gray SH, Eckhoff DE, Dubay DA. HPB (Oxford). 2013 Aug 26. doi: 10.1111/hpb.12149. [Epub ahead of print]

783.	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
	Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26.

784.	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
	Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26.

785.	HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study
	Attallah AM, Omran MM, Attallah AA, Abdallah SO, Farid K, Darwish H, El-Dosoky I, Shaker YM. Br J Cancer. 2013 Sep 17;109(6):1657-65. doi: 10.1038/bjc.2013.481. Epub 2013 Aug 27.

786.	Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy
	Ma WJ, Wang HY, Teng LS. World J Surg Oncol. 2013 Aug 27;11(1):212. [Epub ahead of print]

787.	Performance of serum ?-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass
	Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, Lai PB, Lam CW, Yeo W, Yu SC. HPB (Oxford). 2013 Aug 26. doi: 10.1111/hpb.12146. [Epub ahead of print]

788.	Update on hepatocellular carcinoma breakthroughs: Poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy
	Guillot C, Hall J, Herceg Z, Merle P, Chemin I. Clin Res Hepatol Gastroenterol. 2013 Aug 13. pii: S2210-7401(13)00149-6. doi: 10.1016/j.clinre.2013.07.006. [Epub ahead of print]

789.	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
	van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. J Hepatol. 2013 Aug 20. pii: S0168-8278(13)00598-9. doi: 10.1016/j.jhep.2013.07.043. [Epub ahead of print]

790.	Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival
	Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Value Health. 2013 Jul-Aug;16(5):760-8. doi: 10.1016/j.jval.2013.03.1630. Epub 2013 May 28.

791.	Liver Stiffness Is Associated With Risk of Decompensation, Liver Cancer, and Death in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis
	Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, Kamath PS, Talwalkar JA. Clin Gastroenterol Hepatol. 2013 Aug 15. pii: S1542-3565(13)01167-1. doi: 10.1016/j.cgh.2013.07.034. [Epub ahead of print]

792.	Recurrence Patterns and Prognostic Factors in Patients with Hepatocellular Carcinoma in Noncirrhotic Liver: A Multi-Institutional Analysis
	Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL, Choti MA, Pawlik TM. Ann Surg Oncol. 2013 Aug 20. [Epub ahead of print]

793.	Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6R? signaling
	Gruber S, Straub BK, Ackermann PJ, Wunderlich CM, Mauer J, Seeger JM, Büning H, Heukamp L, Kashkar H, Schirmacher P, Brüning JC, Wunderlich FT. Cell Rep. 2013 Aug 29;4(4):669-80. doi: 10.1016/j.celrep.2013.07.023. Epub 2013 Aug 15.

794.	Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
	Radwan MM, Radwan BM, Nandipati KC, Hunter WJ 3rd, Agrawal DK. Expert Rev Clin Immunol. 2013 Aug;9(8):727-38. doi: 10.1586/1744666X.2013.816484.

795.	National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in taiwan: a preliminary report
	Chang CH, Lin JW, Wu LC, Liu CH, Lai MS. Med Care. 2013 Oct;51(10):908-13. doi: 10.1097/MLR.0b013e3182a502ba.

796.	Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States
	Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Aliment Pharmacol Ther. 2013 Oct;38(7):703-12. doi: 10.1111/apt.12450. Epub 2013 Aug 19.

797.	Lack of association of EPHX1 gene polymorphisms with risk of hepatocellular carcinoma: a meta-analysis
	Duan CY, Liu MY, Li SB, Ma KS, Bie P. Tumour Biol. 2013 Aug 17. [Epub ahead of print]

798.	Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials
	Cheung F, Wang X, Wang N, Yuen MF, Ziea TC, Tong Y, Wong VT, Feng Y. Evid Based Complement Alternat Med. 2013;2013:487919. doi: 10.1155/2013/487919. Epub 2013 Jul 17.

799.	Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders
	Fransen van de Putte DE, Makris M, Fischer K, Yee TT, Kirk L, van Erpecum KJ, Patch D, Posthouwer D, Mauser-Bunschoten EP. J Hepatol. 2013 Aug 23. pii: S0168-8278(13)00604-1. doi: 10.1016/j.jhep.2013.08.010. [Epub ahead of print]

800.	Alpha-fetoprotein-L3 in hepatocellular carcinoma: A meta-analysis
	Yi X, Yu S, Bao Y. Clin Chim Acta. 2013 Oct 21;425:212-20. doi: 10.1016/j.cca.2013.08.005. Epub 2013 Aug 13.

801.	Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: Long-Term Results and Prognostic Factors in 168 Patients with Cirrhosis
	Lee DH, Lee JM, Lee JY, Kim SH, Han JK, Choi BI. Cardiovasc Intervent Radiol. 2013 Aug 3. [Epub ahead of print]

802.	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study
	Ripoll C, Genescà J, Araujo IK, Graupera I, Augustin S, Tejedor M, Cirera I, Aracil C, Sala M, Hernandez-Guerra M, Llop E, Escorsell A, Vega Catalina M, Cañete N, Albillos A, Villanueva C, Abraldes JG, Bañares R, Bosch J. Hepatology. 2013 Jul 31. doi: 10.1002/hep.26629. [Epub ahead of print]

803.	Epidermal growth factor, its receptor and transforming growth factor-?1 in the diagnosis of HCV-induced hepatocellular carcinoma
	Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Med Oncol. 2013 Sep;30(3):673. doi: 10.1007/s12032-013-0673-x. Epub 2013 Aug 3.

804.	Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma
	Sharma BK, Srinivasan R, Kapil S, Singla B, Saini N, Chawla YK, Chakraborti A, Duseja A, Kalra N, Dhiman RK. Mol Cell Biochem. 2013 Nov;383(1-2):103-112. Epub 2013 Aug 4.

805.	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma
	Gish RG, Finn RS, Marrero JA. Clin Adv Hematol Oncol. 2013 Apr;11 Suppl 5:1-22; quiz 2 p following p22.

806.	Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization
	Jin YJ, Lee JW, Park SW, Lee JI, Lee DH, Kim YS, Cho SG, Jeon YS, Lee KY, Ahn SI. World J Gastroenterol. 2013 Jul 28;19(28):4537-44. doi: 10.3748/wjg.v19.i28.4537.

807.	Hepatitis B virus subgenotype C2- and B2-associated mutation patterns may be responsible for liver cirrhosis and hepatocellular carcinoma, respectively
	Chen YM, Wu SH, Qiu CN, Yu DJ, Wang XJ. Braz J Med Biol Res. 2013 Aug;46(7):614-22. doi: 10.1590/1414-431X20133032. Epub 2013 Jul 30.

808.	Missed Opportunities for Hepatocellular Carcinoma Screening in an HIV/Hepatitis C Virus-Coinfected Cohort
	Beauchamp E, Rollet K, Walmsley S, Wong DK, Cooper C, Klein MB; for the Canadian Co-infection Cohort Study (CTN222). Clin Infect Dis. 2013 Nov;57(9):1339-1342. Epub 2013 Jul 29.

809.	Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection
	Kim JW, Shin SS, Kim JK, Choi SK, Heo SH, Lim HS, Hur YH, Cho CK, Jeong YY, Kang HK. Korean J Radiol. 2013 Jul-Aug;14(4):626-35. doi: 10.3348/kjr.2013.14.4.626. Epub 2013 Jul 17.

810.	HBV infection and hepatocellular carcinoma
	Iavarone M, Colombo M. Clin Liver Dis. 2013 Aug;17(3):375-97. doi: 10.1016/j.cld.2013.05.002. Epub 2013 Jul 3.

811.	Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma
	Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. J Cancer. 2013 Jul 18;4(6):502-13. doi: 10.7150/jca.6503. Print 2013.

812.	Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments
	He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC. World J Gastroenterol. 2013 Jul 28;19(28):4552-8. doi: 10.3748/wjg.v19.i28.4552.

813.	Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
	Zhai B, Sun XY. World J Hepatol. 2013 Jul 27;5(7):345-52. doi: 10.4254/wjh.v5.i7.345.

814.	Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma
	Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim MJ. Liver Int. 2013 Jul 3. doi: 10.1111/liv.12270. [Epub ahead of print]

815.	Imaging features following transarterial chemoembolization and radiofrequency ablation of hepatocellular carcinoma
	Brennan IM, Ahmed M. Semin Ultrasound CT MR. 2013 Aug;34(4):336-51. doi: 10.1053/j.sult.2013.04.004.

816.	The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients
	Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC, Zeng YX. Ann Surg Oncol. 2013 Jul 27. [Epub ahead of print]

817.	Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: a systematic review
	Shimakawa Y, Yan HJ, Tsuchiya N, Bottomley C, Hall AJ. PLoS One. 2013 Jul 19;8(7):e69430. doi: 10.1371/journal.pone.0069430. Print 2013.

818.	Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma
	Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. World J Hepatol. 2013 Jul 27;5(7):364-71. doi: 10.4254/wjh.v5.i7.364.

819.	Hepatocellular Carcinoma Screening Practices in the Department of Veterans Affairs: Findings from a National Facility Survey
	El-Serag HB, Alsarraj A, Richardson P, Davila JA, Kramer JR, Durfee J, Kanwal F. Dig Dis Sci. 2013 Jul 19. [Epub ahead of print]

820.	Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
	Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ, Ross PJ. Br J Cancer. 2013 Aug 20;109(4):888-90. doi: 10.1038/bjc.2013.410. Epub 2013 Jul 23.

821.	Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization
	Choi J, Ryu JK, Lee SH, Hwang JH, Ahn DW, Kim YT, Yoon YB, Yoon CJ, Kang SG, Chung JW. J Palliat Med. 2013 Sep;16(9):1026-33. doi: 10.1089/jpm.2013.0067. Epub 2013 Jul 26.

822.	Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
	Schuppan D, Schattenberg JM. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76. doi: 10.1111/jgh.12212.

823.	Tumor microenviroment and hepatocellular carcinoma metastasis
	Wang H, Chen L. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:43-8. doi: 10.1111/jgh.12091.

824.	Is Liver-Specific Gadoxetic Acid-Enhanced Magnetic Resonance Imaging a Reliable Tool for Detection of Hepatocellular Carcinoma in Patients with Chronic Liver Disease?
	Wu LM, Xu JR, Gu HY, Hua J, Chen J, Zhu J, Zhang W, Hu J. Dig Dis Sci. 2013 Jul 25. [Epub ahead of print]

825.	A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse
	Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M, Tomezzoli A, Martignoni G, Guglielmi A. PLoS One. 2013 Jul 10;8(7):e68203. doi: 10.1371/journal.pone.0068203. Print 2013.

826.	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization
	Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ. PLoS One. 2013 Jul 9;8(7):e68193. doi: 10.1371/journal.pone.0068193. Print 2013.

827.	Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis
	Liao M, Huang J, Zhang T, Wu H. PLoS One. 2013 Jul 3;8(7):e68453. doi: 10.1371/journal.pone.0068453. Print 2013.

828.	Efficacy of TACE in TIPS Patients: Comparison of Treatment Response to Chemoembolization for Hepatocellular Carcinoma in Patients With and Without a Transjugular Intrahepatic Portosystemic Shunt
	Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK Jr, Fidelman N. Cardiovasc Intervent Radiol. 2013 Oct;36(5):1336-43. doi: 10.1007/s00270-013-0698-8. Epub 2013 Jul 18.

829.	Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma
	Cucchetti A, Piscaglia F, Cescon M, Ercolani G, Pinna AD.

830.	Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis
	Tomiyama Y, Takenaka K, Kodama T, Kawanaka M, Sasaki K, Nishina S, Yoshioka N, Hara Y, Hino K. Intern Med. 2013;52(14):1553-9. Epub 2013 Jul 15.

831.	Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
	Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Gastroenterology. 2013 Jul 13. pii: S0016-5085(13)01012-3. doi: 10.1053/j.gastro.2013.06.057. [Epub ahead of print]

832.	Local Therapies for Unresectable Primary Hepatocellular Carcinoma
	Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 May. Report No.: 13-EHC069-EF.?AHRQ Comparative Effectiveness Reviews. Belinson S, Yang Y, Chopra R, Shankaran V, Samson D, Aronson N.

833.	Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C
	Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. J Gastroenterol. 2013 Jul 17. [Epub ahead of print]

834.	Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection
	Chen YL, Chen CH, Hu RH, Ho MC, Jeng YM. ScientificWorldJournal. 2013 Jun 12;2013:380797. doi: 10.1155/2013/380797. Print 2013.

835.	Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma
	Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. World J Gastroenterol. 2013 Jun 28;19(24):3872-82. doi: 10.3748/wjg.v19.i24.3872.

836.	Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma
	Hu T, Guo H, Wang W, Yu S, Han L, Jiang L, Ma J, Yang C, Guo Q, Nan K. Oncol Rep. 2013 Oct;30(4):1707-14. doi: 10.3892/or.2013.2608. Epub 2013 Jul 9.

837.	Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy
	Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX. J Hematol Oncol. 2013 Jul 10;6:51. doi: 10.1186/1756-8722-6-51.

838.	Spontaneous clearance of serum hepatitis C virus RNA during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis C
	Minami T, Tateishi R, Shiina S, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Yoshida H, Koike K. Hepatol Res. 2013 Jul 11. doi: 10.1111/hepr.12203. [Epub ahead of print]

839.	Expression of GOLM1 Correlates with Prognosis in Human Hepatocellular Carcinoma
	Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Ann Surg Oncol. 2013 Jul 10. [Epub ahead of print]

840.	Hepatocellular carcinoma and food contamination: aflatoxins and ochratoxin A as a great prompter
	Felizardo RJ, Câmara NO. World J Gastroenterol. 2013 Jun 28;19(24):3723-5. doi: 10.3748/wjg.v19.i24.3723.

841.	Active treatments are a rational approach for hepatocellular carcinoma in elderly patients
	Suda T, Nagashima A, Takahashi S, Kanefuji T, Kamimura K, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. World J Gastroenterol. 2013 Jun 28;19(24):3831-40. doi: 10.3748/wjg.v19.i24.3831.

842.	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
	Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C, Cheng AL. Oncology. 2013;85(1):44-52. doi: 10.1159/000350841. Epub 2013 Jul 4.

843.	Contrast-enhanced ultrasound in the characterization of hepatocellular carcinomas treated by ablation: comparison with contrast-enhanced magnetic resonance imaging
	Qu P, Yu X, Liang P, Cheng Z, Han Z, Liu F, Yu J. Ultrasound Med Biol. 2013 Sep;39(9):1571-9. doi: 10.1016/j.ultrasmedbio.2013.03.030. Epub 2013 Jul 3.

844.	Consequences of needle tract seeding of hepatocellular cancer after liver transplant
	Lopez KT, Kuwada SK, Wong LL. Clin Transplant. 2013 Jul;27(4):E400-6. doi: 10.1111/ctr.12160. Epub 2013 Jul 10.

845.	Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis
	Tsung PC, Ryu SH, Cha IH, Cho HW, Kim JN, Kim YS, Moon JS. Clin Mol Hepatol. 2013 Jun;19(2):131-9. doi: 10.3350/cmh.2013.19.2.131. Epub 2013 Jun 27.

846.	Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells
	Kanki K, Akechi Y, Ueda C, Tsuchiya H, Shimizu H, Ishijima N, Toriguchi K, Hatano E, Endo K, Hirooka Y, Shiota G. J Hepatol. 2013 Jul 2. pii: S0168-8278(13)00441-8. doi: 10.1016/j.jhep.2013.06.024. [Epub ahead of print]

847.	Human early liver regeneration after hepatectomy in patients with hepatocellular carcinoma: special reference to age
	Shirabe K, Motomura T, Takeishi K, Morita K, Kayashima H, Taketomi A, Ikegami T, Soejima Y, Yoshizumi T, Maehara Y. Scand J Surg. 2013 Jun 1;102(2):101-5. doi: 10.1177/1457496913482250.

848.	Value of Interleukin 28B Genetic Polymorphism on Retreatment Outcomes of Chronic Hepatitis C Genotype 1 Relapsers by Peginterferon Alfa plus Ribavirin
	Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ. J Gastroenterol Hepatol. 2013 Jul 5. doi: 10.1111/jgh.12329. [Epub ahead of print]

849.	Fatty liver disease--a practical guide for GPs
	Iser D, Ryan M. Aust Fam Physician. 2013 Jul;42(7):444-7.

850.	Diagnostic accuracy of des-gamma-carboxy prothrombin versus ?-fetoprotein for hepatocellular carcinoma: A systematic review
	Li C, Zhang Z, Zhang P, Liu J. Hepatol Res. 2013 Jul 9. doi: 10.1111/hepr.12201. [Epub ahead of print]

851.	Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma
	Nishikawa H, Osaki Y. Hepatol Res. 2013 Jul 2. doi: 10.1111/hepr.12194. [Epub ahead of print]

852.	Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma
	Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, Min BY, Jang ES, Kim JW, Park GJ, Lee YJ, Lee KH, Ahn S. BMC Cancer. 2013 Jul 8;13:335. doi: 10.1186/1471-2407-13-335.

853.	Occult hepatitis B in patients on hemodialysis: a review
	Fontenele AM, Filho NS, Ferreira AS. Ann Hepatol. 2013 Jul-Aug;12(4):527-31.

854.	United States Women Receive More Curative Treatment for Hepatocellular Carcinoma Than Men
	Cauble S, Abbas A, Balart L, Bazzano L, Medvedev S, Shores N. Dig Dis Sci. 2013 Jun 29. [Epub ahead of print]

855.	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound
	Zocco MA, Garcovich M, Lupascu A, Di Stasio E, Roccarina D, Annicchiarico BE, Riccardi L, Ainora ME, Ponziani F, Caracciolo G, Rapaccini GL, Landolfi R, Siciliano M, Pompili M, Gasbarrini A. J Hepatol. 2013 Jun 25. pii: S0168-8278(13)00427-3. doi: 10.1016/j.jhep.2013.06.011. [Epub ahead of print]

856.	Surgical resection versus liver transplant for patients with hepatocellular carcinoma
	Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Cochrane Database Syst Rev. 2013 Jun 29;6:CD006935. doi: 10.1002/14651858.CD006935.pub2

857.	Skills and Requirements of a Transplant Hepatologist: Board Certification of the Italian Association for the Study of the Liver (AISF)
	Burra P, Belli L, Fagiuoli S, Angelico M, Costa AN, Caraceni P, Toniutto P. Dig Liver Dis. 2013 Jun 28. pii: S1590-8658(13)00185-0. doi: 10.1016/j.dld.2013.04.014. [Epub ahead of print]

858.	Hepatic resection for hepatocellular carcinoma patients on hemodialysis for uremia: a nationwide cohort study
	Yeh CC, Lin JT, Jeng LB, Charalampos I, Chen TT, Lee TY, Wu MS, Kuo KN, Liu YY, Wu CY. World J Surg. 2013 Oct;37(10):2402-9. doi: 10.1007/s00268-013-2137

859.	Relationship Between 13C-Aminopyrine Breath Test and the MELD Score and Its Long-Term Prognostic Use in Patients with Cirrhosis
	Giannini EG, Savarino V. Dig Dis Sci. 2013 Jul 2. [Epub ahead of print]

860.	Liver diseases and aging: friends or foes?
	Sheedfar F, Biase SD, Koonen D, Vinciguerra M. Aging Cell. 2013 Jul 1. doi: 10.1111/acel.12128. [Epub ahead of print]

861.	Evaluation of alpha-fetoprotein staging system for hepatocellular carcinoma in noncirrhotic patients
	Burnett NP, Dunki-Jacobs EM, Callender GG, Anderson RJ, Scoggins CR, McMasters KM, Martin RC. Am Surg. 2013 Jul;79(7):716-22.

862.	Significance of Incorporation of Model for End-Stage Liver Disease Score with TNM Staging in Patients with Hepatocellular Carcinoma Undergoing Hepatic Resection
	Ling CH, Chau GY, Hsia CY, King KL. Hepatogastroenterology. 2013 Jun;60(125):1142-7. doi: 10.5754/hge11939.

863.	Tumor Necrosis Factor-? 238 G/A Polymorphism and Risk of Hepatocellular Carcinoma: Evidence from a Meta-analysis
	Cheng K, Zhao YJ, Liu L, Wan JJ. Asian Pac J Cancer Prev. 2013;14(5):3275-9.

864.

Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: Etiological factors or risk markers?

Lukanova A, Becker S, Hüsing A, Schock H, Fedirko V, Trepo E, Trichopoulou A, Bamia C, Lagiou P, Benetou V, Trichopoulos D, Nöthlings U, Tjønneland A, Overvad K, Dossus L, Teucher B, Boeing H, Aleksandrova K, Palli D, Pala V, Panico S, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Siersema PD, Peeters PH, Quiros JR, Duell EJ, Molina-Montes E, Chirlaque MD, Gurrea AB, Dorronsoro M, Lindkvist B, Johansen D, Werner M, Sund M, Khaw KT, Wareham N, Key TJ, Travis RC, Rinaldi S, Romieu I, Gunter MJ, Riboli E, Jenab M, Kaaks R. Int J Cancer. 2013 Jun 25. doi: 10.1002/ijc.28342. [Epub ahead of print]

865.	Transarterial embolization of metastatic mediastinal hepatocellular carcinoma
	Chen CC, Yeh HZ, Chang CS, Ko CW, Lien HC, Wu CY, Hung SW. World J Gastroenterol. 2013 Jun 14;19(22):3512-6. doi: 10.3748/wjg.v19.i22.3512.

866.	Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities
	Wu KT, Wang CC, Lu LG, Zhang WD, Zhang FJ, Shi F, Li CX. World J Gastroenterol. 2013 Jun 21;19(23):3649-57. doi: 10.3748/wjg.v19.i23.3649.

867.	Worse Outcome of Sorafenib Therapy Associated with Ascites and Child-Pugh Score in Advanced Hepatocellular Carcinoma
	Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, Kim CM. J Gastroenterol Hepatol. 2013 Jun 25. doi: 10.1111/jgh.12310. [Epub ahead of print]

868.	Controversy over the use of intraoperative blood salvage autotransfusion during liver transplantation for hepatocellular carcinoma patients
	Zhai B, Sun XY. World J Gastroenterol. 2013 Jun 14;19(22):3371-4. doi: 10.3748/wjg.v19.i22.3371.

869.	Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients
	Hsu CS, Huang CJ, Kao JH, Lin HH, Chao YC, Fan YC, Tsai PS. PLoS One. 2013 Jul 23;8(7):e70458. doi: 10.1371/journal.pone.0070458. Print 2013.

870.	Prognostic significance of HIF-1? expression in hepatocellular carcinoma: a meta-analysis
	Zheng SS, Chen XH, Yin X, Zhang BH. PLoS One. 2013 Jun 14;8(6):e65753. doi: 10.1371/journal.pone.0065753. Print 2013.

871.	Factors associated with early cancer-related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion
	Sasaki K, Matsuda M, Ohkura Y, Kawamura Y, Inoue M, Hashimoto M, Ikeda K, Kumada H, Watanabe G. J Hepatobiliary Pancreat Sci. 2013 Jun 20. doi: 10.1002/jhbp.13. [Epub ahead of print]

872.	Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling
	Lim HY, Sohn I, Deng S, Lee J, Jung SH, Mao M, Xu J, Wang K, Shi S, Joh JW, Choi YL, Park CK. Ann Surg Oncol. 2013 Jun 26. [Epub ahead of print]

873.	Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma
	Nishikawa H, Osaki Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Arimoto A, Kita R, Kimura T. J Gastrointestin Liver Dis. 2013 Jun;22(2):173-81.

874.	Occupational Exposure to Hepatitis C Virus: Early T-Cell Responses in the Absence of Seroconversion in a Longitudinal Cohort Study
	Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Herrine SK, Stevens M, Schmitt J, Rehermann B.

875.	Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design
	Reig M, Rimola J, Torres F, Darnell A, Lope CR, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J. Hepatology. 2013 Jun 20. doi: 10.1002/hep.26586. [Epub ahead of print]

876.	Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
	Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y, Okusaka T. J Gastroenterol. 2013 Jun 23. [Epub ahead of print]

877.	SIRT3 expression in hepatocellular carcinoma and its impact on proliferation and invasion of hepatoma cells
	Zhang B, Qin L, Zhou CJ, Liu YL, Qian HX, He SB. Asian Pac J Trop Med. 2013 Aug;6(8):649-52. doi: 10.1016/S1995-7645(13)60112-1.

878.	S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors
	Yuan RH, Chang KT, Chen YL, Hsu HC, Lee PH, Lai PL, Jeng YM. PLoS One. 2013 Jun 13;8(6):e65501. doi: 10.1371/journal.pone.0065501. Print 2013.

879.	Patterns of Consultation and Treatment of Patients with Hepatocellular Carcinoma Presenting to a Large Academic Medical Center in the US
	Stacy S, Hyder O, Cosgrove D, Herman JM, Kamel I, Geschwind JF, Gurakar A, Anders R, Cameron A, Pawlik TM. J Gastrointest Surg. 2013 Jun 19. [Epub ahead of print]

880.	Validation of organ procurement and transplant network (OPTN)/united network for organ sharing (UNOS) criteria for imaging diagnosis of hepatocellular carcinoma
	Fowler KJ, Karimova EJ, Arauz AR, Saad NE, Brunt EM, Chapman WC, Heiken JP. Transplantation. 2013 Jun 27;95(12):1506-11. doi: 10.1097/TP.0b013e31828eeab2.

881.	Hospice offers more palliative care but costs less than usual care for terminal geriatric hepatocellular carcinoma patients: a nationwide study
	Hwang SJ, Chang HT, Hwang IH, Wu CY, Yang WH, Li CP. J Palliat Med. 2013 Jul;16(7):780-5. doi: 10.1089/jpm.2012.0482. Epub 2013 May 13.

882.	Genetic Polymorphisms in DNA Repair Genes XRCC4 and XRCC5 and Aflatoxin B1-related Hepatocellular Carcinoma
	Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, Wei ZH, Liu M, Zeng LX, Mo XQ, Zhang JJ, Xue F, Zhai B, Xia Q. Epidemiology. 2013 Sep;24(5):671-81. doi: 10.1097/EDE.0b013e31829d2744.

883.	Genetic Polymorphisms in DNA Repair Genes XRCC4 and XRCC5 and Aflatoxin B1-related Hepatocellular Carcinoma
	Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, Wei ZH, Liu M, Zeng LX, Mo XQ, Zhang JJ, Xue F, Zhai B, Xia Q. Epidemiology. 2013 Sep;24(5):671-81. doi: 10.1097/EDE.0b013e31829d2744.

884.	Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: A systematic review and meta-analysis
	Xu Y, Li L, Xiang X, Wang H, Cai W, Xie J, Han Y, Bao S, Xie Q. Gene. 2013 Sep 25;527(2):584-93. doi: 10.1016/j.gene.2013.05.085. Epub 2013 Jun 17.

885.	Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma
	Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A. J Hepatol. 2013 Jun 17. pii: S0168-8278(13)00418-2. doi: 10.1016/j.jhep.2013.06.008. [Epub ahead of print]

886.	Consensus report of the Fifth International Forum for Liver MRI
	Zech CJ, Bartolozzi C, Bioulac-Sage P, Chow PK, Forner A, Grazioli L, Huppertz A, Laumonier H, Min Lee J, Murakami T, Ricke J, Sirlin CB. AJR Am J Roentgenol. 2013 Jul;201(1):97-107. doi: 10.2214/AJR.12.9491.

887.	Clinical characteristics and outcome of hepatocellular carcinoma in children and adolescents
	Zhang XF, Liu XM, Wei T, Liu C, Li MX, Long ZD, Lv Y. Pediatr Surg Int. 2013 Aug;29(8):763-70. doi: 10.1007/s00383-013-3334-4. Epub 2013 Jun 22.

888.	Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
	Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1343-1352. Epub 2013 Jun 18.

889.	A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma
	Wang J, He XD, Yao N, Liang WJ, Zhang YC. Can J Gastroenterol. 2013 Jun;27(6):351-63.

890.	Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma
	Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, Ao JY, Li JQ, Wang L, Wu WZ, Tang ZY. PLoS One. 2013 May 31;8(5):e65023. doi: 10.1371/journal.pone.0065023. Print 2013.

891.	Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma
	Muir K, Hazim A, He Y, Peyressatre M, Kim DY, Song X, Beretta L. Cancer Res. 2013 Aug 1;73(15):4722-31. doi: 10.1158/0008-5472.CAN-12-3797. Epub 2013 Jun 7.

892.	Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma
	Ahn S, Hyeon J, Park CK. Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):286-94.

893.	Recurrence after Liver Transplantation for Hepatocellular Carcinoma According to Up-to-Seven Criteria
	Gugenheim J, Bredt LC, Iannelli A, Decaens T, Roudot-Thoraval F, Meyer C, Durand F, Bernard PH, Boillot O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C, Hadni-Bresson S. Hepatogastroenterology. 2013 Jun 6;60(126):799-806. doi: 10.5754/hge12997. [Epub ahead of print]

894.	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments
	Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC, Lin HC. Int J Cancer. 2013 Jun 10. doi: 10.1002/ijc.28311. [Epub ahead of print]

895.	A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis
	Xu C, Yan Z, Zhou L, Wang Y. J Cancer Res Clin Oncol. 2013 Aug;139(8):1417-24. doi: 10.1007/s00432-013-1458-5. Epub 2013 Jun 7.

896.	Identification of FKBP11 as a biomarker for hepatocellular carcinoma
	Lin IY, Yen CH, Liao YJ, Lin SE, Ma HP, Chan YJ, Chen YM. Anticancer Res. 2013 Jun;33(6):2763-9.

897.	Assessing liver dysfunction in cirrhosis: Role of the model for end-stage liver disease and its derived systems
	Lee YH, Hsu CY, Huo TI. J Chin Med Assoc. 2013 Aug;76(8):419-24. doi: 10.1016/j.jcma.2013.04.010. Epub 2013 Jun 5.

898.	Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases
	Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. World J Gastroenterol. 2013 Jun 7;19(21):3207-16. doi: 10.3748/wjg.v19.i21.3207.

899.	Different effects of three polymorphisms in MicroRNAs on cancer risk in Asian population: evidence from published literatures
	Xu Y, Gu L, Pan Y, Li R, Gao T, Song G, Nie Z, Chen L, Wang S, He B. PLoS One. 2013 Jun 4;8(6):e65123. doi: 10.1371/journal.pone.0065123. Print 2013.

900.	Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol
	Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Syst Rev. 2013 Jun 6;2:37. doi: 10.1186/2046-4053-2-37.

901.	Is the American Association for the Study of Liver Diseases recommendation for hepatocellular carcinoma screening a cul-de-sac?
	Braillon A. World J Gastroenterol. 2013 Jun 7;19(21):3369-70. doi: 10.3748/wjg.v19.i21.3369.

902.	Clinical Evaluation of Transcatheter Arterial Chemoembolization with 2-Day-soluble Gelatin Sponge Particles for Hepatocellular Carcinoma-Comparison with Insoluble Gelatin Sponge Particles
	Kawai N, Sato M, Minamiguchi H, Ikoma A, Sanda H, Nakata K, Sato H, Sakaguchi H, Nakai M, Sonomura T. J Vasc Interv Radiol. 2013 May 30. pii: S1051-0443(13)00741-0. doi: 10.1016/j.jvir.2013.03.013. [Epub ahead of print]

903.	Sorafenib: from literature to clinical practice
	Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C. Ann Oncol. 2013 Apr;24 Suppl 2:ii30-7. doi: 10.1093/annonc/mdt055.

904.	Multidisciplinary approach for HCC patients: hepatology for the oncologists
	Barone C, Koeberle D, Metselaar H, Parisi G, Sansonno D, Spinzi G. Ann Oncol. 2013 Apr;24 Suppl 2:ii15-23. doi: 10.1093/annonc/mdt053.

905.	Mortality predicted accuracy for hepatocellular carcinoma patients with hepatic resection using artificial neural network
	Chiu HC, Ho TW, Lee KT, Chen HY, Ho WH. ScientificWorldJournal. 2013 Apr 30;2013:201976. doi: 10.1155/2013/201976. Print 2013.

906.	Methodological assessment of HCC literature
	Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Ann Oncol. 2013 Apr;24 Suppl 2:ii6-14. doi: 10.1093/annonc/mdt052.

907.	Intermediate hepatocellular carcinoma: current treatments and future perspectives
	Dufour JF, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho RT. Ann Oncol. 2013 Apr;24 Suppl 2:ii24-9. doi: 10.1093/annonc/mdt054.

908.	High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma
	Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH. Transl Oncol. 2013 Jun 1;6(3):311-8. Print 2013 Jun.

909.	Methylation of the HACE1 Gene is Frequently Detected in Hepatocellular Carcinoma
	Sakata M, Yokomizo K, Kitamura Y, Sakuraba K, Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K. Hepatogastroenterology. 2013 Jun 3;60(124):781-3. doi: 10.5754/hge10439.

910.	Influence of etiology on host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy
	Nagai H, Mukozu T, Kanekawa T, Matsui T, Kanayama M, Wakui N, Momiyama K, Ishii K, Igarashi Y, Sumino Y. Hepatogastroenterology. 2013 Jun 3;60(124):858-63. doi: 10.5754/hge10598.

911.	High-intensity focused ultrasound ablation assisted using color Doppler imaging for the treatment of hepatocellular carcinomas
	Fukuda H, Numata K, Nozaki A, Kondo M, Morimoto M, Maeda S, Tanaka K, Ohto M, Ito R, Ishibashi Y, Oshima N, Ito A, Zhu H, Wang ZB. Abdom Imaging. 2013 Jun 2. [Epub ahead of print]

912.	Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma
	Ding J, Jing X, Liu J, Wang Y, Wang F, Wang Y, Du Z. Eur J Radiol. 2013 May 28. pii: S0720-048X(13)00221-0. doi: 10.1016/j.ejrad.2013.04.025. [Epub ahead of print]

913.	Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma
	Khan R, Zahid S, Wan YJ, Forster J, Karim AB, Nawabi AM, Azhar A, Rahman MA, Ahmed N. Clin Proteomics. 2013 Jun 1;10(1):6. doi: 10.1186/1559-0275-10-6.

914.	Retrospective audit to determine the diagnostic accuracy of Primovist-enhanced MRI in the detection of hepatocellular carcinoma in cirrhosis with explant histopathology correlation
	Baird AJ, Amos GJ, Saad NF, Benson MD. J Med Imaging Radiat Oncol. 2013 Jun;57(3):314-20. doi: 10.1111/1754-9485.12038. Epub 2013 Feb 6.